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ABSTRACT
Microglia are the immune cell of the central nervous system and become reactive 
in  response  to  infection  or  trauma.  In  Multiple  Sclerosis  (MS)  microglia  show  early 
reactivity  which  may  contribute  to  subsequent  neurotoxicity.  Glutamate  has  been 
implicated in the neurodegeneration in MS. Microglia express subtypes of metabotropic 
glutamate  receptors  (mGluRs),  the  activation  of which  can  lead  to  microglial  evoked 
neurotoxicity  (group  II)  or  neuroprotection  (group  III).  This  suggests  that  release  of 
glutamate from neurones or glial cells may activate microglia via these receptors.
Increased microglial  reactivity during disease  is possibly due to an  imbalance of 
mGluR expression with neurotoxic  group  II  increased above  neuroprotective group  III 
mGluRs.  Microglial  expression  of  mGluR  subtypes  was  therefore  investigated  on 
activated compared with untreated cells.  It was found that microglia exposed to myelin 
expressed  increased  levels  of  group  II  and  mGluR 1   and  8  subtypes  compared  with 
control cells.
MS  is  characterised  by  lesions  in  the  CNS  due  to  localised  myelin  breakdown. 
This  research  investigated  the  effects  of  microglial  exposure  to  myelin  and 
demonstrated  that  myelin  induced  microglial  activation,  upregulation  of  iNOS 
expression,  and  increased  TNFa  and  nitrite  release.  Conditioned  medium  from  these 
cells was toxic to neurones in culture. Microglia phagocytose myelin in vitro leading to 
cytokine release and increased affinity for oligodendrocytes, inducing their death by cell 
contact through  TNF  receptors.  This  study examined  whether microglial  phagocytosis 
could be modulated by stimulation of mGluRs and demonstrated that blocking group II 
or stimulation of group I or III mGluRs significantly reduced phagocytic activity.  Since 
myelin induced toxicity was also reduced by blocking microglial group II or stimulating 
group III mGluRs, these results suggest that modulation of microglial mGluRs may be 
of therapeutic benefit in MS.4
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1.0
INTRODUCTION20
1.1  Cells of the Central Nervous system
1.1.1  General Introduction
The  cells  of  the  central  nervous  system  (CNS)  comprise  neurones  and  glia. 
These  broad  categories  encompass  several  different  types  of cells  that  vary  based  on 
their  structure,  chemistry  and  function.  The  CNS  consists  of  around  1012  neurones 
which facilitate  synaptic transmission and communication across the CNS (Bear et al., 
2001). Action potentials carry electrical information from one neurone to another along 
their  axons.  Neurones,  however,  are  outnumbered  by  non-neuronal  cellular  elements 
collectively  referred  to  as  ‘neuroglia’  which  make  up  around  90%  of the  cells  in  the 
brain.  The  term  neuroglia  ‘nerve  glue’,  was  employed  by  Rudolph  Virchow  in  1859 
who believed glia to function as an inactive connective tissue to hold neurones together 
(Bear et al., 2001). For a long time this view of glia as simple supporting cells providing 
trophic  support  to  neurones  presided  but  it  has  now  become  apparent  that  glial  cells 
have a far more diverse function in the CNS. Using silver staining, Del Rio Hortega was 
first  able  to  distinguish  between  the  main  types  of supporting  cell  in  the  CNS  which 
include astrocytes, oligodendrocytes and macrophages (Barron,  1995).
1.1.2  Astrocytes
Astrocytes  are  stellate  process-bearing  cells  with  even  distribution  throughout 
the CNS.  Embryonically,  astrocytes develop  from  radial  glial  cells,  which  retract their 
processes as they mature, thus serving as astrocyte progenitors (Ransom and Sontheimer 
1992; Chanas-Sacre et al., 2000; Mori et al., 2005). Neurones and oligodendrocytes are 
enveloped as astrocytes extend processes to the pia mater and the ependyma to form the 
glia  limitans,  thus  providing  an  interface  where  neurones  and  astrocytes  may  interact.21
Astrocytes  are  connected  to  each  other  by  gap junctions  which  allow  ions  to  diffuse 
across the brain parenchyma.
Astrocytes  are  responsible  for  initiating  and  maintaining  the  endothelial  tight 
junctions  of the  blood  brain  barrier  (BBB)  and  also  produce  several  growth  factors 
which  regulate the  morphology,  differentiation  or survival  of neurones.  They  provide 
the  link  between  vasculature  and  neurones,  transporting  and  processing  glucose  from 
the  blood  stream  to  produce  lactate  which  is  the  main  energy  substrate  for  neurones 
(Tsacopoulos  and  Magistretti  1996;  Magistretti  and  Pellerin  1999).  Astrocytes  also 
function as buffer cells at the  synaptic cleft. Due to their high potassium permeability, 
astrocytes can  take  up excess potassium and  store  it to  protect neighbouring  neurones 
from  depolarisation  (Newman  and  Reichenbach  1996).  Expression  of  transporter 
proteins  on  their  cell  surface  membranes  also  allows  astrocytes  to  buffer 
neurotransmitters  such  as  glutamate  and  gamma-aminobutyric  acid  (GABA)  from  the 
synapse (Kimelberg and Katz  1985; Kimelberg and Norenberg  1989;  Schousboe et al., 
2004), thus preventing excessive stimulation or excitotoxicity (Ransom et al.,  1995).
Astrocytes  are  the  largest  of  the  glial  cells  (40-50p  m)  and  make  up 
approximately  30-40%  of  the  glial  population  (Aldskogius  and  Kozlova,  1998). 
Astrocytes  have  unique  morphological  features  including  their  stellate  shape  and  the 
presence  of glial  end  feet on capillaries.  Astrocytes are the  only glial  cells to contain 
intermediate filaments made of glial fibrillary acidic protein (GFAP)  and  are therefore 
easily identifiable (reviewed by: Eng et al., 2000).
1.1.3  Oligodendrocytes
The  myelin  sheath  is  formed  by  specialised  glial  cells.  Oligodendrocytes  and 
Schwann  cells  are  responsible  for  the  myelination  of  CNS  and  peripheral  nervous 
system  (PNS)  axons  respectively.  These  cells  wrap  myelin  sheaths,  produced  from22
extensions  of their  cell  membranes,  around  axons  (Figure  1.1).  Oligodendrocytes  are 
capable of forming up to 50 sheath segments therefore allowing myelination of several 
axons  from  the  same  cell  (Compston  et  al.,  1997).  Oligodendrocytes  also  regulate 
extracellular potassium  ion  concentrations  and  are  able to  secrete  neurotrophic  factors 
including  nerve  growth  factor  (NGF),  brain  derived  nerve  factor  (BDNF),  and 
neurotrophin 3 (NT-3) (Dai et al., 2001).
Oligodendrocyte
Myelin
sheath
Node of  Axons
Ranvier
Figure 1.1  Schematic diagram of an oligodendrocyte cell.
Oligodendrocytes  extrude  processes  which  wrap  themselves  around  portions  of 
surrounding  axons.  As  each  process  wraps  itself  around,  it  forms  layers  of 
myelin. Each process thus becomes a segment of the axon's myelin sheath. Areas 
of exposed axon between myelin sheaths are known as the Nodes of Ranvier.
1.1.3a  Myelin
Oligodendrocyte  membrane  extensions  are  wrapped  around  axons  resulting  in 
apposition  between  the  intracellular  or  extracellular  surface  membranes.  The 
intracellular  apposition  is  referred  to  as  the  major  dense  line  while  the  extracellular 
apposition  is  named  the  intraperiod  line.  The  areas  of myelin  free  axon  between  the23
myelin sheaths are known as the nodes of Ranvier which facilitate the fast transmission 
of action potentials.
Myelin  contains  a  high  lipid  content  of around  70-75%,  which  helps  with  its 
function as an axonal insulator, and around 25% protein. The main myelin proteins are 
proteolipid  protein  (PLP)  which  makes  up  50%,  and  myelin  basic  protein  (MBP) 
isoforms which make  up  30% of total myelin protein.  Myelin associated  glycoprotein 
(MAG) and myelin  oligodendrocyte glycoprotein (MOG) are  present to a much  lesser 
extent making up about 1.5% of total myelin protein (Cuzner and Norton  1996).
Myelin  serves two  important functions;  Firstly,  action  potentials are conducted 
faster as depolarisation of the axon ‘jumps’ from node to node (Ransom and Sontheimer 
1992;  Edgar  and  Garbem  2004).  Secondly,  myelin  allows  conservation  of metabolic 
energy as channel activity is confined to the small area of the nodes of Ranvier (Bear et 
al., 2001). The crucial role of myelin in the transfer of information across the brain and 
normal  functioning  of  axons  is  demonstrated  by  the  CNS  demyelinating  disorder 
multiple sclerosis which will be discussed in detail later.
1.1.4  Macrophages
These  cells  are  derived  from  bone  marrow  promonocytes,  which  then 
differentiate  into circulating blood monocytes and  finally  localise throughout the  body 
as mature macrophages where they make up the mononuclear phagocyte system (Figure 
1.2).  Macrophages  contain  considerable  rough-surfaced  endoplasmic  reticulum  and 
mitochondria.  They  can  be  localised  throughout  connective  tissue  and  around  the 
basement membrane of small blood vessels and in particular in the liver (Kupffer cells), 
lungs (alveolar macrophages), and  lymph node medullary sinuses where they can fulfil 
their role  as  peripheral  immune  cells  (Roitt and  Delves,  2003).  Some  macrophages  in 
the  brain  are  known  as  perivascular  macrophages  although  other  macrophage24
populations  are  also  known to  infiltrate the  CNS  after blood  brain  barrier breakdown. 
Resident microglial cells can adopt similar morphology and  functions as macrophages, 
these cells will be discussed in detail later.
Figure 1.2  EM photograph of a macrophage cell.
Image taken from www.malp-research.de/
1.1.5  The blood brain barrier
The  CNS  is  protected  to  a  certain  extent from  circulating  blood  borne  solutes. 
Without a barrier mechanism, circulating blood molecules, for instance hormones which 
can  act  as  neurotransmitters,  could  interfere  with  synaptic  transmission  and  cell 
interactions  (Pardridge  et  al.,  1987).  The  CNS  is  therefore  separated  from  circulating 
haematopoietic  cells  by the  tight junctions formed  by  capillary  and  venule  endothelial 
cells  (Reese  and  Kamovski,  1967).  Endothelial  cells  together  with  perivascular 
microglia  and  notably  astrocytes,  constitute  the  BBB  thus  creating  the  unique 
microenvironment of the CNS.  However, due to the high metabolic requirements of the 
brain, the  BBB  has transport mechanisms for the specific nutrients required  for normal 
brain function (Comford and Landon,  1985) including molecular exclusion pumps such 
as p-glycoprotein that maintain  gradients between the  blood  and the  brain (Tsuji et al., 
1992; Tatsuta et al.,  1992).
The  original  idea  of  a  barrier  mechanism  separating  the  brain  from  blood 
circulation  came  from  studies  of  dye  injections  into  the  circulation.  In  the  early 
twentieth century, Goldman (1909,  1913), showed that while the brain could  be stained25
with trypan blue when  injected  into the brain ventricular system,  intravenous  injection 
led to staining of all organs with the exception of the brain and spinal cord (Reviewed 
by Ribatti et al., 2006).  It was also observed that transplanted tissue grafts in the brain 
were tolerated for relatively  long periods  in the brain without evidence  of an  immune 
response  (Widner et al.,  1989;  Young et al.,  1989).  Indeed,  endothelial tight junctions 
and  the  fact  that  the  brain  has  no  conventional  lymphatic  drainage  system  results  in 
highly  restricted  access  to  blood  and  lymph  borne  immune  cells  such  as  T  and  B 
lymphocytes and monocytes (Aloisi et al., 2000).
It is now known that immune regulatory functions  can  still preside  in the  CNS 
despite  the  BBB  as  demonstrated  by  several  studies.  These  include  Medawar  et  al., 
(1948)  who  showed  that  allogenic  skin  grafts  implanted  into  the  brains  of sensitised 
rabbits were rejected.  Investigation  into the pathogenesis of multiple  sclerosis has also 
highlighted the permeability of the BBB. T-cell infiltration into the CNS occurs in viral 
and autoimmune encephalitis  (Weiner et al.,  1984),  and has also been demonstrated  in 
the  brains  of  MS  patients  (Hauser  et  al.,  1986),  although  the  extent  of  lymphocyte 
infiltration  has  been  shown  to  be  dependent  on  lesion  location  (Bo  et  al.,  2003).  The 
induction  of a  successful  immune  response  within  the  CNS  is  dependent  on  T  cell 
contact  with  the  endothelial  cell  wall  and  penetration  of the  cells  through  the  BBB 
(Naparstek et al.,  1984). It has been suggested that microglial cells and astrocytes act as 
regulatory cells at the  interface  between the  brain and the  components of the  immune 
system controlling the action of cellular and humoral elements of the  immune response 
(Frei et al.,  1988).
Increased  permeability  of  the  BBB  is  central  to  several  neuropathological 
conditions including MS. Generally, disruption of the BBB leads to the accumulation of 
blood  derived  fluids  around  brain  blood  vessels.  In  MS,  T-cells  and  macrophages 
invade the brain through the disrupted BBB, initiating inflammatory cascades.26
1.2  Microglia
Microglia are a major glial component of the central nervous system (CNS), and 
constitute  5-15% of the total brain cell population (Carson, 2002).  Microglial cells are 
expressed ubiquitously throughout the brain and spinal cord, although there are regional 
differences  in  cell  number  and  a  larger proportion  of microglia  in the  grey  compared 
with  the  white  matter  (Lawson  et  al.,  1990).  While  microglia  are  a  distinct  cell  type 
expressing  a  unique  ramified  morphology  at  rest,  certain  stimuli  cause  them  to 
transform  into  activated  cells,  which  then  display  the  morphological  features  and 
functions of macrophages (Kreutzberg,  1996; Stence et al., 2001).
The  hallmark  of  microglia  is  their  ability  to  become  reactive  with  a  graded 
response  to  pathological  challenge.  Microglia  possess  many  functional  properties 
including  migration,  proliferation,  displacement  of synaptic  boutons  (Ling  1981),  and 
also  act  as  brain  macrophages,  antigen  presenting  cells,  and  immunoeffector  cells 
involved in local inflammatory processes in the brain (Guilian,  1987; Streit et al.,  1988).
1.2.1  Origins of microglia
It  has  been  suggested  that  microglia  enter  the  brain  as  monocytes  during 
embiyonic  development,  then  differentiate  into  glial  cells  displaying  many  of the  cell 
surface  antigens  of macrophages  (Lee  et al.,  2002),  (Figure  1.3).  There  is  now  much 
evidence pointing to the monocytic origin of microglia.  Carbon  particles used  to  label 
monocytes  injected  into the blood  stream  of postnatal rats were  later localised  in cells 
resembling mature  microglia (Ling et al  1980).  Furthermore,  both  resting and  reactive 
microglia can be visualised by B4 isolectin which is a marker also used for labelling of 
blood  monocytes  (Streit  and  Kreutzberg  1987),  and  immunocytochemical  labelling  of 
macrophages infiltrating the CNS has been used to chart the change from rounded cells27
to  highly  specialised  microglia  (Hume  et  al,  1983;  Perry  et  al.,  1985).  Indeed  several 
microglial cell  surface antigens are either associated or exclusive to cells of monocytic 
lineage  such as the Fc receptors (CD 16a and CD 16b) and complement type 3  receptors 
(C D lib)  (Perry  et  al.,  1985,  Perry  and  Gordon,  1987).  Studies  using  bone  marrow 
chimeras have also shown that the CNS becomes populated with cells expressing donor 
specific markers (Hickey and Kimura,  1988).
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Figure 1.3  Origins and development of microglia.
Microglia  develop  as  monocytes  from  bone  marrow  before  entering  the  developing 
brain  as  amoeboid  microglia.  In  the  adult  brain  microglia  maintain  a  ramified  state, 
which  is thought to maintain  neuronal  health.  During disease  microglia may  become 
activated  which  can  be  harmful  to  neurones  and  surrounding  cells.  Adapted  from 
Kazuyuki et al., (2001).28
1.2.2  Microglia in the developing brain
Large  numbers  of CNS  macrophages  are  found  in  the  developing  brain  during 
the late stages of embryogenesis at time points that correlate with the rapid upregulation 
in  naturally  occurring  neuronal  apoptotic  cell  death,  which  is  a  vital  feature  of 
development  (Oppenheim,  1981).  These  large  populations  of macrophages  generally 
disappear by the late postnatal period (Ling and Wong,  1993). It has been suggested that 
the  recruitment  of  CNS  macrophages  is  driven  by  the  chemotactic  stimulus  of 
degenerating cells (Perry et al.,  1985). Indeed large numbers of amoeboid microglia are 
present in the developing corpus callosum at sites of axonal loss (Frei et al,  1988).
Antigen microglia amoeboid microglia
F4/80 ++ ++
FcR ++ ++
CR3 ++ ++
CD45 +/- +
CD4 +/- +
MHC class II +/- +
EDI - ++
Table 1.1  Antigens  expressed  on  ramified  and  amoeboid  microglia.
++  strong  expression,  +  moderate  expression,  +/-  weak  expression,  -  no 
expression. Adapted from Perry and Gordon (1989).
1.2.3  Microglial structure and morphology
Microglia were  first described  by Rio-Hortega  in  silver-carbonate  stained  brain 
slices  at  the  light  microscope  level  as  a  morphologically  distinct  cell  type  with  long 
branched  processes  (see  Ling  and  Wong,  1993;  Banati  and  Graeber  1994).  This 
downregulated  immunophenotype  is  indicative  of  microglial  cells  ‘at  rest’  (Figure 
1.4A).  Microglial  activation  is associated with cell  transformation to  macrophages and 
is a continuous rather than an all or nothing response causing a range of morphological29
changes  from  retraction  of  processes  to  full  conversion  into  condensed,  granular 
amoeboid cells (Figure  1.4B).  The functional activation state of microglia is dependent 
on several factors including the extracellular matrix substrate and cytokine composition 
of the  microenvironment (Milner and  Cambell  2003).  Different patterns  of microglial 
activation will in turn have distinct consequences for surrounding tissues (Morgan et al., 
2005). Microglial morphology mirrors different functional states including cytokine and 
chemokine release, altered ion channel and cell surface antigen expression, chemotactic 
movement and phagocytic behaviour (Hanisch, 2002).
Amoeboid  or  immature  microglia  are  found  in  perinate  and  neonate  brains. 
Amoeboid  cells  transform  into  ramified  cells  during  postnatal  development  (Ling, 
1981). Amoeboid microglia express increased expression of CD4 in rats and  leukocyte 
common antigens (CD45), which may be a reflection of plasma protein infiltration into 
the cerebrospinal  fluid (CSF)  in  immature brains as  both  plasma protein concentration 
in  CSF,  and  CD4  and  CD45  expression,  decrease  in  the  maturing  CNS  (Perry  and 
Gordon,  1987).  This  suggests  that damage to the  BBB  could  result  in  upregulation  of 
macrophage  antigens  on  microglia.  It  has  become  clear  that  changes  in  the  CNS 
microenvironment regulate the  morphology and  expression  of cell  surface  antigens on 
microglia,  thus  influencing  their  expression  of  cytoplasmic  enzymes  and  secretory 
factors (Aloisi et al., 2000; 2001).
Resting  microglia  have  rod  shaped  cell  somata,  indeed  the  first  description  of 
microglia  by  Franz  Nissl  in  1899  used  the  term  ‘rod  cells’  to  depict  their  ramified 
morphology.  Observation  by electron  microscopy  (EM)  shows that ramified  microglia 
have flattened or angular nuclei (Ling and Wong,  1993). Resting microglial cells extend 
long  processes  from  their  somata,  which  collectively  form  a  network  that  covers  the 
parenchyma,  although  it  is  rare  that  microglial  processes  overlap  or  touch.  Ramified 
microglia  lack  hydrolytic  enzymes  and  the  capacity  to  engulf particles.  Interestingly,30
recent studies using two  photon  microscopy  have  shown  that resting  microglia are  not 
as quiescent as was previously assumed (Davalos et al., 2005; Nimmerjahn et al., 2005). 
Although cell somata remained fixed, the branching microglial processes are extremely 
motile  and  directly contact astrocytes,  neurones  and  blood  vessels  (Nimmerjahn et al., 
2005),  which  further  suggests  that  resting  microglia  maintain  and  monitor  the  CNS 
microenvironment.
Microglial  activation  is  a  graded  response  to  pathogenic  insult.  Activation 
stimulates proliferation and migration to the site of injury and results in morphological, 
immunophenotypic  and  functional  changes  (Kreutzberg,  1996).  Morphologically, 
activation causes microglia to retract processes and become more rounded and granular 
resembling  amoeboid  cells.  Observation  by  EM  shows  rounded  nuclei  and  large 
amounts  of cytoplasm  containing  Golgi  apparatus,  rough  endoplasmic  reticulum  (ER) 
and  numerous  lysosomal  and  phagosomal  granules  (Ling  and  Wong  1993). 
Immunophenotypic  changes  include  upregulation  of  immune  molecules  such  as  the 
CR3  complement receptors (CD1 lb) and the major histocompatibility complex (MHC) 
class  I  and  II  antigens  (Graeber  at  al.,  1988,  1989,  Streit  et  al  1989)  required  for 
phagocytic  and  antigen  presenting  functions  respectively.  Functionally,  activated 
microglia  release  a  number  of  inflammatory  mediators  including  reactive  oxygen 
species, nitric oxide, glutamate, cytokines such as interleukin  1   (IL-ip), tumour necrosis 
factor  a  (TNF-a),  interferon  y  (IFN-y)  and  transforming  growth  factor  p  (TGF-p) 
(Gerbicke-Haerter,  1996).
Figure  1.4  Morphology  of 
ramified  and  activated 
primary microglia
Primary  microglia  were 
stained  with  fluorescein 
diacetate to show (A),  resting/ 
ramified  and  (B).  activated 
microglia  (x400
magnification).  Photographs: 
Dr. J M Pocock31
Most  scientists  agree that  microglia are  a distinct cell  type.  Indeed  microglia, 
unlike  macrophages  have  a  distinctive  ramified  morphology  and  the  capacity  to 
proliferate  in  vitro  (Giulian  and  Baker,  1986).  Microglia  have  also  been  shown  to 
express spikes on their membranes in comparison to the smooth or ruffed appearance of 
macrophage membranes (Giulian et al.,  1995). However, upon activation microglia and 
macrophages share most phenotypical markers and can exert similar effector functions. 
The  differentiation  between  macrophages  that  have  infiltrated  the  CNS  due  to  BBB 
breakdown, perivascular macrophages and resident microglia is therefore very difficult 
and a primary concern when using brain sections.  While most of the work in this study 
used  primary microglia cultured  in vitro, the  lack of a purely microglial marker made 
differentiation between microglia and macrophages in brain sections impossible.
1.2.4  Substances released from activated microglia
Activated microglia constitutively and  inducibly express or release a number of 
CNS signalling ligands, which facilitate the rapid induction of inflammation and can be 
deleterious  to  neuronal  survival.  These  substances  have  been  implicated  in  neuronal- 
glial  interactions through activation and inhibition of pathways that regulate cell death 
or survival, proliferation, and activation.
1.2.4a  Cytokines
Many  cellular  interactions  between  tissues  in  the  body  rely  on  the  production 
and  transfer  of cytokines  and  chemokines.  These  signalling  proteins  are  produced  by 
numerous  cell  types  and  control  cell  differentiation,  growth  and  survival  (Hanisch,
2002),  and  furthermore,  control the  processes and  outcome  of traumatic  infections  or 
degenerative  insults  (Hopkins  and  Rothwell,  1995).  Activated  microglia  have  been 
shown to release a number of cytokines. These include IL-ip, which has been shown to32
enhance  activation  of the  immune  response  including  the  astrocytic  contribution  to 
inflammatory processes  (Giulian  et al.,  1987),  FasL  (Badie  et al.,  2000;  Terrazzino  et 
al., 2002), and TNFa (Hanisch et al., 2002, Taylor et al., 2005).
Fas  (CD95)  is  a  member  of a  large  family  of cytokines  that  includes  TNFp 
(lymphotoxin) and tumour necrosis factor alpha (TNFa).  These cytokines exert effects 
on  the  inflammatory  response,  cell  death  and  proliferation  (Vilcek  and  Lee,  1991; 
Gebicke-Haerter,  2001).  The  death  inducing receptor Fas  is  involved  in  the  apoptotic 
pathway and is released by activated microglia. Both Fas ligand (FasL) and its receptor 
Fas  show  upregulated  expression  in  acute  and  chronic  neurobiological  conditions 
(Dowling et al.,  1996;  D’Souza et al.,  1996;  Felderhoff-Mueser et al.,  2002),  and may 
contribute  to  neurotoxicity  by  inducing apoptosis  (Griffith  et  al.,  1995;  Nagata  et  al.,
1999).  Furthermore,  recent  studies  have  demonstrated  that  the  neurotoxic  effects  of 
microglial TNFa release are dependent on the co-release of FasL (Taylor et al., 2005).
TNFa binds two receptors, p55 (TNFR1) and p75  (TNFR2) with equal affinity. 
These  receptors  are  linked  to  different  signal  transduction  pathways  (Mattson  et  al., 
1997).  Both  receptors  are  expressed  by  microglia  in  vitro  (Dopp  et  al.,  1997).  TNFa 
stimulation of TNFR1  has been shown to induce apoptosis and activation of NF-kB thus 
leading to  induction  of proinflammatory and  immunomodulatory  genes  (Tartaglia and 
Goeddel,  1992),  whereas  stimulation of TNFR2  can  be  protective  (Yang et al.,  2002). 
The  inflammatory  response  has  enormous  capacity  for  amplification  therefore 
necessitating  in-built  mechanisms  for  its  modulation  and  suppression.  It  has  recently 
been shown that cerebellar granule cells (CGCs) in culture constitutively express higher 
amounts  of apoptosis  inducing  TNFR1,  thus  rendering  them  particularly  sensitive  to 
microglial TNFa secretion (Taylor et al., 2005).
TNFa is primarily produced by macrophages and microglia and is constitutively 
released at very low levels by ramified unstimulated microglia (Lee et al., 2002; Taylor33
et al., 2005). Low levels of TNFa can also induce neuroprotective effects (Carlson et al.,
1999),  such  as  enhancing the  survival  of cultured  hippocampal  and  cortical  neurones 
(Cheng  et  al.,  1994).  However  TNFa  is  also  associated  with  early  release  from 
microglia  following activation  (Taylor et al.,  2005).  TNFa  in  turn  activates  microglia 
potentiating  the  release  of  further  neurotoxic  substances  (Gebicke-Haerter,  2001). 
Although not directly neurotoxic to neurones in culture (Ciesielski-Treska et al.,  1998; 
Taylor  et  al.,  2005),  TNFa  becomes  neurotoxic  when  released  as  a  glial-derived 
inflammatory response and has been shown to act  in concert with  FasL (Taylor et al.,
2005)  and glutamate release (Floden et al., 2005).
1.2.4b  Reactive oxygen and nitrogen species
Initiation  of microglial  phagocytosis  results  in  upregulation  of nicotinamide- 
adenine-dinucleotide  phosphate  (NADPH)  (Ueyama  et  al.,  2004).  Electrons  from 
NADPH are transferred by the flavocytochrome oxidase enzyme to molecular oxygen to 
form  reactive  oxygen  species  (ROS).  The  reaction  catalysed  by  NADPH  can  be 
summarised by
NADPH + 0 2 ------►   NADP+ + .0 2'
The  small  superoxide  anion  can  then  be  converted  to  hydrogen  peroxide  by 
superoxide  dismutase  and  then  to  hydroxyl  radicals  (*OH  ).  Each  of these  reactive 
oxygen  products  are  highly  reactive  and  are  released  as  part  of  the  inflammatory 
response  to  kill  invading  pathogens  especially  those  engulfed  by  phagocytosis  (Roitt 
and Delves, 2003).
Nitric oxide (NO), as well as performing as a physiologic mediator (Chen et al.,
2000), is involved in the innate inflammatory response and can operate against invading34
microorganisms  in  the  cytosol.  Inducible  nitric  oxide  synthase  (iNOS)  is  the  enzyme 
responsible for production of NO  from the terminal nitrogen atom of L-arginine in the 
presence of NADPH and O2 (Minghetti et al.,  1997).
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Inducible  nitric  oxide  is  implicated  in  the  pathogenesis  of  inflammatory 
demyelinating  diseases,  as NO  and  peroxynitrite  are toxic  to  oligodendrocytes,  axons 
and  neurones,  inhibiting  mitochondrial  respiratory  chain  complexes,  reducing  ATP 
levels, and causing Na/Ca influx (Bolafios et al.,  1994, Ding et al.,  1997). Insult induced 
activation of microglia initiates the production of NO and reactive oxygen intermediates 
(Taupenot et  al.,  1996;  Kingham  et al.,  1999),  which  are  toxic to  neurones  in  culture 
(Thery et al.,  1991).  Furthermore, NO can react with the superoxide free radicals (02 ) 
that  are  also  released  by  microglia  (Woodroofe  et al.,  1989)  and  can  form  the  highly 
reactive peroxynitrite (ONOO“), which can be toxic to neurones (Kim and Ko.,  1998). 
Cytokines also have  an effect on  iNOS expression and NO release,  indeed  it has been 
shown that TNFa and NO may mutually provoke the release of the other in vitro (Sun et 
al,  1998). Although it has now been suggested that the toxic effects ascribed to NO may 
in  fact  be  due  to  peroxynitrite  and  other  metabolic  derivatives,  it  is  clear  that  either 
directly or indirectly,  NO release can have  detrimental  consequences for tissues  in the 
CNS.35
1.2.4c  Glutamate
Glutamate  is the  primary  excitatory transmitter  in the  mammalian  CNS  and  is 
responsible for fast synaptic transmission. Glutamate is one of the 20 amino acids in the 
body that are the ‘building blocks’ of protein and is therefore abundant in all cells of the 
body  including  neurones.  Glutamate  is  released  from  presynaptic  vesicles  by  Ca2+ 
dependent  mechanisms.  However,  excessive  glutamate  release  can  lead  to 
excitotoxicity.  High extracellular glutamate has been associated with  influx of Na+ and 
Ca2+ through both ligand and voltage gated channels leading to raised intracellular Ca2+ 
activation of a range of enzymes and cell death (Meldrum and Garthwaite,  1990).
Although  low  levels  of  glutamate  agonists  have  been  shown  to  be 
neuroprotective  against  subsequent  excitotoxic  neurotoxicity  (Chuang  et  al.,  1992),  it 
has  also  been  demonstrated  that  glutamate  can  induce  N-methyl-D-aspartate  (NMDA) 
mediated neurotoxic effects (Piani et al,  1991,  Piani and Fontana  1994,  Kingham et al., 
1999). Activated microglia release glutamate, furthermore it has been demonstrated that 
glutamate is a major component of activation induced microglial neurotoxicity (Piani et 
al.,  1991,  1992;  Patrizio and  Levi  1994).  Glutamate  release from  microglia occurs  via 
the  cysteine-glutamate  antiporter  and  through  a  bafilomycin  A-sensitive  mechanism 
(Kingham et al.,  1999), which may in turn lead to activation of microglial metabotropic 
glutamate  receptors  (mGluRs).  Excess  glutamate  can  also  prevent  the  uptake  of 
cysteine,  a  necessary  building  block  of  glutathione.  Glutathione  is  known  to  afford 
significant protection  from  injury associated  with  oxidative  stress  (Ishida et al.,  2006; 
Shih et al., 2006).36
1.3  Glutamate receptors
Glutamate  is  the  primary  excitatory transmitter  in  the  mammalian  CNS  and  it 
acts  through  a number  of ionotropic  (ligand  gated  cation  channels)  and  metabotropic 
receptors. Metabotropic receptors are coupled to guanosine triphosphate (GTP)-binding 
proteins more commonly known as G-proteins.  Fast synaptic transmission  is mediated 
primarily  by  ionotropic  glutamate  receptors  (iGluRs)  but  metabotropic  glutamate 
receptors  (mGluRs)  also  contribute  by  coupling  with  G-proteins  and  thus  controlling 
membrane enzymes and ion channels.
1.3.1  Ionotropic glutamate receptors
There  are  three  types  of iGluRs which  are  named  after the  agonists that were 
originally found to activate them (Figure  1.5). They are NMDA, a-amino-3-hydroxy-5 - 
methyl-4-isoazolepropionic  acid  (AMPA)  and  2-carboxy-3-carboxymethyl-4- 
isopropenylpyrrolidine (Kainate) receptors, which share common structural features that 
place them within one superfamily. AMPA and NMDA receptors mediate the majority 
of fast excitatory transmission in the brain.
AMPA receptors are permeable to Na+ and K+ and are impermeable to Ca2+. At 
negative membrane potentials, activation of AMPA receptors leads to influx of Na+ ions 
into the cell causing depolarisation. NMDA receptor activation also results in Na+ influx 
but in contrast to AMPA receptors, NMDA receptors are permeable to Ca2+ ions and the 
inward ionic current is voltage dependant. This is caused by blockade of the receptor by 
Mg2+ ions which block the pore at normal negative membrane potentials (Mayer et al., 
1984;  Nowak  et  al.,  1984).  Only  when  the  membrane  becomes  depolarised,  usually 
following  AMPA  receptor  activation,  are  these  Mg2+  ions  removed.  This  results  in37
influx of Ca2+ through the NMDA  receptor leading to  intracellular signalling cascades, 
which can induce long lasting changes in synaptic transmission (Nakanishi et al.,  1998).
Excessive  activation  of  iGluRs,  however  causes  neuronal  death  through 
excitotoxicity  as  they  are  the  main  routes  for  Ca2+  entry  into  the  neurone.  Damage 
occurs  due  to  Ca2+  induced  stimulation  of intracellular enzymes  that  break down  vital 
neuronal  proteins,  lipids  and  nucleic  acids  (Doble,  1995).  The  targeting  of iGluRs  for 
therapeutic use has therefore several  limitations, namely  interference with fast synaptic 
transmission or increased  risk of excitotoxic damage.  Modulation of mGluR activation 
has  thus  become  an  increasingly  important  treatment  strategy  as  this  route  minimises 
these  adverse  side  effects.  Indeed,  mounting  evidence  suggests  that  stimulation  of 
mGluR  subtypes  mediate  distinct  facilitatory  or  inhibitory  actions  on  neuronal 
excitation  and  excitability  and  may  therefore  be  of  therapeutic  benefit  in 
neurodegenerative processes (Nicoletti et al.,  1996).
Glutamate
Figure 1.5  Neuropharmacology of iGluR synaptic transmission.
Each  ionotropic  glutamate  receptor  subtype  is  named  after  the  original 
chemical agonist found to activiate them.  Each iGluR subtype also has several 
splice variants. Adapted from Watkins, (2000).
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1.3.2  G-protein coupled receptors
Most  signalling  between  cells  depends  upon  the  release  of soluble  molecules 
that  bind  to  receptors  on  a target  cell  subsequently  inducing  a  signalling  cascade.  G- 
proteins  are  frequently  used  to  communicate  extracellular  signals  received  at the  cell 
surface  receptor  into  intracellular responses.  Most G-protein coupled  receptors  consist 
of a polypeptide with seven membrane spanning alpha helices. Two of the extracellular 
loops of the polypeptide form the transmitter binding sites, while two of the intracellular 
loops can bind to and activate G-proteins. Structural variations on the intracellular loops 
determine  which  G-proteins  and  therefore  which  effector  systems  are  activated.  The 
intracellular  C-terminus  regulates  receptor  activity  by  interacting  with  proteins 
including calmodulin (Bhave et al., 2003; Pin et al., 2003).
1.3.2a  G-protein coupled effector mechanisms
Each  G-protein  has  three  subunits  a  p  and  y.  Unactivated  G-proteins  have  a 
guanosine diphosphate (GDP) molecule bound to their a subunit and the whole complex 
is  mobile  on  the  intracellular  membrane.  When  the  G-protein  binds  to  an  activated 
metabotropic  receptor,  the  GDP  is  exchanged  for  a  guanosine  triphosphate  (GTP) 
molecule  thus  activating the  complex  resulting  in  a  conformational  change  in  the  Ga 
subunit which decreases its affinity to the Gpy subunit. The dissociated Ga + GTP and 
Gpy subunits can then stimulate or inhibit specific effector pathways (Bear et al., 2001). 
These  include direct activation of potassium channels or the production of intracellular 
second  messengers  such  as  adenylate  cyclase  (AC)  (Rodbell  et  al.,  1971)  and 
phosholipase  C  (PLC)  (Abbracchio  et  al.,  1995;  Baek  et  al.,  1996).  Other  second 
messenger pathways activated by G proteins  include MAPK (Blaukat et al.,  2000) and 
ion  channels  (Postma  et  al.,  1996;  Komwatana et  al.,  1998).  G-proteins  can  be  either 
stimulatory  or  inhibitory  and  consequently  modulate  positive  or  negative  effects  ondownstream signalling (Bear et al., 2001). The signal  is terminated by GTPase activity 
of the Ga subunit which hydrolyses the bound GTP to GDP causing re-association with 
Gpy allowing the cycle to begin again (Figure  1.6). There are four major subfamilies of 
G-proteins;  these  are  Gs,  G*, Gq,  G12,  which  vary  in the  composition  of the  a  subunit 
(Fields and Casey,  1997) (Table  1.2).Receptor
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Figure 1.6  Mode of activation of G proteins.
(A)  In  its  inactive  state  the  a  subunit  of  the  G  protein  binds  GDP.  (B )  When  a 
transmitter activates the G-protein coupled receptor the GDP is exchanged for GTP. (C) 
Activation  causes  the  G  protein  to  split  and  the  Ga  with  GTP  subunit  activates  an 
effector  protein.  (D )  The  Ga  subunit  removes  the  phosphate  (P O 4)  from  GTP  thus 
converting it back to GDP and terminating activity and allowing Ga and G|3y subunits to 
rejoin allowing the cycle to begin again. Adapted from Bear et al., (2001).
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subfamily Ga subunit Signalling pathway
Gz U Adenylate cyclase
Gj, U Adenylate cyclase
Gi2 li Adenylate cyclase
G, Gj3 U Adenylate cyclase
Go U Ca2+ channels
Gk fl K+  channels
Gt fl cGMP-PDE
Gs Gs
ft Adenylate cyclase
G,2
G,2
g ,3
Gq ft phospholipase C p
G,
G]4
G,5
ft phospholipase C p 
ft phospholipase C p
G]6 ft phospholipase C p
Table 1.2  Mammalian G-protein families.
G-proteins are subdivided on the basis of their subunit composition and 
can  be  further  subdivided  in  relation  to  further  variations  within  the 
subunit.  Stimulation  either  upregulates  (  ft  )  or  inhibits  (  U  )  the 
indicated second messenger pathway. (Adapted from  Fields and Casey,
1997).
1.3.2b  Second messenger cascades
Activated  G-proteins  can  either  activate  or  inhibit  several  membrane  bound 
enzymes.  These  include  AC  which  converts  ATP to  cAMP  and  subsequently  leads  to 
activation of protein kinase A (PKA) (Figure  1.7). Another pathway involves activation 
of PLC  (Abbrachio  et  al.,  1995,  Baek  et  al.,  1996),  which  then  acts  on  a  membrane 
phospholipid  causing  it  to  split  into  diacylglycerol  (DAG)  which  activates  protein 
kinase C (PKC), and  inositol-1,4,5-triphosphate (IP3), a water soluble molecule (Figure 
1.8).  Diffusion of IP3  into the cytosol  allows binding to  IP3   gated  calcium  channels onorganelles resulting in Ca2+ release, which can trigger activation of calcium-calmodulin- 
dependent  protein  kinase  (CaMK)  (Berridge,  1984).  Activation  of  protein  kinases 
triggers phosphorylation of proteins.  This process changes the conformation of a given 
protein  and  therefore  affects  its  function.  Indeed  the  phosphorylation  of ion  channels 
results in an altered functional state (Gudenmann et al.,  1997).
Second messenger cascades are  important for several reasons.  Primarily,  signal 
cascades  allow  amplification  of  a  given  signal.  Also,  the  use  of  small  diffusible 
messengers permits signalling over a distance instead of in localised areas. Furthermore, 
the generation of more long lasting chemical changes is possible and the many stages of 
a  second  messenger  cascade  allow  downstream  regulation  or  interaction  from  other 
systems (Bear et al., 2001).43
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Figure  1.7  Stimulatory  or  inhibitory effects  of G  proteins  coupled  to  adenylate 
cyclase.  (1)  Binding of transmitter to  stimulatory  G  proteins  (Gs)  leads to  activation 
(green  arrows)  of adenylate  cyclase,  which  generates  cAMP,  which  in  turn  activates 
the  downstream  enzyme  protein  kinase  A.  (2)  Binding of transmitter to  inhibitory  G 
proteins (G j)  leads to inhibition (red lines) of adenylate cyclase activity. Adapted from 
Bear et al., (2001).
Figure 1.8  Second messengers generated by stimulation of phospholipase C
(1)  Various  G-proteins  stimulate  the  enzyme  PLC  which  acts  on  membrane 
phospholipid  PIP2-   (2)  PIP2  is  split  into  DAG  and  IP3  (3)  DAG  stimulates  the 
downstream enzyme PKC. (4)  IP3  stimulates IP3 gated Ca2+ channels on smooth ER 
and other organelles  inducing release of Ca2+ from  intracellular stores which can go 
on to stimulate downstream enzymes. Adapted from Bear et al., (2002).44
1.3.2c  MAPK cascade
The  transmission  of  extracellular  signals  into  their  intracellular  targets  is 
mediated  by a network of interacting proteins that regulate a  large  number of cellular 
processes.  The  mitogen  activated  protein  kinase  (MAPK)  signalling  cascade  involves 
activation  of  several  membrane  signalling  molecules  followed  by  a  sequential 
stimulation  of  several  cytoplasmic  protein  kinases  collectively  known  as  mitogen- 
activated protein kinases (Seger and Krebs,  1995).
Mitogen-activated  protein  kinases  are  serine/threonine-specific  protein  kinases 
that respond to extracellular stimuli (mitogens) and regulate various cellular activities, 
such as gene expression, mitosis, differentiation, and cell survival/apoptosis (Pearson et 
al., 2001). MAPK pathways are linked to many G-protein linked cell surface receptors 
and  as  such,  a host of signalling molecules  including cytokines  and  neurotransmitters 
can  selectively  activate  these  cascades  via  receptor  activation  of intracellular  second 
messengers. All MAPK pathways operate through sequential phosphorylation events to 
phosphorylate transcription factors and regulate gene expression (Tamura et al., 2002).
Several MAPK cascades have been identified in mammalian cells, including the 
extracellular signal-regulated kinase pathways (ERK1/2, ERK5) and the stress activated 
kinase  pathways,  c-Jun  N  terminal  (JNK)  and  p38  MAPK.  Extracellular  signal- 
regulated  kinases  are  widely  expressed  and  are  involved  in the  regulation  of meiosis, 
mitosis,  and  post-mitotic  functions  in  differentiated  cells.  Many  different  stimuli 
activate  the  ERK  pathway.  Phosphorylation  of ERKs  leads  to  the  activation  of their 
kinase activity (Boulton and Cobb,  1991).
Activated  Ras  activates  the  protein  kinase  activity  of  RAF  kinase,  a 
serine/threonine-selective  protein  kinase.  RAF  kinase  phosphorylates  and  activates 
MEK, another serine/threonine kinase.  MEK phosphorylates and activates extracellular 
signal-regulated kinase. The series of kinases from RAF to MEK to ERK is an example45
of a protein kinase cascade.  Such  series of kinases provide  opportunities  for feedback 
regulation and signal amplification (Avruch et al., 2001).
1.3.3  Metabotropic glutamate receptors
Functional mGluRs  possess a bi-lobed extra-cellular N terminal domain which 
contains the glutamate binding site.  In the absence of ligands or when antagonised, the 
bi-lobed  extracellular domain  of the  homodimer are  separated  into  an  open  formation 
(Kunishima et al., 2000). Once activated by a selective agonist they close together thus 
triggering  intracellular  signal  transduction.  An  extracellular cysteine  rich  region  links 
mGluRs  to  a  G-protein  coupled  receptor  transmembrane  heptahelical  domain  that 
mediates G-protein activation (Kunishima et al., 2000).
To date, eight members of the mGluR family have been identified (mGluR 1-8). 
These  have  been  divided  into  subgroups  based  on  sequence  homology,  second 
messenger  coupling  and  pharmacology.  Group  I  subtypes  include  mGluRl  (splice 
variants  a,  b,  c,  d,  e and  g)  and  5  (splice  variants  a and  b),  group  II  subtypes  include 
mGluR2 and 3, and group III  subtypes which include mGluR4 (splice variants a and b) 
mGluR6,  mGluR7  (splice  variants  a  and  b)  and  mGluR8.  All  mGluRs  belong  to  the 
family C  G-protein coupled  receptors.  Group  I  mGluRs  couple  via the  Gq /Gn  to  PLC 
(De  Blasi  et al.,  2001).  Group  I  mGluRs  are  unlike  other subgroups  in  that the  splice 
variants,  mGluR la  and  mGluR5a  and  b,  are  directly  coupled  to  the  IP3  receptors  on 
endoplasmic reticulum by homer proteins (Xiao et al.,  1998; Tu et al.,  1998), which are 
involved in mGluR trafficking (Ango et al., 2002). The group II and III receptors couple 
via  Gj-protein  to  inhibit  AC  activity  and  are  negatively  coupled  to  forskolin  sensitive 
cAMP production. (Reviewed by Kew and Kemp, 2005).
A  number  of agonists  and  antagonists  for  metabotropic  glutamate  receptors  are 
highly selective for members within each group. Agonists bind the receptor and mimick46
the  action of endogenous  ligands  while  antagonists  block  receptors  from  activation  by 
agonists.  Although  a  number  of  splice  variants  have  been  shown  to  exist  for  many 
receptors,  these  generally  involve  changes  in  amino  acid  structure  down-stream  from 
the  N-terminal  domain,  and  therefore  don’t  generally  affect  the  pharmacology  of the 
receptor for agonist or antagonist binding (O'Hara et al.,  1993).
The  compounds used  in this  study (Table  1.3)  included  ADA  a group  I  selective 
mGluR  agonist  with  more  potency  at  mGluR5  than  mGluR 1   (Klein  et  al.,  1997).  A 
relatively  potent  and  selective  antagonist  of group  I  mGluRs,  AIDA,  was  used  which 
had  no effect on  group  II  or group  III receptors  nor on  ionotropic  glutamate  receptors 
(Moroni  et  al.,  1997).  The  group  II  receptor agonists  included  DCIIV  a  highly  potent 
agonist for group II mGluRs (Brabet et al.,  1998), and NAAG a highly selective agonist 
for  the  subtype  mGluR3  with  very  weak  activation  of NMDA  receptors.  MCCG,  a 
selective  antagonist  of  group  II  mGluRs  (Thomas  et  al.,  2000)  was  used  to  block 
activation  of the  group  II  subtype.  The  group  III  agonist  used,  AP4,  was  selective  for 
group  III  receptors  alone  (Tones  et  al.,  1995).  However,  MAP4,  although  a  selective 
antagonist for group III  mGluRs,  has also  been  shown to have group  II  and  III  agonist 
properties in some neurochemical systems (Sekiyama et al.,  1996).
Subtypes Selective Agonists Antagonists
Group I mGlul,  mGlu5 DHPG
ADA
AIDA
Group II mGlu2,  mGlu3 DCG-IV
L-CCG
NAAG  only mGlu3
MCCG
Group III mGlu4, mGlu6, 
mGlu7, mGlu8
AP4 MAP4
Table 1.3  Agonists and antagonists used for specific groups of mGluRs
To  date  eight  subtypes  of the  mGluR  family  have  been  identified.  These  have  been 
divided  into subgroups based on sequence homology, second messenger coupling and 
pharmacology.  Subgroups  of mGluRs  can  be  specifically  stimulated  or  inhibited  by 
selective agonists and antagonists.47
1.3.3a  Microglial metabotropic glutamate receptors
Microglia  possess  functional  group  I,  II  and  III  mGluRs.  To  date,  microglia 
have been shown to express mGluR5 (Biber et al.,  1999) mGluR2 and mGluR3 (Taylor 
et al., 2002) mGluR4, mGluR6 and mGluR8 (Taylor et al., 2002, 2003). Glial cells play 
a  vital  role  in  maintaining  glutamate  homeostasis  and  are  also  a  primary  source  of 
glutamate  released  during  excitotoxic  stress  in  pathological  conditions.  This  suggests 
that  excess  glutamate  released  from  either  neurones  or  microglia  themselves  may 
stimulate  microglial  mGluRs  culminating  in  a  cycle  of activation  and  neurotoxicity 
(Taylor  et  al.,  2002).  As  such,  control  of  microglial  reactivity  by  modulation  of 
microglial  mGluRs  may  be  a  potential  therapeutic  strategy  in  neurodegenerative 
diseases where microglial activation is implicated.
1.3.3b  Neuronal metabotropic glutamate receptors
Metabotropic  glutamate  receptors  can  influence  fast  synaptic  transmission  by 
activation  of slow  excitatory  postsynaptic  potentials  but  in  general  they  have  a  more 
modulatory  role  that  includes  the  regulation  of  neuronal  excitability,  synaptic 
transmission  and  plasticity.  Neuronal  group  I  mGluRs  are  typically  found  post 
synaptically in somatodendritic neurones and are thought to increase neuronal excitation 
thus  reinforcing  excitatory  synaptic  transmission  (Sourdet  et  al.,  2003).  In  contrast, 
neuronal group II and III receptors are localised at presynaptic terminals away from the 
active  zone  of neurotransmitter release  (Nolan  and  Logan,  1998).  Activation  of these 
receptors  decreases  neuronal  excitation and  glutamate  release,  but only  in  response to 
concentrations  of  glutamate  high  enough  to  spread  back  to  presynaptic  regions 
(Holscher et al.,  1999;  Cartmell  and  Schoepp,  2000).  Stimulation of neuronal  mGluRs 
has been shown to induce neuroprotective effects although these results remain open to 
conjecture.48
Hippocampal  (Blaabjerg  et  al.,  2003)  and  CGC  (Pizzi  et  al.,  1996)  neurones 
could  be  protected  from  subsequent excitotoxicity  by pre-incubation  with  the  group  I 
agonist  3,5-Dihydroxyphenylglycine  (DHPG)  which  resulted  in  reduced  NMDA 
mediated  inward  currents  suggesting  inhibition  of  NMDA-receptor  function.  The 
DHPG  conferred  neuroprotection  was  inhibited  by  mGluRl  but  not  mGluR5 
antagonism  suggesting  that  this  effect  was  due  to  activation  of the  mGluRl  subtype 
alone (Blaabjerg et al., 2003).
It has been found that Alzheimer’s disease  (AD)  patients show upregulation of 
neuronal  group  II  mGluR2  expression,  which  was  closely  associated  with 
hyperphosphorylated  tau deposition and  correlated  with  the  severity of neurofibrillary 
pathology (Lee et al., 2004). However, activation of group II neuronal mGluRs has also 
been  shown  to  be  neuroprotective,  where  group  II  mGluR  agonists  reduced  neuronal 
degeneration  induced  by  hypoxia  and  glucose  deprivation  (Buisson  and  Choi.,  1995), 
and  similarly  reduced  the  death  of  neurones  in  vitro  after  exposure  to  cytotoxic 
concentrations of NMDA  (Bruno et al.,  1994;  Battaglia et al.,  1998).  It is possible that 
increased  mGluR2  expression  in  AD  is  a compensatory  response  to  neuronal  damage 
attempting to reduce excitability and subsequent excitotoxicity.
Stimulation of group III neuronal mGluRs can also be neuroprotective. Using a 
model of diffuse brain injury (DBI) in rats, it has been demonstrated that injection of the 
group  III  agonist  L-AP4  protects  against  neuronal  damage  and  promotes  improved 
motor  and  cognitive  performance  compared  with  controls.  Group  III  expression  was 
also markedly upregulated after DBI especially in the area of impact, again suggesting a 
compensatory response (Zhou et al., 2004).
It has  been  proposed that the timing of mGluR agonist treatment  is the  crucial 
mediator  of neuroprotection.  Indeed  pre-treatment  of neuronal  cultures  is  thought  to 
transiently  increase  calcium  influx  thus  inducing  sensitisation  or  internalisation  of49
neuronal  NMDA  receptors  that  in  turn  causes  a  weakened  response  to  subsequent 
exposure to NMDA (Baskys and Blaabjerg 2005).
1.3.3c  Oligodendroglial metabotropic glutamate receptors
Metabotropic  glutamate  receptors  3  and  5  are  highly  expressed  in 
oligodendrocyte progenitor cells (OPC) and mature oligodendrocytes (OL), although in 
mature  OLs  mGluR5  expression  is  markedly  reduced  (Deng  et  al.,  2004;  Luvt  et  al.,
2006). Activation of group I mGluRs on OLs reduces their vulnerability to excitotoxic 
insult  (Kellans  et  al.,  2001)  by  reducing  downstream  oxidative  stress  and  inhibiting 
ROS  accumulation  and  intracellular  glutathione  loss  (Deng  et  al.,  2004).  The  down 
regulation of mGluR5  in mature OLs results in a notably lowered response to the group 
I agonist compared with OPCs ( Luvt et al., 2006), which may explain the vulnerability 
of mature OLs to excitotoxic damage.
1.3.3d  Astrocytic metabotropic glutamate receptors
Astrocytes express subtypes from all three groups of mGluRs including mGluR 1  
(Agrawal et al.,  1998), mGluR5 (Biber et al.,  1999), and mGluR2, 3, 4, 6 and 7 (Yao et 
al.,  2005).  Studies  have  shown  that  activation  of group  II  and  group  III  mGluRs  on 
astrocytes  can  be  neuroprotective  via  restoration  of the  capacity  for  glutamate  uptake 
and  increased  glutathione  levels  (Zhou  et  al.,  2006;  Yao  et  al.,  2005),  and  release  of 
TGFp  (D’Onofrio  et  al.,  2001;  Bruno  et  al.,  1998).  The  role  of  group  I  mGluRs, 
however  remains  uncertain.  Activation  of astrocytic  group  I  mGluRs  in  rat  astrocytes 
induced  a  significant  upregulation  in  their  capacity  to  take  up  aspartate  through 
activation  of  glutamate  transporter  1   (GLT-1)  (Vermeiren  et  al.,  2005).  The  same 
agonist  in human astrocyte  cultures,  however,  caused  a  significant down  regulation  of50
both  glutamate-aspartate  transporter  (GLAST)  and  GLT-1  protein  (Aronica  et  al.,
2003).
1.4  Neuronal glial interactions
Signalling  between  neurones  and  microglia  is  central  to  the  regulation  of 
microglial reactivity and neuronal survival (Cuzner and Woodroofe, 2002). The plethora 
of receptors  for CNS  signalling molecules expressed  by microglia suggests a complex 
role  in the  maintenance of the  CNS  microenvironment.  Ramified  microglia  in  normal 
conditions  are  known  to  actively  interact  with  surrounding  glial  cells  and  neurones, 
thereby  fulfilling  important  neurotrophic  roles  (Streit,  2002;  Davalos  et  al.,  2005; 
Nimmerjahn  et al.,  2005).  Indeed  ‘resting’  microglia  have  recently  been  shown  to  be 
surprisingly  active  with  highly  motile  processes  functioning  as  monitors  of  CNS 
microenvironment and  possibly facilitating rapid  responses to  brain  injury (Davalos et 
al., 2005; Nimmerjahn et al., 2005).
Normal  neuronal  activity  is  signalled  by the  release of fractalkine and ATP,  an 
activity  associated  transmitter,  stimulating  the  release  of  neurotrophic  factors  by 
neighbouring  microglia  (Hanisch  2002).  Indeed  substances  released  by  healthy 
neurones have been shown to neutralise the effects of microglial activators such as LPS, 
and  IFN-y  (reviewed  by  Aloisi  et  al.,  2001)  and  inhibit  microglial  TNFa  production 
(Mott  et  al.,  2004).  It  has  recently  been  demonstrated  that  interaction  of the  neuronal 
membrane  protein  CD200  with  the  myeloid  cell  receptor  CD200R  can  promote 
microglial  ramification  and  that  CD200  deficient  mice  show  increased  microglial 
activation  in  the  resting  CNS  (Hoek  et  al,  2000).  Other  glial  cells  such  as  astrocytes 
have  also  been  shown  to  down  regulate  microglial  activation  (Aloisi  et  al.,  1997).51
Neurotrophins  such  as  NGF,  BDNF  and  NT-3  are  capable  of  inhibiting  microglial 
expression  of MHC  class  II  antigens  and  the  co-stimulatory  molecules  implicated  in 
antigen  presentation  (Neumann  et  al.,  1998),  which  lead  to  initiation  of  the 
inflammatory  response.  However,  high  extracellular ATP  levels  associated  with tissue 
damage and in particular high ATP release from astrocytes induces microglial activation 
and  migration towards the  injury  site  (Davalos et al.,  2005).  The  release of neurotoxic 
factors may in turn activate more microglia, this cycle is also exacerbated by disruption 
o f‘calming’  inputs from damaged neurones (Figure  1.9).
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Figure.  1.9  Microglial and neuronal interactions
Microglia  release  neurotrophic  compounds  at  rest  which  are  thought  to 
promote  neuronal  survival.  Neurones  are  also  thought  to  release 
substances which  limit microglial  activation.  Upon  activation,  microglia 
release  neurotoxic  factors  which  induce  neuronal  death  therefore 
upsetting the  neurotrophic  communication  between  cells.  Adapted  from 
Hanisch et al., (2002).52
1.4.1  Microglial functions- cvtotoxic or neuroprotective role?
Although  microglia  monitor  and  maintain  neuronal  health,  promoting  growth 
and  development  (Hanisch,  2002),  few  pathological  disturbances  in  the  CNS  occur 
without their involvement (Kreutzberg,  1996).  Microglial  cells  are extremely  sensitive 
to  changes  in  CNS  homeostasis  and  become  activated  under  most  neuropathological 
circumstances  including  peripheral  nerve  injury,  trauma  and  stroke,  inflammatory 
disease  and  neurotoxic  injury  (Streit,  2000).  Involvement  of  microglia  in  the 
inflammatory  response  or  homeostatic  maintenance  seems  to  hang  in  a  precarious 
balance based on complex interactions within their microenvironment.
A  primary  characteristic  of  microglia  is  their  extremely  fast  activation  in 
response  to  changes  in  the  brain’s  structural  integrity  or  alterations  in  CNS 
microenvironment,  often  preceding  reactions  of  any  other  cell  type  in  the  CNS 
(Kreutzberg,  1996).  Microglia  can  be  activated  by  a  wide  variety  of  cytokines, 
neurotransmitters,  neurotoxins,  proteases,  and  extra-cellular matrix  molecules  released 
in  the  inflamed  CNS  and  once  activated  induce  further  inflammation.  (Raivich  et  al.,
2004).  Excessive  inflammation  in  the  CNS  can  lead  to  irreversible  neurone  loss  and 
atrophy  (Lehnardt  et al.,  2003).  The  effects  of microglial  activation  are  however  still 
uncertain.  Although  it  is  known that activated  microglia can  become  neurotoxic  it has 
also been suggested that activation may in some cases promote neuroprotection. Indeed, 
lesion  experiments  have  shown  that  activated  microglia  migrate  to  and  shield  injured 
areas by extension of their processes (Nimmerjahn et al., 2005).
Microglial  involvement  in the  inflammatory response  has become an  important 
area  of research  as  it  has  become  increasingly  apparent  that  many  neurodegenerative 
disorders  are  accompanied  by  immune  reactions  and  microglial  activation  (Mattson  et 
al.,  1997). Chronic microglial activation has been implicated in multiple sclerosis (MS), 
AD  and  Parkinson’s  disease  (PD)  (Gebicke-Haerter,  2001).  It  has  been  shown  that53
activated microglia release a number of potentially neurotoxic factors which can induce 
neuronal  damage.  Reducing microglial  reactivity  and  neurotoxicity  could therefore  be 
of therapeutic benefit in a number of CNS disorders (Nicoletti et al.,  1996; Pocock and 
Liddle, 2001).
1.4.2  Cell death
Two  structurally  and  biochemically  distinct types  of cell  death,  apoptosis  and 
necrosis  were  described  by  Kerr  et  al.,  (1972).  Necrosis  is  pathological  cell  death 
induced by departures from physiological conditions.  Disruptions to the  structural and 
functional  integrity  of the  plasma membrane  can  lead to  abnormalities  in  intracellular 
Na+  and  Ca2+  levels  and  inflammation  (Martin  et  al.,  1999).  The  other  form  of cell 
death, apoptosis, refers to the ability of cells to undergo programmed cell death (PCD). 
Apoptosis  is  generally  seen  as  physiological  cell  death  and  involves  active  intrinsic 
mechanisms  controlling  a  cell  death  pathway  (Payne  et  al.,  1995).  Each  form  of cell 
death can be recognised morphologically by several distinct characteristics (Table  1.4).54
Apoptosis Necrosis
Energy
requirement
ATP required for active process 
of apoptosis
No ATP required
Cells affected Isolated single cells Clusters of cells
Cell volume 
Homeostasis
Preserved in early stages Lost in early stages
Plasma
membrane
Preservation of integrity, 
blebbing of cell surface
Loss of integrity
Cytoplasmic
organelles
Compaction and contraction, 
formation of apoptotic bodies
Swelling of structures
Nuclear
chromatin
Condensation and fragmentation Karyolysis and pyknosis
DNA Internucleosomal fragmentation Random degradation
Cellular response No inflammation or neutrophilic 
infiltration
Marked inflammatory 
response with Leukocyte 
infiltration
Rate of 
progression
Normally ‘all or none’ 
phenomenon
Normally a ‘dose dependent’ 
phenomenon
Table  1.4  Cellular  features  of  apoptotic  and  necrotic  cell  death.
Adapted from Sathasivam et al., 2001.55
Laboratory  assays  for  apoptosis  include  the  TUNEL  assay  where  broken 
deoxyribonucleic acid (DNA) ends are  labelled preferentially although this method can 
also  detect necrotic cell death.  The  characteristic  bands  caused  by DNA  laddering can 
also be viewed by agarose gel electrophoresis (Otsuki and Shibata, 2003). However, the 
method  used  in this  study  was  direct  inspection  of pyknotic  condensed  nuclei  using  a 
fluorescence  microscope.  This  is  generally  agreed  to  be  a  safe  way  of  discerning 
between apoptotic and necrotic cells (Figure  1.10).  We also used a caspase assay which 
uses  inhibitors  of caspases  that  bind  covalently  to  active  caspases  and  have  a  green 
fluorescence.  Any unbound compound diffuses out of the cell  so the  fluorescent signal 
is a direct marker of how much active caspase 3 or 7 is expressed by the cells.
Figure 1.10  Morphology of apoptotic nuclei
(A)  Oligodendrocyte  cells  stained  with  Hoechst  which  is  a  nuclear  stain.  White 
arrows  show apoptotic  nuclei which are clearly condensed  and  pyknotic.  (B) Phase 
contrast image of the same field.  x400 magnification.56
1.4.3  Molecules involved in apoptosis
Apoptosis  can  be  mediated  by  both  intrinsic  and  extrinsic  pathways.  Extrinsic 
pathways  require  ligation  of  a  receptor  complex.  The  most  documented  extrinsic 
pathways  include  members  of the  TNF  superfamily,  TNF  and  Fas.  TNF  binds  with 
TNFR1  which  induces  activation  of  effector  caspases  (Chen  et  al.,  2002).  The 
interaction between Fas and FasL results  in activation of the death  inducing signalling 
complex  which  includes  the  Fas  associated  death  domain  (FADD)  and  activation  of 
caspases  8  and  10  (Wajant  et  al.,  2002).  Intrinsic  apoptosis  is  usually  a  response  to 
stress.  Mitochondria  contain  apoptogenic  factors  such  as  cytochrome  c  and  second 
mitochondrial  derived  activator  of caspases  (SMAC),  which  when  released  into  the 
cytosol  lead  to  activation  of caspases  (Zamzami  et  al.,  1998).  Members  of the  Bcl2 
family which are either pro-apoptotic (Bax, Bak, Bad) or anti-apoptotic (Bcl-xL,  Bcl2) 
control the release of these factors (Murphy et al., 2000).
Caspases belong to a family of proteases and are the effector cells of apoptosis 
(Figure  1.11).  As  with  other  multicomponent  cascades,  caspases  are  activated  by 
proteolytic cleavage of the proenzyme next in the chain.  Caspases function as initiators 
of cell  disassembly  in  response to  pro-apoptotic  stimuli,  or as effectors  with  an  active 
role  in  cell  destruction  through  regulation  of proteolytic  cleavages  (Slee  et al.,  1999). 
The  caspase  cascade  terminates  with  the  rapid  nuclear  fragmentation  caused  by  a Ca- 
dependent  endonuclease  which  acts  on  the  DNA  between  nucleosomes  (Hudig  et  al., 
1993). The relative expression of these proteins within cells determines the threshold for 
apoptosis  and  may  explain  the  vulnerability  of certain  cell  types  to  death  inducing 
signals (reviewed by Bergman and Blaydes, 2006).Sequence  i  function
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Figure 1.11  Sequence homology and function of caspases.
Caspases are the effectors of apoptosis  and  are  divided  into  initiator 
caspases,  which  cleave  inactive  proforms  of effector  caspases,  and 
effector  caspases,  which  cleave  other protein  substrates  resulting  in 
apoptosis. Adapted from Thomberry and Lazebnik (1998).58
1.5  Immunity
The  word  immunity  is  derived  from  the  Latin  word  immunitas,  which  means 
‘freedom  from.’  Humans have  developed  a series  of defence mechanisms  designed  to 
keep us free from infection. The first line of defence is our skin, which is impermeable 
to most infectious agents.  Membranes lining the  inner surfaces of the body exposed to 
bacteria  also  produce  mucus,  which  is  designed  to  prevent  bacterial  adherence  to 
epithelial cells.  Microbial agents are trapped and removed by movement of cilia (Roitt 
and Delves, 2003).
The  immune  response  involves two parts:  A  specific  or acquired  response to  a 
particular antigen and a non-specific innate,  inflammatory response. These two arms of 
the  immune  response are referred to as the acquired  and the  innate  immune  responses 
respectively and both result in inflammation.
1.5.1  Innate immunity
Innate  immunity  is  an  evolutionarily  ancient  system  providing  organisms  with 
immediate  defence  mechanisms  against  infection.  In  contrast  to  acquired  immunity, 
innate  immunity  does  not  have  the  capability  to  specifically  recognise  antigens. 
However,  phagocytic  cells  are  able  to  recognise  a  small  number  of highly  conserved 
structures known as pathogen-associated molecular patterns (PAMPs) present on many 
different  microorganisms  including  the  bacterial  cell  wall  component 
lipopolysaccharide  (LPS).  Recognition  of  PAMPs  leads  to  a  signalling  cascade 
triggering phagocytosis and release of inflammatory mediators thus inducing a localised 
inflammatory response (Janeway et al., 2002).59
1.5.2  The role of microglia in innate immunity
Microglia are often referred to as the resident immune cells of the CNS due to 
their  ability  to  proliferate  and  their  active  migration  towards  sites  of  injury.  Innate 
immunity revolves  around the  initiation  of an  inflammatory response  against  invading 
pathogens  and  is  presided  by  microglia.  Microglial  cells  express  several  receptors  on 
their  cell  membranes,  including  toll  like  receptors  and  complement  receptors,  which 
indicates their complex role as immune regulatory cells in the CNS (Aloisi, 2001).
1.5.2a  Toll-like receptors
Cells of the  immune  system  recognise the  molecular patterns expressed  on the 
surface  of invading  pathogens  (PAMPs),  which  are  expressed  by  a  large  number  of 
infectious  agents  and  differ  from  self  patterns,  through  activation  of  genetically 
conserved  receptors  known  as  toll-like  receptors  (TLRs)  (Medzhitov  and  Janeway, 
2000; Janeway et al., 2002). Lipopolysaccharide, a major constituent of bacterial wall in 
gram-negative bacteria, is bound by plasma LPS-binding protein, which is then captured 
by  microglial  CD 14  acting  as  a  pattern  recognition  receptor  (PRR).  This  complex  is 
then  internalised  activating  Toll  like  receptors  which  in  turn  stimulate  an  NFkB 
transcription  factor  pathway  culminating  in  initiation  of the  phagocytic  process  and 
upregulation of several pro inflammatory genes including IL1, IL6, IL  12, TNFa and B7 
the main co-stimulatory molecule  (reviewed  by Aloisi,  2001).  LPS  has been  shown to 
induce  upregulation  of microglial  CD 14  (Becher and  Antel,  1996).  It has  been  shown 
that LPS  induced  microglial  neurotoxicity can  be  prevented  by  inhibition  of TLR4  on 
microglia  therefore  indicating  a  mechanistic  link  between  innate  immunity,  microglia 
and neurotoxicity (Lehnardt et al., 2003).60
1.5.2b  Complement receptors
The complement system is one of the triggered enzyme cascade systems found 
in  plasma  and  serves  to  attract  phagocytic  cells  to  invading  pathogens.  The  most 
abundant component C3, is split by a convertase enzyme formed from its own cleavage 
product  C3b  and  factor  B,  and  stabilised  against  breakdown  by  association  with 
microbial surfaces (Roitt and Delves, 2003). Microglia express the CR1, CR3  and CR4 
receptors for C3bi which are primarily responsible for clearance of complexes labelled 
with  C3  (Mosley  and  Cuzner,  1996).  Activation  of  microglial  CR3  receptor  also 
increases  release  of  cytotoxic  TNFa  further  contributing  towards  the  inflammatory 
cascade (Williams et al.,  1994).
1.5.3  Acquired immunity
The  cells  of the  acquired  immune  response  are  a  type  of leukocyte  known  as 
lymphocytes.  B  lymphocytes and T lymphocytes are  generated  in the bone marrow by 
stem cells. T cells then travel to and develop in the thymus.  Peripheral  lymphoid tissue 
contains both B and T cells in three different stages of maturation, these are naive cells, 
effector cells and memory cells.
Immature  lymphocytes  with  many  different  antigen  receptors  are  screened  for 
self antigens  during  development  to  minimise  the  risk  of autoimmune  attack.  Cells 
expressing receptors for self antigen and cells with a weak association for MHC antigen 
undergo  programmed  cell  death  before  maturation.  T  cells  surviving  screening  are 
positive  for either CD4  or CD8  depending on whether their T cell  receptor recognises 
MHC-I presented antigens (CD8 +ve) or MHC-II presented antigens (CD4 +ve) (Roitt 
and Delves, 2003).
Invading  exogenous  pathogens  are  phagocytosed  by  antigen  presenting  cells 
(APCs) such as dendritic cells (Inaba et al.,  1983; Banchereau et al.,  1998), or microglia61
(Williams  et  al.,  1994),  which  then  process  and  express  parts  of the  pathogen  in  the 
context of the MHC-II antigens. Endogenous antigens such as viruses within host cells 
are  expressed  in  the  context  of the  MHC-I  antigens.  Mature  lymphocytes  leave  the 
thymus and spread through the body to the lymph nodes but remain inactive or ‘naive’ 
unless  they  bind  with  their  specific  antigen  in  the  context  of an  MHC  class  I  or  II 
protein.  This  under  the  right  conditions  will  induce  activation  and  clonal  expansion 
producing effector cells capable of mounting an acquired  immune response  (Roitt and 
Delves, 2003).
CD8  +ve  or  cytotoxic  T  cells  (Tc)  are  capable  of  killing  infected  cells  by 
releasing cytotoxins. Activation of Tc cells is dependent on several interactions between 
the T cell and the APC.  A  strong reaction between the T cell receptor and the MHC-I 
presented  antigen  is  required  along with  stimulation  by  interaction  between  CD28  on 
the Th cell and the proteins CD80 (B7.1) or CD86 (B7.2) on the APC without which the 
T cells become anergic (Mueller et al.,  1989; Liu and Linsley,  1992) and apoptotic (Liu 
and Janeway,  1990). Activation induced clonal expansion of Tc cells also requires IL-2 
produced by the activation and proliferation of T helper (Th) cells.  Dependence on co­
stimulatory molecules and Th cell activation are  in built mechanisms to protect against 
T cell autoimmunity (Liu and Janeway,  1990).
CD4  +ve  T  cells  or  T  helper  (Th)  cells  do  not  have  phagocytic  or  cytotoxic 
capability  but  they  mediate  these  responses  in  other  cell  types.  Th  cells  recognise 
antigen  presented  in  the  context  of  MHC-II  antigen  which  provides  a  signal  for 
activation.  Th  cell  activation  is  also  dependent  on  co-stimulatory  molecules.  Once 
activated  the  Th  cell  will  proliferate  by  producing  T  cell  growth  factor  IL-2,  into  Th 
effector  and  Th  memory  cells.  Effector  T cells  differentiate  into  two  major  subtypes, 
Thl  and  Th2  cells defined  by the  cytokines they  produce  (reviewed  by:  Constant and 
Bottomly,  1997).  Antigen  presenting  cells  and  the  cytokines  released  during  an62
inflammatory  event  influence  the  differentiation towards  Thl  or  Th2  subtype.  It  has 
been proposed that Thl  cells produce IFN-y and TGFp and are important in maximising 
the  activity  of macrophages  and  microglia  and  the  proliferation  of Tc  cells  (Constant 
and  Bottomly,  1997).  IL-12  released  from  macrophages  and  microglia,  encourages 
development  of  Thl  cells  which  secrete  cytokines  IL-1,  IFNy  and  TNF,  known  to 
further promote microglial activation and inflammation (Abbas et al.,  1996).  Th2 cells 
are thought to produce other cytokines including IL-4 and IL-5 which have a feedback 
effect promoting Th2 activity and have important roles in humoral immunity promoting 
B cell proliferation and antibody production (Roitt and Delves, 2003).
B cells play an important role in the humoral immune response. B cell receptors 
recognise  specific antigen  in their native  form.  Receptor binding with  specific  antigen 
induces B cell differentiation into effector molecules known as plasma cells.  However, 
like  T  cells,  B  cells  need  additional  signals  to  induce  activation.  Some  antigens  are 
capable of delivering both antigen and second signals to the B cell, whereas most are T- 
dependent,  meaning that an  additional  signal  from  a Th2  cell  is  required  for maximal 
antibody  production  from  B  cells.  Antibodies  mark  specific  antigens  for phagocytosis 
and can trigger the complement cascade (Roitt and Delves, 2003).
1.5.4  The role of microglia in acquired immunity
Microglia  express  MHC  class  II  antigens  (Bo  et  al.,  1994)  and  under 
inflammatory  conditions  this  expression  is  rapidly  up-regulated,  thus  suggesting  that 
microglia participate in the antigen presentation occurring during inflammation (Xu and 
Ling,  1994,  1995). Microglia also express B7 (CD80  and CD86) molecules which are 
the  co-stimulatory  receptors  crucial  for  T  cell  activation  therefore  confirming  the 
professional APC status of these cells (De-simone et al.,  1995; Menendez-Iglesias et al.,63
1997;  Wolf et al., 2001). Furthermore, Thl  cell activation also depends on IL-12 which 
is  released  by APCs  including microglia,  upon contact with T cells (Aloisi  et al  1997; 
Becher et al., 2000), allowing microglia to regulate the T cell response. The production 
of IL-12  however is regulated  by TNFa release, and Becher et al.,  (1996,  1999,  2000), 
have  shown  a  causal  connection  between  TNFa  and  IL-12  secretion  by  microglia. 
Microglial  release  of inflammatory  cytokines  including  TNFa  and  IL-1  has  also  been 
implicated  in  the  facilitation  of  leukocyte  entry  into  the  CNS  via  upregulation  of 
adhesion molecules and chemokines (Sedgewick et al., 2000).
Innate  immune  mechanisms  influence  acquired  immunity  thus  linking  the  two 
arms of immune response.  Indeed, the optimal function of cellular acquired immunity is 
dependent  upon  the  activity  of the  innate  system  with  APC  stimulation  and  cytokine 
release  (Unanue,  1997).  Microglia,  as  the  immune  cells  of the  CNS  clearly  have  the 
potential to modulate the T cell driven acquired immunity, whilst also playing an active 
role in the innate arm of the immune response, (Figure  1.12).
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Figure 1.12  Relationship between acquired and innate immunity
Microglia  play  an  important  role  in  innate  immunity,  releasing  inflammatory  mediators 
once activated  including a number of cytokines.  They also transform  into phagocytosing 
cells capable of clearing debris and pathogens marked with complement. At the same time 
the  cytokines  released  by  activated  microglia  are  important  in  the  acquired  immune 
response  and  are  thought to  act as  an  attractant to  primed  T  cells  migrating through  the 
BBB.  T  cells  are  then  re-stimulated  by  microglia  which  can  also  function  as  APCs. 
(Adapted from Roitt and Delves, 2003).64
1.6  Multiple sclerosis
Multiple  sclerosis  is  the  major  human  demyelinating  disease  of  the  central 
nervous  system  affecting  around  85,000  people  in  the  UK.  Disease  onset  typically 
occurs between the ages 29-33 years making MS the most common neurological disease 
of young adults with twice as many women affected as men (Steinman  1996).  MS  is a 
multifaceted inflammatory disease of CNS white matter characterised by T cell, B cell 
and  macrophage  infiltration  whose  antigenic  target  is  thought  to  be  common  myelin 
antigens  (Hafler  2004).  In  MS  the  myelin  sheaths  are  damaged  leading  to  localised 
demyelinated  lesions  in  fact,  the  name  sclerosis  is  derived  from  the  Greek  word 
meaning ‘hardening’ which was an early description of the multiple plaques observed in 
the MS brain.
1.6.1  Clinical course of MS
A  characteristic  feature  of MS  is that symptoms tend  to  worsen  suddenly then 
improve.  Classification of patients  is undertaken based  on  analysis  of clinical  features 
(Lublin and Reingold  1996). Relapsing-remitting multiple sclerosis (RRMS) is the most 
common form of MS in the early phase of the disease.  Symptoms typically evolve over 
a  number  of days  then  stabilize.  This  is  often  followed  by  either  a  full  recovery  or 
improvement  with  some  residual  deficit  within  weeks  either  spontaneously  or  as  a 
response to corticosteroid treatment.  The efficacy of corticosteroid treatment in RRMS 
often decreases with time (Noseworthy et al., 2000).
An initial RRMS disease course frequently deteriorates to secondary progressive 
multiple  sclerosis  (SPMS)  when  disease  symptoms  progress  between  relapses  and 
baseline  neurologic  disability  increases  (Bjartmar  and  Trapp,  2001).  Response  to 
immunotherapy  dwindles  and  eventually  disappears.  The  development  of  SPMS  is65
associated  with  significantly  fewer  gadolinium  enhanced  lesions  and  a  reduction  in 
brain parenchymal volume (Hafler et al., 2004).
In  approximately  10%  of  patients,  MS  begins  with  a  primary  progressive 
phase  (PPMS) (Zamvil and  Steinmann,  2003),  which  is characterised by a progressive 
clinical  course  from  the  onset  of  disease  with  less  inflammation  but  acute 
neurodegeneration.  PPMS  patients  typically  do  not  suffer  acute  attacks  but  undergo 
gradual  clinical  decline.  Progressive  relapsing  multiple  sclerosis  (PRMS)  follows  a 
progressive  clinical  course  from  onset of disease  with  clear acute  relapses  sometimes 
with recovery (Figure  1.13).
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Figure 1.13  Schematic diagram of the clinical progression of MS
The  bold  line  indicates  clinical  disability  (A)  shows  RRMS  with  clinical 
relapses  with  return  to  baseline  neurological  function  but  eventual 
progression to  SPMS.  (B)  SPMS when disease  symptoms progress  between 
relapses  and  baseline  neurological  disability  increases.  (C)  Shows  PPMS 
which  is characterised by progressive disease course from onset.  (D)  Shows 
PRMS  which  follows  a  progressive  course  from  onset  but  has  obvious 
relapses where recovery may or may not occur. (Lublin and Reingold,  1996).66
These  distinctions,  however,  are  very  fluid;  in  the  region  of 40%  of RRMS 
sufferers  will  eventually  stop  having  relapses  instead  developing  the  progressive 
neurodegenerative  symptoms of SPMS.  It has  been  suggested that disease  progression 
in MS  is a continuum with acute  inflammatory events early on followed by secondary 
induction  of  an  underlying  neurodegenerative  process  refractory  to  immunotherapy 
(Hafler 2004).
1.6.2  Pathological features of MS
The  pathology  of  MS  is  well  documented.  On  a  macroscopic  level,  MS  is 
characterised  by  multiple  lesions  or  plaques  occurring  predominantly  in  the  white 
matter of the  brain  and  spinal  cord.  Lesions  are  most  commonly  found  around  blood 
vessels,  and  correspond  to  local  myelin  destruction  or  demyelination  (Conlon  et  al., 
1999;  Noseworthy  et  al.,  2000).  These  lesions  comprise  a  well  demarcated  area 
characterised by a loss of myelin with relative preservation of axons and the subsequent 
formation of astrocytic scars.
At  the  cellular  level,  early  active  lesions  are  characterised  by  infiltration  of 
inflammatory lymphocytes, macrophages and microglia, and oedema formation (Adams 
et al.,  1989; Bruck, 2005a). Macrophages and microglia are frequently found around the 
active edges of the lesion containing lipid filled vesicles of myelin debris (Adams et al., 
1989).  Infiltrating  macrophages  are  mainly  derived  from  resident  microglia  (Li  et al., 
1996).  Chronic  lesions  are  characterised  by  lower  numbers  of  leukocytes  extensive 
demyelination and astrogliosis (Lucchinetti et al.,  1996).  Furthermore,  in PP or SPMS 
there  is  notably  less  inflammatory  activity  and  more  axonal  degeneration  (Lassmann 
1998; Bruck, 2005b).67
1.6.3  Pathogenesis of MS
Although the autoimmune nature of MS has not yet been proven, the importance 
of immunopathological events has been widely documented (Lassmann  1998; Hemmer 
et al., 2002; Neumann et al., 2002). The inflammatory response, involving migration of 
activated  T  lymphocytes,  is  central  to  the  pathogenesis  of demyelination.  The  main 
candidate CNS auto-antigens are thought to be myelin proteins (Zamvil and  Steinman, 
2003).  The  immune  system  has  several  internal  methods  designed  to  avoid  the 
development  of  autoimmune  responses  against  the  CNS.  Indeed  many  of  the 
components of myelin sheaths such as MBP and PLP, are expressed in the thymus thus 
allowing deletion of developing T cells capable of reacting with these molecules (Klein 
et al.,  2000).  It  is  possible that  in  genetically  susceptible  people  myelin  auto-antigens 
remain unchecked or are more readily activated, thus causing a predisposition to MS.
The  initiating  event  for  the  presence  or  activation  of  auto-reactive  T  cells 
remains unknown, a ‘molecular mimicry’ theory has been postulated whereby common 
microbes activate APCs through the normal acquired immune response but also express 
cell  surface  protein  sequences  cross  reactive  with  self myelin  antigens  (Conlon  et al.,
1999).  Another  possibility  is  that  immunoregulatory  defects  in  MS  patients  allows 
activation  of autoreactive  T cells.  Initial  activation  of T cells  is  regulated  by  dendritic 
cells  in the blood,  which are recognised as primary antigen presenting cells (Becher et 
al.,  2006),  inducing proliferation and activation of T cells which subsequently circulate 
around the body,  finally adhering to endothelial  cells and altering the  properties of the 
BBB  to  allow  penetration  (Hafler,  2004).  T  lymphocyte  infiltration  depends  on 
alterations  in  the  expression  of cell  surface  molecules  on  activated  T  cells  as  well  as 
endothelial  cells,  together with the  secretion  of enzymes that degrade  the extracellular 
matrix  (Carrithers  et al.,  2000).  Within  the  CNS,  T cells  are  re-stimulated  by  antigen 
presented by microglia and macrophages (Shrikant and  Benveniste,  1996; Aloisi  et al.,68
2000)  amplifying  the  immune  response.  Thl  cytokines  are  released  initiating  an 
inflammatory  cascade  which  further  activates  microglia  (reviewed  by  Noseworthy 
2000;  Hafler 2004),  (Figure  1.14).  Disease  progression  and demyelination are thought 
to induce production of new myelin epitopes which leads to recruitment of more T cells, 
further exacerbating the inflammatory cascade (Vanderlugt and Miller, 2002).
These  concepts  have  been  reinforced  by  experimental  animal  models  such  as 
experimental  allergic  encephalomyelitis  (EAE)  where  immunisation  with  myelin  or 
myelin proteins with adjuvant induces a CD4 +ve T cell  mediated  destruction of CNS 
myelin very similar to that seen in MS. Indeed, the importance of lymphocyte migration 
into the CNS in MS was highlighted recently during trials for the humanised antibodies 
natizulab and campath IH. These antibodies target the antigens cu  integrins and CD54, 
responsible  for  the  adhesion  and  migration  of  lymphocytes  through  the  BBB,  and 
reduced relapses and the formation of new  lesions  in MS patients  (Miller et al.,  2003; 
Coles  et  al.,  2004).  Furthermore  T  cell  clones  isolated  from  MS  patients  often  show 
specifity for the p85-99 epitope of the myelin basic protein (Pette et al.,  1990; Martin et 
al.,  1990). The possibility that epitope spreading occurs after T cell activation has been 
highlighted by the fact that most MS patients display T cell reactivity to several myelin 
antigens (Ota et al.,  1990), which  is compatible with the theory that MS  is  initiated by 
invading infectious antigens cross reactive with myelin proteins.69
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Figure 1.14  T  cell  migration  and  regulation  of  CNS  T-cell  response  by 
microglia
(1)  Thl  cells  are  activated  in  the  peripheral  lymphoid  system  by  antigen  presenting 
cells  such  as  dendritic  cells.  (2)  Following  activation  they  enter the  blood  stream  in 
search of their target antigen.  (3) Adhesion of T cells to the endothelium occurs after 
binding of ICAM  or VCAM  with  corresponding T cell  receptors  LFA-1  and  VLA-4. 
(4)  This  allows  cross  linking  of ICAM  leading  to  Rho  activation  and  cytoskeletal 
rearrangement  which  therefore  allows  migration  of T  cells  through  the  blood  brain 
barrier.  (5)  Once  in  the  CNS  parenchyma,  T  cells  interact  with  microglia  which 
display  upregulated  MHC-II  following  activation  by  inflammatory  stimuli.  The 
microglia then re-stimulate the T cells and secrete a variety of mediators which further 
exacerbate  the  inflammatory  response  and  also  leads  to  upregulation  of molecules 
such as ICAM and VCAM on the endothelial cell surface which ultimately encourages 
further infiltration of T cells. Adapted from Vanderlugt and Miller, (2002).70
However,  recent evidence  suggests that other factors  are also  important  in  MS 
pathology.  Indeed,  lymphocytes  are  not always  present  in early  demyelinating  lesions 
(Barnett  and  Prineas,  2004)  and  the  presence  of  IgG  and  complement  products  on 
degenerating  myelin  sheaths  in  acute  lesions  suggest  an  important  role  for  humoral 
immunity in MS (Lucchinetti et al.,  1998;  Storch et al.,  1998).  Furthermore, the initial 
event in the newly forming lesion is the apoptotic death of oligodendrocytes occurring 
within  the  first  1-3  days  of  a  relapse  correlating  with  the  peak  in  symptoms  with 
subsequent inflammation due to microglial recruitment and post apoptotic necrosis and 
phagocytosis (Akassoglou et al.,  1998).  Instigatory processes other than autoreactive T 
cell  infiltration  may  be  responsible  for  relapses  since  these  findings  have  not  been 
replicated  in experimental models based on T-cell or antibody mediated autoimmunity 
(Barnett and Prineas, 2004). These may involve activation of microglia which has been 
shown to be toxic to oligodendrocytes (Takahashi et al., 2003; Li et al., 2005). Indeed, it 
has  been  suggested  that  animal  models  using  TNF-transgenic  mice  expressing  high 
levels of glia derived transmembrane TNF,  reflect more closely the pathology of early 
preactive lesions (Barnett et al., 2006), which show early primary demyelination due to 
oligodendrocyte  apoptosis  and  microglial  activation,  followed  later  by  mononuclear 
infiltration, axonal loss and gliosis (Akassoglou et al.,  1998).
A variety of mechanisms are involved  in the pathogenesis of demyelination but 
the precise initiating event remains open to conjecture. Microglia have been  implicated 
in the  demyelination  process due to their ability to phagocytose  myelin  debris,  release 
cytotoxic  substances  and  act as APCs.  MS  is a  disease  with  extreme  heterogeneity  in 
clinical  course  due  to  differing  appearance  and  location  of  lesions.  The  fact  that 
essentially different processes have been implicated in the induction of MS-like plaques 
such  as  autoimmunity  or  viral  infection  suggests  that  MS  may  be  a  disease  with 
heterogeneous  pathogenic  factors.  Indeed,  detailed  analysis  of actively  demyelinating71
lesions  has  shown  fundamental  differences  in  the  pattern  of demyelination  between 
patients  and  found  that  most  lesions  can  be  divided  into  two  main  groups.  One  with 
characteristically  high  infiltration  of  inflammatory  cells  such  as  macrophages  and 
microglia  and  localisation  of activated  complement  and  IgG  on  degenerating  myelin 
sheaths more suggestive of T-cell or humoral inflammatory mediated damage. The other 
presenting  with  primary  oligodendrocyte  dystrophy  and  notable  absence  of  IgG 
deposition  is  suggestive  of viral  or  toxin  induced  demyelination  (Lucchinetti  et  al.,
2000).  However,  lesion  differences  between  patients  have  also  been  attributed  to 
lesional evolution rather than pathogenic heterogeneity (Barnett et al., 2006).
As  previously  discussed,  the  immune  system  has  evolved  several  effector 
mechanisms designed to destroy  invading pathogens.  Unfortunately these mechanisms 
can  also  damage  host  tissue  in  autoimmune  mediated  disease  which  means  that  a 
multitude  of  immune  regulated  pathways  may  mediate  demyelination.  However,  the 
same inflammatory mediator may affect different cells in varying degrees depending on 
functional properties of surrounding cells, which may lead to primary demyelination in 
some  cases  and  axonal  degeneration  in  others.  It  is  also  probable  that  genetically 
determined  susceptibility  of target  cells  regulates  the  nature  and  magnitude  of tissue 
damage caused  by  immune mediated pathways (Compston et al.,  2006).  These  factors 
may be responsible for the heterogeneity in MS lesions which develop in the context of 
a complex interaction of antigen dependent and independent mechanisms.
1.6.4  Axonal damage and inflammation
The ability of high dose steroids to reverse MS symptoms suggests that the acute 
oedema and  inflammation and its subsequent resolution underlie relapse and remission. 
Indeed,  therapies  for  MS  at  present  are  anti-inflammatory.  Studies  using  MRI  and 
evoked  potentials  have  shown  that  acute  relapses  are  caused  by  focal  inflammatorydemyelination  (McDonald,  2000).  Clinical  deficits  are  therefore  due  to  nerve 
conduction blocks caused by inflammation and associated demyelination. Remission is 
probably the result of attenuated inflammatory response allowing some remyelination to 
occur  thus  restoring  saltatory  conduction.  Remyelination  and  recovery  after  relapse 
often  declines  as  disease  progresses.  This  has  been  attributed  to  the  on-going 
inflammatory  activity  in  localised  areas  which  may  impede  recovery  processes  and 
damage denuded axons (Figure  1.15).
Recently attention has become more focussed on axonal pathology in MS (Trapp 
et  al.,  1998).  The  close  proximity  of areas  of  inflammatory  activity  and  areas  with 
notable axonal loss suggest that axonal loss may be correlated to inflammatory activity 
in demyelinating lesions (Bruck, 2005), and that recurrent inflammation is the cause of 
permanent axonal damage (McDonald 2000).  It has been proposed that the build up of 
axonal  loss  is what leads to  secondary progressive  form  of MS  and  is  responsible  for 
clinical outcome (Owens, 2003; Neumann 2003). These observations were mirrored in a 
recent  study  which  found  that  in  acute  EAE,  axonal  loss,  demyelination  and 
inflammation  all  correlated  with  clinical  scores  indicating  a  contributory  role  for 
microglia and other immune cells in the pathology of early disease. However in chronic 
EAE  animals,  only  axonal  loss  correlated  with  clinical  scores  suggesting  that 
irreversible neurological deficit was due to axonal loss (Papadopoulos et al., 2006).73
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Figure 1.15  Course of inflammation and axonal damage in MS
Inflammatory  episodes  (shown  in  red)  are  frequent  in  relapsing  remitting  MS 
although not all episodes are noticeable at a clinical level (green dashed line).  It 
is probable that disease progression is a result of continued inflammatory activity 
with  demyelination  and  increased  axonal  damage.  Progressive  disease  is 
characterised  by  infrequent  inflammation  but  increased  axonal  loss  and  gliosis. 
Adapted from Compston and Coles (2002).
1.7  The role of microglia in multiple sclerosis
Although  the  immune  response  is  meant  as a  protective  mechanism,  excessive 
inflammation  is a common  cause  of damage  in the  CNS.  It  is  becoming  more  widely 
accepted  that  CNS  inflammation  plays  a  role  in  most  neurodegenerative  disorders. 
Indeed  microglial  and  macrophage  activation  and  associated  upregulation  of MHC-II 
have  been  implicated  in MS (Woodroofe et al.,  1986;  Hayes et al.,  1987; Gehrmann et 
al.,  1995),  suggesting  the  involvement  of  the  innate  immune  response.  Strategies 
attenuating underlying inflammatory activity could therefore be of therapeutic benefit to 
MS patients.
Rapid  recruitment  of microglia  occurs  in  both  MS  and  EAE.  Indeed,  the  high 
levels  of  inflammatory  infiltrates  including  T  cells  and  B  cells,  and  the  rapid 
upregulation  of  macrophages  and  microglia  in  lesions  are  consistent  changes
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documented  in  MS  (Cuzner  et  al.,  1988;  Sobel  et  al.,  1989;  McCombe  et  al.,  1994; 
Brack et al.,  1995; Li et al.,  1996).  Indeed  Schonrock et al.,  (1998),  demonstrated that 
microglial  proliferation was  evident  in  MS  lesions,  particularly  in  early active  lesions 
compared  with  demyelinated  and  early  remyelinated  lesions.  The  presence  of myelin 
and myelin degradation products within microglia (Hill et al., 2004), in lesions strongly 
suggests an active role for microglia in the demyelination process.
Oligodendrocytes  are  extremely  vulnerable  to  damage  by  microglial  released 
factors  associated  with  the  immune  response  including  pro-inflammatory  cytokines, 
ROS  and  NO,  and  glutamate  which  will  be  discussed  later.  Activated  microglia  also 
show  increased  capacity  for  binding  of oligodendrocytes  and  phagocytosis  of myelin 
compared  with  that  of  macrophages  (Mosley  et  al.,  1996).  Although  it  has  been 
demonstrated that the degree of oligodendrocyte loss  in MS  lesions is not homogenous 
and differs between MS patients,  it is known that capacity for remyelination  is closely 
correlated to the extent of oligodendrocyte survival (Luccinetti et al.,  1999).  Microglial 
toxicity to oligodendrocytes is therefore a relevant concern in the pathogenesis of MS.
Microglia also function as effector cells in the acquired immune response acting 
as  APCs  as  already  discussed.  It has  been  postulated  that  T-cell  infiltration  occurs  in 
response  to  cytokine  induced  up-regulation  of  endothelial  cell  adhesion  molecules 
(Tomimoto  et  al.,  1993;  Sedgewick  et  al.,  2000).  It  is  possible  that  T  cells  are  then 
presented  with a potential  MS  antigen  in the context of microglial  MHC  II  molecules, 
inducing T cell  activation  and proliferation and  stimulating the  adaptive  response thus 
exacerbating BBB damage and subsequent T cell infiltration. Indeed activated microglia 
show  upregulated  MHC  class  II  molecules  (Matsumoto  et  al.,  1992;  Bo  et  al.,  1994), 
and co-stimulatory molecule B7 expression allowing maximal activation of T cells and 
subsequent immune response (Windhagen et al.,  1995).75
Positron emission tomography mapping of microglial activation in MS using the 
radioligand  [nC]  (R)-PK11195,  which  binds  invading  blood  borne  cells  of monocyte 
lineage  and  activated  microglial  cells,  detects  signal  even  in white  matter regions that 
would  normally  be  classified  as  ‘normal  appearing’  and  during  remission  of disease 
(Banati  et  al.,  2000).  These  findings  are  in  accordance  with  those  of Barnett  at  al., 
(2004), which put forward the importance of the humoral response in preactive  lesions 
and  furthermore  suggest  an  underlying  role  of microglia  in  the  ultimate  progressive 
nature of MS.  However, the exact role of microglia in MS  is  still  not fully understood 
since  it  is  becoming  increasingly  evident  that  microglia  also  secrete  substances  with 
anti-inflammatory properties such as TGFp and IL-10 which are thought to be potential 
mediators  of  remyelination  or  disease  remission  (Diemel  et  al.,  1998;  Ledeen  and 
Chakraborty,  1998).
1.7.1  Inflammatory mediators in MS
The  inflammatory reaction  is associated with  upregulation of a number of pro- 
inflammatory  mediators  which  have  been  identified  within  MS  lesions  including  the 
cytokines IFN-y, TNFa and TGFp (Brosnan et al  1996), NO (Liu et al., 2001; Broholm 
et  al.,  2004;  Hill  et  al.,  2004),  and  glutamate  (Werner  et  al.,  2001;  Srinivasan  et  al., 
2005).  This  project  has  focussed  on  regulation  of  TNFa,  iNOS  and  glutamate 
production  by  microglial  cells,  their  role  in  MS  will  therefore  be  discussed  in  more 
detail (Figure  1.16). While the diversity of interactions combined with the abundance of 
inflammatory mediators in MS makes it difficult to pin point a direct link between these 
particular  molecules  and  tissue  damage,  there  is  substantial  evidence  to  suggest  that 
they participate in the demyelination process.76
1.7.1a  TNFa
High  levels  of TNFa  expression  both  at  mRNA  and  protein  levels  have  been 
demonstrated in active MS lesions (Olsson  1995, Brosnan et al.,  1995). This expression 
being  particularly  localised  to  microglial  cells  (Renno  et  al.,  1995).  Myelin 
phagocytosis by microglia occurs in vitro and  induces microglial activation,  leading to 
cytokine release and increased affinity for oligodendrocytes, inducing their death by cell 
contact through  TNF  receptors  (Zajicek  et al.,  1992;  Williams  et al.,  1994).  Findings 
indicating  that  microglial  expression  of  cell  surface  TNFa  could  directly  induce 
oligodendrocyte damage (Merill et al.,  1993), and that transmembrane TNFa can induce 
demyelination when produced by astrocytes but not neurones (Akassoglou et al.,  1998), 
suggest that appropriate cellular contact appears to be an important factor in the toxicity 
of TNFa.  Oligodendrocyte  apoptosis  in  mixed  glial  cultures  induced  by  TNFa  was 
prevented  by  blockade  of AMPA/Kainate  receptors  therefore  indicative  of a  cytokine 
induced  failure  of  the  glutamate  buffering  function  of  astrocytes  (Takahashi  et  al., 
2003).
Mice over expressing TNFa suffered from chronic  inflammatory demyelinating 
disease  (Probert  et  al.,  1995).  However,  the  role  of TNFa  in  MS  pathology,  remains 
unclear,  studies using animal  models of MS have also  shown that TNF  is not required 
for induction of disease and  furthermore that treatment with TNF  reduced the  severity 
of  disease  (Liu  et  al.,  1998).  Furthermore,  MS  patients  who  received  neutralizing 
antibodies to TNFa did  not show improved  clinical  scores compared with those taking 
antibodies  to  IFN  (Skurkovich  et  al.,  2001).  Interestingly,  oligodendrocytes  express 
both TNFR1  and  TNFR2  and  as  in neuronal cultures (Taylor et al.,  2005),  it has been 
proposed  that  apoptosis  inducing  TNFR1  is  upregulated  on  oligodendrocytes  in  MS 
lesions as a result of chronic  inflammation (Tchelingerian et al.,  1995).  Stimulation of 
p75  TNFR2  receptor,  however,  has been  shown to  promote oligodendrocyte  precursor77
growth in chemically induced demyelination which may explain the seemingly dual role 
of TNFa  in  inflammation  and  suggests  a  role  for  TNF  in  repair  and  remyelination 
(Arnett et al., 2001).
1.7.1b  Nitric oxide
There has also been much interest in the role of NO in MS. NO is a non-specific 
inflammatory mediator released from microglia and macrophages which are prolific  in 
early lesions, indeed the iNOS expressed in chronic active plaques is amplified in areas 
of higher inflammation (reviewed by Smith et al.,  1999),  and  is associated with  CD64 
(Okuda  et  al.,  1995;  Ruuls  et al  1995;  Hill  et  al.,  2004).  Expression  of iNOS  is  also 
upregulated  in astrocytes and macrophages in post mortem studies of patients with MS 
(Bo  et  al.,  1994,  DeGroot  et  al.,  1997).  Furthermore,  MBP  fragments  are  found  in 
microglial cells expressing iNOS suggesting a direct involvement in the demyelination 
process  in active plaques (Hill et al., 2004). NO may also  induce cerebral vasodilation 
which could facilitate the entry of leukocytes through the BBB by reducing the velocity 
of the surrounding blood flow (Smith and Lassmann, 2002).
Since  both  neurones  and  oligodendrocytes  have  high  metabolic  requirements, 
NO  and  reactive  nitrogen  species  may  contribute  to  neurodegeneration  and 
demyelination via impairment of mitochondrial energy metabolism and subsequent ATP 
depletion  (Bolanos et al.,  1995).  Indeed,  oligodendrocytes are  more  susceptible to NO 
mediated damage than either astrocytes or microglia (Merrill et al.,  1993). Furthermore, 
axons exposed to NO in vivo can undergo continued conduction block, especially when 
electrically active during NO exposure (Smith et al., 2001), which is more likely in MS 
lesions  due  to  demyelination.  Sodium  and  calcium  channel  blockers  can  reduce  NO 
mediated  axonal  degeneration  by  preventing the  accumulation  of these  ions,  which  is78
the result of Na+ /K+ pump failure and  reversal  of the Na+/Ca2+ exchanger  due to NO 
mediated impairment of mitochondrial ATP production (Kapoor et al., 2003).
At the clinical level, patients with RRMS display significantly higher expression 
of  nitrate  and  nitrite,  the  stable  derivatives  of  NO,  in  the  CSF,  serum  and  urine 
compared  with  controls  (Giovannoni,  1998;  Acar  et  al.,  2003;  Rejdak  et  al.,  2004). 
Studies  using  animal  models  of MS  have  also  demonstrated  that  in  diseased  animals, 
microglia  and  macrophages  secrete  significantly  increased  amounts  of  nitrate  and 
nitrite, (MacMicking et al.,  1992). Furthermore, Inhibitors of iNOS have been shown to 
reduce the inflammation and demyelination in animal models of MS (Rose et al.,  1998), 
which further suggests a central role for NO in demyelination.
However, the actual role of NO in MS pathology remains unclear. Other studies 
using animal models have shown that iNOS  inhibitors worsened disease course (Ruuls 
et al.,  1996), and that iNOS knockout led to increased susceptibility to initiation of EAE 
(Sahrbacher et al.,  1998).  Furthermore, NO production from microglia has been shown 
to  inhibit T cell  proliferation  by modulating the  inhibitory  effect of interferon  gamma 
receptor on the proliferation of encephalitogenic T cells (Willenborg et al.,  1999).  The 
role  of iNOS  in  MS  is  at present  unclear  but  it  is  possible  that  at  different  stages  of 
disease, NO mediates different effects ranging from cytotoxic to immunomodulatory.  It 
has been suggested that the  pro-oxidant or antioxidant effects of NO are dependent on 
the  concentrations  and  ratio  of superoxide  to  NO.  This  divergence  in  function  may 
explain  the  different  effects  of NO  inhibition  in  in  vivo  models  (Smith  and  Lassman 
2002).
1.7.1c  Glutamate in MS
Evidence  suggests  that  glutamate  excitotoxicity  may  also  play  a  role  in  the 
neuronal  and  oligodendrocyte  damage  in  MS  and  EAE  (Smith et al.,  2000;  Werner et79
al.,  2001;  Matute  et al.,  2001;  Groom  et al.,  2003).  Studies  using magnetic  resonance 
spectroscopy have shown that levels of glutamate are  significantly higher in acute MS 
lesions  and  NAWM  when  compared  with  control  subjects  (Srinivasan  et  al.,  2005). 
Furthermore, microglia and macrophages express high levels of glutamine, a marker for 
glutamate  production,  in  areas  of  white  matter  inflammation  close  to  dystrophic 
neurones in MS compared with control patients (Werner et al., 2001). Oligodendrocytes 
are  responsible for the maintenance  of glutamate  homeostasis  in the  white  matter and 
have  been  shown to express glutamate transporters (Pitt et al.,  2003).  However,  it has 
been suggested that oligodendrocyte metabolism of glutamate in active and chronic MS 
lesions is impaired (Werner et al., 2001).
Oligodendrocytes and axons are sensitive to oxidative stress as a result of their 
high  metabolic  requirements.  They  also  express  AMPA/  kainate  receptors  which 
mediate  excitotoxicity  stimulated  by  glutamate  (McDonald  et  al.,  1998).  Indeed 
stimulation  of AMPA  receptors  is  toxic  to  oligodendrocytes  in  vitro  (Matute  et  al., 
1997;  McDonald  et  al.,  1998),  inducing  rapid  Ca2+  influx  (Fern  and  Moller  2000; 
Yoshioka  et  al.,  2000),  competitive  inhibition  of cystine  uptake  and  oxidative  stress 
(Rosin  et  al.,  2004).  Agonist  concentrations  similar  to  those  affecting  neuronal  and 
oligodendrocyte  cultures,  however,  do  not  induce  astrocytic  death  (McDonald  et  al., 
1998).
Microglial  products  IL-1 (3  and  TNFa  induce  oligodendrocyte  death  in  mixed 
glial  cultures  which  is  prevented  by  AMPA  receptor  blockade  thus  pointing to  a  link 
between microglial activation, excess extracellular glutamate and oligodendrocyte death 
(Takahashi  et  al.,  2003).  TNFa  has  also  been  shown  to  reduce  oligodendrocyte 
glutamate  transporters  and  inhibit  glutamate  uptake  (Pitt  et  al.,  2003),  therefore 
impeding homeostatic function and leading to cell death.80
The  role  of  glutamate  in  MS  is  highlighted  by  the  distinctly  reduced 
oligodendrocyte  death  and  axonal  damage  and  subsequent  amelioration  of  disease 
recorded  after treatment  of EAE  mice  with  antagonists  to NMDA  and  AMPA/kainate 
receptors  (Achiron  et  al.,  2000;  Pitt et al.,  2000;  Smith  et al.,  2000).  Furthermore,  the 
glutamate  receptor  antagonist  and  sodium  channel  blocker,  riluzole,  suppresses 
inflammation  and  demyelination  in  EAE  (Gilgun-sherki  et  al.,  2003)  and  slows  the 
progression of CNS atrophy in PPMS (Killestein et al., 2005).
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Figure 1.16  Possible mechanisms of degeneration during inflammation
T  cells  re-stimulated  in  the  CNS  activate  local  cells  including  microglia  which 
trigger  an  inflammatory  cascade.  Activated  microglia  release  a  number  of 
inflammatory  mediators  which  may  damage  oligodendrocytes  and  exposed  axons. 
NO  can  cause  axonal  conduction  block  while  TNFa  and  glutamate  are  toxic  to 
oligodendrocytes and neurones. Activated microglia also phagocytose myelin which 
may promote demyelination.81
1.7.2  Metabotropic glutamate receptors in MS
Stimulation of group II mGluRs has been shown to promote microglial reactivity 
and  neurotoxicity;  conditioned  medium  from  microglia treated  with  group  II  agonists 
DCGIV  or  l-CCG  induced  increased  apoptosis when  applied to  neuronal  cultures  and 
the  group  II  antagonist  MCCG  significantly  reduced  apoptosis  induced  by 
chromogranin A  (CGA)  (Taylor et al.,  2002).  Microglia  in chronic  active  MS  plaques 
display  increased  expression  of both  groups  I  and  II  mGluRs  (Geurts  et  al.,  2003). 
Recently, group II and mGlul  immunoreactivity has been detected  in activated but not 
ramified  microglia  of chronic  active  MS  lesions  (Guerts  et  al.,  2003).  These  findings 
suggest  a  central  modulatory  role  for  group  I  and  II  mGluRs  in  the  inflammatory 
response.
Stimulation of group  III  mGluRs can attenuate the  subsequent neurotoxicity of 
microglia  stimulated  with  CGA  or  LPS  possibly  providing  some  form  of therapeutic 
benefit. Indeed group III mGluR agonists L -AP4 or RS-PPG significantly reduced CGA 
or LPS  induced  microglial  mitochondrial  depolarisation  and  apoptosis  back to  control 
levels  (Taylor  et  al.,  2003).  Microglial  mGluR8  immunoreactivity  is  also  strongly 
increased  in  actively  demyelinating  lesions  compared  with  cells  in  preactive  lesions 
which  are  charachterised  by discrete white  matter abonormalities and  phagocytic  cells 
that do not contain myelin breakdown products. This suggests that increased expression 
of  mGluR8  occurs  in  response  to  demyelination  not  simply  microglial  activation 
(Geurts  et  al.,  2005).  This  may  be  an  attempt  to  limit  the  toxicity  of  microglia  to 
oligodendrocytes.
Astrocyte  secretion  of  RANTES,  a  T  cell  chemoattractant  that  has  been 
implicated  in MS and EAE,  showing increased expression correlated with the  intensity 
of inflammation (Ransohoff.  1999), was significantly reduced by co incubation with L- 
AP4  a  neuroprotective  (Taylor  et  al.,  2003),  group  III  mGluR  agonist.  Treatment  of82
EAE mice with L-AP4 lowered RANTES mRNA expression and significantly increased 
the  rate  of  recovery  (Besong  et  al.,  2002).  Together,  these  findings  suggest  that 
microglial mGluR expression is modulated in MS lesions which may in turn affect the 
inflammation and subsequent degeneration which are features of this disease.
1.8  Aims
Microglia clearly play an  important role  in MS  pathology as  general mediators 
of inflammation  through  secretion  of toxic  inflammatory  products  and  also  at  a  more 
specific level with a distinct role in demyelination through toxicity to oligodendrocytes 
and  active  phagocytosis  of myelin.  It  is  also  possible  that  microglia  are  a  part  of the 
initial events in MS pathogenesis, acting as APCs and releasing chemoattractants which 
attract autoreactive T cells into the CNS or initiating oligodendrocyte apoptosis through 
release of toxic factors.
Microglia  express  mGluRs  which  can  be  neurotoxic  (group  II)  or  protective 
(group  III).  Microglial  neurotoxicity during disease  progression could  be  explained  by 
increased  expression  or  activation  of  one  subtype  over  another.  Loss  of  microglial 
regulation  during the  progression  of MS  could therefore  be  due to  changes  in  mGluR 
expression.  This  project  will  analyse  expression  of  mGluR  subtypes  on  activated 
compared  with  unstimulated  microglia  and  also  assess  the  expression  of  microglial 
mGluRs during disease progression using an animal model of MS.
Since  microglia  are  known  to  phagocytose  myelin,  this  study  will  aim  to 
determine  the  effects  of  myelin  on  microglia  by  assessing  levels  of  activation, 
expression and release of inflammatory mediators and subsequent toxicity to neurones. 
Given that microglial mGluR stimulation has been shown to modulate the reactivity of83
microglia  we  will  also  investigate  whether  microglial  reactivity  after  incubation  with 
myelin  can  be  modulated  by  stimulation  of  their  mGluRs  since  this  may  have 
implications for therapeutic strategies in MS. Phagocytosing microglia are thought to be 
‘super  activated’  displaying  similar  morphology  and  functions  to  activated 
macrophages,  it  is possible that in this  state they release  substances  deleterious to the 
survival  of  surrounding  cells.  As  such  this  study  will  also  explore  whether  myelin 
phagocytosis can be modulated by stimulation of microglial mGluRs.84
2.0
MATERIALS AND METHODS85
2.1  Materials
This section lists that materials used and the company that supplied them. All analytical 
reagent grade chemicals used in this study were from Sigma, (Dorset, UK).
MATERIAL SUPPLIER
Ampicillin Sigma (Dorset, UK)
AMT HCL Sigma (Dorset, UK)
ARA-C Sigma (Dorset, UK)
Avidin-Biotin Complex Sigma (Dorset, UK)
Benzamadine Sigma (Dorset, UK)
Bradford protein assay reagent kits PerbioScience (Cheshire, UK)
BSA Sigma (Dorset, UK)
Buffer saturated phenol Invitrogen (Paisley, UK)
CaspaTag Chemicon (Hampshire, UK)
Citifluor® antifade reagent Citifluor Ltd (London, UK)
CO2 Gas, tissue culture grade BOC gases (Guilford, UK)
DAPI Sigma (Dorset, UK)
Dextran beads Invitrogen (Paisley, UK)
Dil fluorescent labelling Invitrogen (Paisley, UK)
DNA ladder (lOObp) Promega (Paisley, UK)
dNTP (lOOmM) Invitrogen (Paisley, UK)
Donkey anti-goat IgG (HRP) Autogen Bioclear (Wiltshire UK)
DPX mountant VWR International (Leicester UK)
Dulbecco’s modified Eagles’ medium (DMEM) Sigma (Dorset, UK)86
Earle’s balanced salt solutions (EBSS)
Enhanced chemiluminescence reagent (ECL)
Foetal calf serum
Folin- Ciocalteu reagent
Formaldehyde
Fraction V Albumin
Glass coverslips (13mm)
Glutamate dehydrogenase 
Goat anti-mouse (HRP)
Goat anti-rabbit (HRP)
Goat anti rabbit (TRITC)
Greiss reagent 
Hoechst 33342 (2’[epoxyphenyl]-5
-[4-methyl-1  -piperazinyl]-2,5’-bi-1  H-benzimidazol) Sigma (Dorset, UK)
Life Technologies (Paisley, UK) 
Amersham (Buckinghamshire, UK) 
Life technologies (Paisley, UK) 
VWR International (Leicester UK) 
VWR International (Leicester, UK) 
Sigma (Dorset, UK)
Scientific  Laboratory  Supplies 
(Nottingham, UK)
Sigma (Dorset, UK)
Autogen Bioclear (Wiltshire,UK) 
Autogen Bioclear (Wiltshire,UK) 
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Ipegal
Lipopolysaccharide (LPS) 
Methanol
Minimum essential medium 
mGlul,5, 2,3,4,6,7,8 primers 
Mouse anti-pactin 
Mouse anti-ED-1 
Mouse anti-Pan Cadherin 
Mouse anti-PERK 
New bom calf serum 
Oligo (dT)i2-i8 primer
Sigma (Dorset, UK)
Sigma (Dorset, UK)
VWR International (Leicester, UK) 
Life technologies (Paisley, UK) 
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Serotec (Oxford, UK)
Abeam (Cambridge, UK)
Autogen Bioclear (Wiltshire,UK) 
Invitrogen (Paisley, UK)
Invitrogen (Paisley, UK)OX-42
Penicillin
Percoll
Propidium Iodide 
Protein A/G agarose beads 
PP2
PVDF membrane
(Immobilon-P-polyvinylidene di-fluoride)
Rabbit anti-iNOS
Rabbit anti-total-ERK
Rabbit anti-pan Cadherin
Rabbit anti-mGluRl
Rabbit anti-mGluR 2
Rabbit anti-mGluR 2/3
Rabbit anti-mGluR 4
Rabbit anti-mGluR 5
Rabbit anti-mGluR 7
Rabbit anti-mGluR 8
SDS polyacrylamide gels (10%)
Sheep anti mouse (TRITC)
Sheep anti mouse (FITC)
Soybean trypsin inhibitor 
Taq DNA polymerase 
TBE buffer (lOx)
Tissue culture plasticware
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Autogen Bioclear (Wiltshire, UK) 
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Autogen Bioclear (Wiltshire, UK) 
Sigma (Dorset, UK)
Sigma (Dorset, UK)
BD Biosciences (Oxford, UK)
New England Biolabs (Herts, UK) 
Abeam (Cambridge, UK)
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Upstate (Buckinghamshire, UK) 
Bio-Rad (Hertfordshire, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Sigma (Dorset, UK)
Invitrogen (Paisley, UK)
Invitrogen (Paisley, UK)
Scientific Laboratory Supplies 
(Nottingham, UK)88
TNFa Quantikine ELISA kits
Trypsin
Trizol reagent
Tween 20
U0126
Wistar rats (bred and reared in house)
R&D systems (Oxford, UK) 
Sigma (Dorset, UK) 
Invitrogen (Paisley, UK) 
Sigma (Dorset, UK)
Promega (Southampton, UK) 
Charles River UK (Kent, UK)89
2.2  Methods
2.2.1  Isolation and culture of primary microglia
Microglial cells were isolated from 3-14 day old Wistar rat pups. Animals were 
killed by cervical dislocation and decapitation in accordance with the United Kingdom 
Animals (Scientific Procedures) Act of 1986. 4-6 Brains were transferred into 40 mis of 
ice  cold  phosphate-buffered  saline  (PBS,  140mM NaCl,  5mM  KC1,  25mM Na2HPC>4, 
2.9mM  Na2HPC>4.2 H2 0 ,  llmM   glucose,  0.2%  BSA,  pH  7.4).  The  brains  were 
homogenised  with  a  glass  hand  held  homogeniser  and  teflon  pestle  (Thomas  B841 
homogeniser with  number  S  947  teflon pestle,  USA)  until  smooth,  and  centrifuged  at 
500g for 10 minutes at RT (Eppendorf 5804R centrifuge using rotor A-4-44 with swing 
out buckets). The pellet was then resuspended in 70% isotonic Percoll diluted with PBS, 
this  was  overlaid  with  35%  isotonic  Percoll  and  finally  with  PBS.  This  gradient  was 
centrifuged at 1250g for 45 minutes at RT. After removal of myelin, cells at the 35/70% 
interface  (Figure 2.1) were collected and washed  in  PBS  by centrifugation at 500g for 
10 minutes at RT.
The  pellet  was  then  resuspended  in  minimum  essential  medium  (MEM) 
supplemented  with  Earle’s  salts  (25mM  KC1,  30mM  glucose,  25mM  NaHCCh,  ImM 
glutamine, 10%  heat  inactivated  foetal  calf  serum,  50U/ml  penicillin,  50pg/ml 
streptomycin, 3.3pg/ml ampicillin) and cell number calculated using a haemocytometer. 
Trypan blue (0.001%) was used to ensure viability of microglial cells. Cells were plated 
on  13mm glass coverslips at 9 x  104 cells per coverslip. Forty minutes after plating, the 
cells were washed in medium to remove debris, adhered cells were left in fresh medium. 
Cultures were maintained at 37°C in 5% CO2. Cells were routinely used at 1   day in vitro 
(DIV).  After  1   DIV,  microglia  exhibited  a  resting,  ramified  morphology  with  only  a 
small  number of cells  staining  for ED-1  (see  Immunolocalisation  2.2.12),  an  antibody90
that recognises a lysosomal protein (Graeber et al.,  1990;  Slepko and Levi,  1996).  ED-1 
binds  with  an  antigen  expressed  on  the  membranes  of  cytoplasmic  granules,  like 
phagolysosomes,  as  well  as  on  the  cell  surface,  and  expression  correlates  with 
phagocytic activity of the respective cell type (Damoiseaux et al.,  1994), therefore high 
levels  of ED-1  staining  are  associated  with  macrophages  or activated  microglia  while 
low  ED-1  expression  is  related  to  resting,  ramified  microglia  (Graeber  et  al.,  1990; 
Slepko and Levi,  1996).
1% PBS—
35% percoll— 
70% percoll—W
Myelin debris 
->  Microglia
Red blood cells
Figure 2.1  Schematic diagram of a percoll gradient
Following centrifugation, red blood cells are pelleted at the bottom of the tube while 
microglia collect at the  70/35%  percoll  interface.  Myelin  is collected  and  removed 
from the 35% percoll-PBS interface
2.2.2  Growth and maintenance of N9 microglial cell line
The  N9  cell  line  was  kindly  provided  by  Dr.  Paola  Ricciardi-Castagnoli  and 
initially  derived  from  embryonic  day  13  mouse  microglial  cultures  (Corradin  et  al., 
1993).  Responses  from  these  cells  were  similar to  those  from  primary  cultures  of rat 
microglia  (Kingham  and  Pocock,  2000).  Stocks  of  N9  cells  were  preserved  in  N9 
freezing medium  (10% DMSO, 90% FCS) and  stored at -80°C.  N9 cells were cultured 
in  DMEM  supplemented  with  4.4mM  NaHCC>3,  50pM  p-mercaptoethanol,  5%  foetal91
calf  serum,  50U/ml  penicillin,  50pg/ml  streptomycin,  3.3pg/ml  ampicillin,  50mg/ml 
kanamycin and 50mg/ml gentamycin, at 37°C in a humidified atmosphere of 5% carbon 
dioxide  in air and passaged  regularly with  a  sterile  cell  scraper.  N9s were  plated at a 
density  of 4  x  104  cells  per  13mm  coverslip  or at 2.5  x  105  cells  per  lysate  dish  and 
routinely used after 1  DIV.  N9 cells were found to express different mGluR profiles to 
primary microglia and were therefore not used for toxicity, modulatory or phagocytosis 
experiments.  Throughout  this  thesis  these  cells  will  be  referred  to  as  N9  cells  to 
differentiate them from the primary microglia.
2.2.3  Myelin preparation 
2.2.3a  Myelin isolation
Whole  brains  were  removed  from  adult rats  following  decapitation  and  placed 
on ice. The brains were washed in lx PBS then resuspended in 0.32M sucrose (made up 
in  lOmM  Tris  HC1,  pH7.4)  at  lOml/g  wet  weight,  and  homogenised  using  an  Ultra- 
Turrax  homogeniser  (Janke  and  Kunkel  Ika  Werk)  for  2  minutes.  The  resulting 
suspension was layered onto 0.8M sucrose in  lOmM Tris-HCl and centrifuged at 20,000 
rpm for 30 minutes at RT (in a Beckman J2-21  centrifuge with rotor JS-4.2, USA). The 
interfaces were then removed,  pooled and made up to 240mls  in  lOmM Tris-HCl then 
centrifuged  at 20,000 rpm  for  10 minutes at RT.  Pellets were  retained  and  exposed to 
osmotic shock in dH20 for 30 minutes at 4°C, after which samples were centrifuged and 
washed in lOmM Tris-HCl before repeating the whole process again. Finally the sample 
was resuspended  in Tris-HCl for analysis of protein concentration (Lowry et al.,  1951; 
Norton and Podulso,  1973).92
2.2.3b Myeln labelling
Myelin was labelled using Dil fluorescent labelling dye from Invitrogen. Myelin 
was incubated with Dil fluorescent labelling dye at a concentration of 12.5pg per ml of 
myelin  sample for 30 minutes at 37°C  with  constant end over end  roatation.  Labelled 
myeln was then washed three times in sterile PBS to remove any unbound dye.
2.2.4  Measurement of protein in myelin samples
The total protein concentration of myelin samples was determined by the Folin 
phenol method (Lowry et al.,  1951), which is based on a two-step colour reaction.  In an 
alkaline  solution  copper  associates  with  protein  and  subsequently  reduces  the  Folin 
reagent to  form  a  blue  coloured  product.  To  maximise  the  colour resulting  from  the 
reduction, 0.4M sodium hydroxide is present to neutralise any acid released on addition 
of the  Folin’s  solution  and  sodium  carbonate  is  added  to  buffer  the  reagents  to  an 
optimal  pH  of  10.  The  optical  density,  read  at  750nm,  is  proportional  to  the  copper 
bound protein.
For protein analysis, an aliquot of each sample was thawed on ice and diluted to 
1   in 30 using 0.05M NaOH.  Standards of bovine serum albumin (BSA) fraction V were 
prepared (0,  5,  10,  15, 20 and 30 pg/ml) in a volume of 150pl.  Samples and standards 
were  assayed  in  duplicate.  50pl  of each  diluted  sample  was  placed  in  a  10ml  conical 
tube  (Fisher  Scientific,  Loughborough,  UK)  with  lOOpl  distilled  water.  50jul  0.4M 
NaOH  was  added  to  each  tube  (standards  and  samples),  followed  by  1ml  of freshly 
prepared  solution  X  (2%  Na2C0 3 ,  0.02%  K2  Tartrate  in  0.1M  NaOH  added  to  1% 
CUSO4.5 H2O in a ratio of 99:1).  All tubes were vortexed,  and  left for  15min.  lOOpl of 
Folin and  Ciocalteu’s  reagent (diluted  1:1  with water;  VWR) was added to  each tube. 
After vortex mixing the tubes, they were incubated in the dark for a further 30 min. The 
absorbance  of  each  sample  was  read  on  an  Ultraspec  2000  spectrophotometer93
(Amersham  Pharmacia  Biotech  UK  Ltd.,  Buckinghamshire,  UK),  with  water  as  a 
reference  reading  repeated  in  between  samples.  The  generation  of a  linear  standard 
curve  allowed conversion  of optical  density to  pg of protein per sample,  any  samples 
with concentrations above the  level  of the  standard curve were  re-assayed with a  1:50 
dilution.
2.2.5  Treatment of microglial cultures
Microglia  were  routinely  used  one  day  after  plating.  Microglial  cells  were 
exposed to Lipopolysaccharide (LPS) or myelin at defined concentrations for stipulated 
times.  (For  concentrations  see  Table  2.1).  In  experiments  modulating  mGluRs, 
microglia  were  pre-treated  with  the  appropriate  mGluR  agonist  or  antagonist  for  30 
minutes at 37°C before incubation with an activator.  For inhibition of iNOS, microglia 
were incubated with the selective iNOS inhibitors AMT-HC1 (150nm) (Kingham et al.,
1999)  for  1   hour  prior  to  addition  of  activators.  In  experiments  modulating 
phosphorylation  of ERK  proteins,  U0126  (5pM)  (Favata  et  al.,  1998)  was  applied  to 
cultures for 30 minutes preceding microglial activation.
At  specified  times,  conditioned  medium  was  collected  from  the  microglia 
(MGCM)  and  centrifuged  at  500g  (in  a Jouan  centrifuge,  St  Herblain,  France),  for  5 
minutes to allow removal of debris or floating cells. The supernatants were then frozen 
in  1ml aliquots to minimise excessive freeze thaw cycles, and stored at -20°C for future 
measurement of particular substances (eg:  TNFa,  glutamate,  nitrite) or stored  in sterile 
eppendorfs  for  application  to  neurones  and  subsequent  assessment  of apoptosis.  The 
cells  were  then  fixed  in  4%  formaldehyde-  phosphate-buffered  saline  (F-PBS,  4% 
formaldehyde,  140mM  NaCl,  5mM  KC1,  25mM  Na2HP04,  2.9mM  Na2HP04.2H20, 
llmM   glucose,  0.2%  BSA,  pH  7.4)  and  stored  at 4°C  for  immunolocalisation.  Fixed94
cells were later probed for mGluR or ED-1  expression (Table 2.2).  Microglia were also 
lysed for western blotting or mRNA was extracted for reverse transcription.
A g o n i s t /
c o m p o u n d
C o n c e n t r a t i o n A n t a g o n i s t C o n c e n t r a t i o n
G r o u p   I A D A 2 5 0 p M A I D A 2 5 0   p M
G r o u p   I I D C G I V 5 0 0 n M M C C G 5 0 0 p M
G r o u p   I I I A P 4 lO O p M M A P 4 5 0 0 p M
A c t i v a t o r s L P S l p g / m l
M y e l i n 0 . 0 0 1 -   l O p g / m l
i N O S   i n h i b i t o r A M T - H C L 1 5 0 n M
M E K   i n h i b i t o r U 0 1 2 6 l p M -   5 p M
R h o   k i n a s e   i n h i b i t o r Y - 2 7 6 3 2 lO O n M
S r c   k i n a s e   i n h i b i t o r P P 2 5 0 - 1 0 0 n M
Table 2.1  Concentrations of mGluR agonists, antagonists and activators used
These compounds were added at given concentrations to microglia or CGCs in vitro.
Concentrations were selected based on previous studies.
2.2.6  Assessment of microglial phagocytic activity
Microglia  were  incubated  at  37°C  with  20pg/ml  fluorescently  labelled  dextran 
beads  or 2  pg/ml  fluorescently  labelled  myelin  for  2,  4  or  24  hours.  Subsets  of cells 
were  pre-treated  with  mGluR  agonists  or  antagonists,  U0126  or  PP2  for  30  minutes 
prior  to  incubation  with  either  dextran  beads  or  fluorescent  myelin  (Table  2.1). 
Microglia  that  were  exposed  to the  rho  kinase  inhibitor Y-27632  were  incubated  with 
this  compound  for  24  hours  before  exposure  to  labelled  myelin  as  described  above 
(Table 2.1).  To ensure that the observed fluorescence was due to phagocytosis and  not 
binding, subsets of microglia were pre-treated with  154mM sodium azide in sterile PBS 
for  5  minutes  at  37°C  before  exposure  to  labelled  myelin  (Nesti  et  al.,  2004),  or 
incubated  with  labelled  myelin  at 4°C.  Coverslips were  then  removed  from the wells,95
washed in warm basic medium (120mM NaCl, 3.5mM KC1, 0.4mM KH2PO4, 20mM N- 
Tris,  5mM NaHCOs,  1.2mM NaS0 4 ,  5mM glucose) to remove any free dextran beads 
or  fluorescent  myelin  from  the  cells,  and  immediately  observed  in  a  fluorescence 
microscope  (Zeiss,  Oberkochen  Germany).  To  ascertain  that  un-phagocytosed  myelin 
was  removed  from the microglia,  a subset of cells were  incubated with cold  stripping 
wash (0.5M sodium chloride, 0.2M acetic acid in sterile PBS) for 2 minutes which strips 
substances  bound  to  cells  (Nesti  et  al.,  2004).  Fluorescence  from  40kDa  beads  was 
captured  with  a  FITC  filter  set and  manual  exposure  of 20000ms.  Fluorescence  from 
lOkDa  beads  was  captured  with  a  rhodamine  filter  set  and  manual  exposure  of 
15000ms.  The  fluorescence  from  cells  incubated  with  labelled  myelin  was  measured 
with a rhodamine filter set and manual exposure of 2000ms. A phase contrast image of 
the same field was also acquired for quantification of phagocytosing cells.
2.2.7  Preparation of cerebellar granule neurones
Cerebellar granule neurones (CGCs) were prepared from 3-6 day old Wistar rats 
(Evans and Pocock,  1999). Animals were killed by cervical dislocation and decapitation 
in accordance with the Animals (Scientific Procedures) Act of 1986 (United Kingdom). 
Cerebella  were  removed  into  chilled  Solution  B  (lOOmM  phosphate  buffered  salts 
Dulbecco’s  formula  (PBS),  lOmM  glucose,  0.3%  fatty  acid  free  BSA,  0.38% 
MgS0 4 .7 H20 ) and mechanically dissociated with a sterile razor blade then incubated in 
0.25% trypsin for 20 minutes at 37°C with regular agitation.  Solution W (16% solution 
C made up in solution B, 20mls) was then added to the cell  suspension and cells were 
pelleted by centrifugation at 500g for 5 minutes and resuspended in solution C (lOOmM 
PBS, 0.3% fatty acid free BSA,  lOmM glucose, 0.38% MgS0 4 .7 H20 ,  lOOU/ml DNAse, 
50pg/ml  soybean  trypsin  inhibitor).  This  solution  was  pipetted  on  top  of EBSS/BSA 
(Earle’s balanced salt solution with 26mM NaHCC>3, 3mM MgS0 4 .7 H20 , 4% fatty acid96
free  albumin;  5mls)  and  centrifuged  for  10  minutes  at  500g.  After  removal  of EBSS 
solution  from  the  pellet,  cells  were  resuspended  in  culture  medium  and  plated  at  a 
density of 6 x 105 on  13mm coverslips. Cultures were maintained at 37°C in 5% CO2 in 
MEM  (with  Earle's  salts  supplemented  with  25mM  KC1,  30mM  glucose,  25mM 
NaHCC>3,  ImM  glutamine,  10%  foetal  calf  serum,  50U/ml  penicillin,  and  50pg/ml 
streptomycin, 3.3  pg/ml ampicillin). This medium was the same as that used to culture 
microglia  thus  allowing  us  to  add  conditioned  medium  from  the  microglia  to  the 
neurones.
Coverslips  were  prepared  beforehand.  This  involved  soaking  in  ethanol  for  7 
days with regular agitation before baking at 180°C for a further 7 days. Coverslips were 
then  soaked  in  Poly-D-lysine  (15mg/l)  for  1   hour  at  37°C  before  use.  CGCs  were 
incubated  for  1   DIV at  37°C  in  a  humidified  atmosphere  of  5%  CO2  in  air  before 
addition  of medium  supplemented with arabinofuranoside  (ARA-C:  lOpM) to  prevent 
glial cell proliferation. After a further 2 DIV lOOpl sterile dH20  was added to each well. 
CGCs were routinely used 7-9 days after plating. Cultures contained few contaminating 
cells indicated by positive immunoreactivity to the microglial marker OX-42 (Kingham 
and  Pocock  1999)  that  recognises  the  CR3  complement  receptor  (CD1 lb/CD 18) 
(Graeber et al 1989).
2.2.8  Treatment of cerebellar granule neurones
CGCs were routinely used after 7 DIV.  At this time,  half of the CGC medium 
was removed  leaving 200pl in the wells. This was replaced with microglial conditioned 
medium which was added to each well for a 50:50 dilution (200jul) and incubated for 24 
hours at 37°C for assessment of subsequent apoptosis and death.97
2.2.9  Assessment of cell viability
2.2.9a  Assessment of apoptosis using Hoechst 33342 staining
Apoptotic  cells  were  counted  using the  fluorescent  dye  2’[epoxyphenyl]-5-[4- 
methyl-l-piperazinyl]-2,5’bi-lH-benzimidazol  (Hoechst  33342)  (Rivera  et  al.,  1998; 
Kingham et al.,  1999) which binds to the minor groove of DNA with preference for AT 
sequences  (Portugal  and  Waring,  1988).  Cells  were  fixed  in 4%  paraformaldehyde  in 
phosphate buffered saline (F-PBS) (4% formaldehyde,  140mM NaCl, 5mM KC1, 25mM 
Na2HPC>4, 2.9mM Na2 HP0 4 .2 H2 0 ,  llmM glucose,  0.2% BSA, pH 7.4) and incubated 
with  Hoechst  33342  (17.8pM)  for  10  minutes  in  the  dark.  Cells  were  viewed  at 
excitation 365nm with emission over 490nm recorded using a fluorescence microscope 
(Zeiss,  Oberkochen  Germany).  Apoptotic  cells  presented  with  condensed  pyknotic 
nuclei  which  were  more  intensely  stained  than  healthy  living  cells  that  exhibit  much 
weaker  staining  (Kingham  and  Pocock.  1999)  Apoptotic  cells  were  counted  as  a 
percentage of the total number of cells per field.
2.2.9b  Assessment of caspase expression and cell death
The expression of active caspase-3  was quantified  in  live cells using CaspaTag 
Caspase3  (DEVD) activity kit.  Caspase  3  belongs to the  subset of caspases  known  as 
effector  caspases  that  cleave  selected  substrates  thus  leading  to  the  typical  changes 
associated  with  apoptosis,  and  was  therefore  used  as  a  marker  for  cells  undergoing 
apoptosis.  All  cells  were  counterstained  with  propidium  iodide  (PI)  which  only 
permeates  cells  with  disrupted  plasma  membranes  where  it  intercalates  between  the 
bases of DNA, and is therefore a marker for cell death.
After removal of 200pl of CM, 3 pi of CaspaTag solution was added with the PI 
(5pg/ml) and incubated for 30 minutes at 37°C. Coverslips were then removed from the 
wells,  washed  in  warm  basic  medium  (120mM  NaCl,  3.5mM  KC1,  0.4mM  KH2P04,98
20mM  N-Tris,  5mM  NaHC0 3 ,  1.2mM  NaSC>4,  5mM  glucose)  and  immediately 
observed  in  a  fluorescence  microscope.  CaspaTag  fluorescence  was  captured  with  a 
FITC  filter set and manual exposure of 20000ms.  PI fluorescence was captured with a 
rhodamine  filter set and  a manual  exposure  of 500ms.  A  phase  contrast  image  of the 
same field was also acquired for quantification of viable compared with dead cells as a 
percentage of total cells per field.
2.2.10  Enzyme-linked immunosorbant assays
The enzyme-linked Immunosorbant assay (ELISA) is a method which allows the 
amount  of  a  given  antigen  in  a  sample  to  be  quantified.  This  method  employs  a 
quantitative sandwich enzyme immunoassay technique. The wells of a 96 well plate are 
coated  with  a  monoclonal  antibody  specific  for  a  given  protein,  any  of this  protein 
present  in  the  samples  will  bind  to  the  immobilised  antibody.  A  second  polyclonal 
antibody  linked  with  a  chromogenic  enzyme  is  then  incubated  prior to  addition  of a 
substrate  solution which causes an enzyme reaction producing colour in the wells.  The 
intensity of the  colour measured  is proportional to the amount of protein bound  in the 
initial step.
For the  quantitative  determination  of rat Tumor Necrosis  Factor alpha  (TNFa) 
concentration  in  cell  culture  supernatants,  Quantikine  M  Rat TNFa  Immunoassay  kits 
(R&D  systems,  Oxford  UK),  were  used  according  to  the  manufacturer’s  instructions. 
The plates are pre-coated with a specific monoclonal antibody for TNFa. After pipetting 
50pl  of assay  diluent  to  each  well,  50pl  of the  supernatant  collected  from  treated  or 
untreated microglia, or 50pl of standard were added in duplicate and incubated at room 
temperature for 2 hours.  Following 5  washes with the wash buffer provided,  rat TNFa 
conjugate was added to the wells and incubated at room temperature for 2 hours. After a 
final 5 washes,  100pl of substrate solution was added to the wells and incubated for 3099
minutes at room temperature in the dark. Stop solution (1M hydrochloric acid) was then 
added to the wells  in the  same  order, the  optical  density of each well was determined 
within  30  minutes  using  a  microplate  reader  set  to  450nm  with  a  reference  filter  of 
540nm.  TNFa concentrations  in  cell  supernatants were  determined  using the  standard 
curve from each plate (see Figure 2.2)
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Figure 2.2  Representative graph of a TNFa standard curve
The  optical  density  of  the  colour  reaction  from  known 
concentrations  of  TNFa  were  measured  to  construct  a  standard 
curve by which other samples could be measured.
2.2.11  Glutamate measurement
The presence of glutamate in MGCM was analysed by fluometric quantification 
of NADPH,  which  is  produced  though  the  reaction  of glutamate  with  NADP+  in  the 
presence  of glutamate  dehydrogenase  (Nicholls  and  Sihra,  1986).  This  reaction yields 
one mol of NADPH for every mol of glutamate meaning that NADPH levels measured 
are directly proportional to glutamate levels in the supernatant.
MGCM  (lOOpl)  was  diluted  in  basic  medium  (120mM  NaCl,  3.5mM  KC1, 
0.4mM KH2P04, 20mM N-Tris,  5mM NaHC03,  1.2mM NaS04,  5mM glucose; 900pl) 
then  incubated  with  NADP+  (ImM)  and  glutamate  dehydrogenase  (32.4U/ml)  for  8100
minutes at 37°C in the dark. NADPH  levels were then measured using a Perkin Elmer 
fluorimeter  with  excitation  set  at  340nm  and  emission  greater  than  400nm  was 
collected.  The  concentration  of  glutamate  was  determined  against  a  standard  curve 
(Figure 2.3).  Glutamate experiments were performed  in duplicate on samples collected 
from three separate experiments.
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Figure 2.3 Representative graph of a glutamate standard curve
The optical density of known glutamate  samples were measured to 
construct  a  standard  curve  by  which  other  samples  could  be 
measured
2.2.12  Immunolocalisation
2.2.12a  Fluorescent staining of primary cells
This method localises the expression of labelled proteins throughout the cell thus 
allowing the  sub-cellular expression  of a  given  protein  to  be  analysed  under different 
stimuli.  Double  immuncytochemical  staining  was  performed  using 
immunofluorescence.  See  table  2.2  for  a  list  of  proteins  probed  for  and  respective 
blocking and antibody conditions used.101
Microglia were activated after  1 DIV then fixed in 4% F-PBS and stored at 4°C 
until ready for staining. Cells were permeabilised in methanol at -20°C for  10 minutes. 
After  washing  in  PBS,  cells  were  blocked  for  30-60  minutes  in  appropriate  blocking 
serum (eg: 4% Normal goat serum in  lx PBS) followed by addition of primary antibody 
which was incubated with the cells overnight at 4°C (Table 2.2). A negative control  in 
which  primary  antibody  was  omitted  for  each  condition  was  left  in  blocking  serum 
overnight to test the  specifity of staining.  Cells were washed  in three changes of PBS 
then  incubated  with  the  appropriate  secondary  antibody  for  one  hour  at  room 
temperature  (Table  2.2).  All  incubations  were  performed  in  a  humidified  chamber  to 
prevent  excessive  evaporation.  After  a  final  three  washes  the  nuclear  stain  4'-6- 
Diamidino-2-phenylindole  (DAPI) was  applied  for  90  seconds  after which  cells  were 
washed in distilled water and mounted with DPX mountant.
2.2.12b  Fluorescent staining of fixed sections.
Spinal  cord  sections were  kindly supplied by Prof.  Reynolds’  lab.  Spinal cords 
were removed from rats at the acute  initial disease episode (22-27 days post MOG  injection) and 
the  long-term  chronic phase  of disease  (>100 days  post MOG  injection).  Tissue was perfusion and 
post-fixed  in 4%  parafomaldehyde.  Cords  were  then  cut  in  transverse  sections  of 6-8 
microns.  Lesions  in  tissue  were  identified  by  the  clusters  of MHC-1I  labelled  cells 
which are present in inflammatory plaques
Sections were blocked with 5% normal goat serum for  1   hour at RT. A mixture 
of two antibodies (rabbit anti- mGluR,  1:50; and an antibody raised against MHC class 
II antigens, mouse anti- OX6 directly conjugated to FITC,  1:50) in PBS were added to 
the sections and incubated for  1   hour at RT. After 3x 5 minute washes in PBS, sections 
were  incubated  with  a  fluorescent  secondary  antibody  (goat  anti-rabbit  (TRITC 
conjugated),  1:50)  to  detect  cells  labelled  for  mGluRs,  for  1   hour  at  RT.  Following102
another washing stage,  sections were  incubated for 90 seconds with DAPI and washed 
once  more  in PBS before  being mounted  in Citifluor® antifade reagent.  Sections were 
examined under a fluorescent microscope (Zeiss, Oberkohen Germany).
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Table 2.2  Antibody  concentrations  used  for  Immunolocalisation  and  western 
blotting experiments.103
2.2.13  Western Blotting
Western blotting is a technique for quantifying specific protein levels in a given 
sample.  This technique  involves  running the  protein  in  a  sample  through  a  gel  under 
high  electrical  current to  separate  proteins  by  molecular weight,  smaller proteins  will 
travel  further than  large  proteins  in  a  given  time.  These  are  then  transferred  on  to  a 
membrane and probed with antibodies raised against the protein of interest.
2.2.13a Preparation of cell lysates
Following  treatment,  microglial  cells  were  scraped  into  lOpl  ice  cold  RIPA 
buffer (1% NP-40 (Ipegal), 0.5% sodium deoxycholate, 0.1% SDS,  ImM benzamadine, 
4pg/ml leupeptin -  in 50mM Tris (pH 7.5)). This was pooled from 3  coverslips to give 
approximately 30pl of sample. Lysates were incubated on ice for approximately  1   hour 
before  being centrifuged  (in a Jouan centrifuge,  France),  at  13500g for 5  minutes this 
allowed removal of un-lysed protein and debris.
2.2.13b Bradford Protein Assay
The  protein  concentration  of the  cell  lysates  was  calculated  by  the  method  of 
Bradford (Bradford,  1976) using bovine serum albumin (BSA) as standard (Figure 2.4). 
Samples (lpl  each) to be tested were pipetted  into glass tubes  in duplicate then mixed 
with  Bradford  reagent  (1ml).  After  20  minutes  the  optical  density  was  measured  at 
595nm against a Bradford reagent blank. The protein concentration in  lpl of cell lysate 
was  determined  from  the  standard  curve  and  the  amount  of sample  required  to  give 
appropriate protein concentration (45-60ug/ml) was calculated.104
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Figure 2.4  Representative standard curve for protein assay
The  optical  density  (measured  at  595nm),  of  BSA  samples  of  0- 
15pg/ml were measured to construct a standard curve by which other 
samples could be measured
2.2.13c  SDS-Polyacrylamide gel electrophoresis
Protein  in  the  cell  lysates  was  separated  by  SDS-Polyacrylamide  gel 
electrophoresis (SDS-PAGE)  in  BioRad mini  protean II electrophoresis  cells (BioRad, 
UK).  For  western  blot  analysis  of iNOS,  phospho  ERK  or  actin  expression,  samples 
were  resolved  on  a  10%  sodium  dodecyl  sulphate  (SDS)-  polyacrylamide  gel  and 
transferred to Immobilon P polyvinylidene difluoride (PVDF) membranes.
Prior  to  electrophoresis,  samples  were  boiled  for  5  minutes  in  1  OjLtl  laemelli 
sample buffer (1% SDS,  10% glycerol, 2.5% (3-mercaptoethanol,  125mM Tris/HCl,  1% 
bromophenol  blue,  pH  6.8;  30-40pg/well).  BioRad  SDS-PAGE  pre-cast Tris-HCl  gels 
(10%) were prepared and washed in running buffer (125 mM Tris, pH 8.3,  1M Glycine, 
0.01%  SDS)  then  placed  in  the  running  stand  ensuring  a  good  seal  was  formed  to 
prevent leaking of the inner chamber. Molecular weight markers were added to one lane 
of each  gel  followed  by remaining  samples  in the  other  lanes.  The  remaining running 
buffer  was  then  poured  first  into  the  inner  chamber  without  disturbing  the  loaded 
samples,  then  the  outer  chamber  until  the  tank  was  filled.  The  gels  were105
electrophoressed  at  180V  for  approximately  40  minutes  or  until  the  samples  had 
reached the bottom of the gel.
2.2.13d  Electrophoretic Protein transfer
Transfer buffer (25mM Tris,  192mM Glycine, 20% methanol, 0.01% SDS) was 
prepared  while  the  gel  was  running  then  put  in  the  freezer  to  cool.  The  glass  plates 
holding the gel were separated and the gel was cut in the bottom left hand comer on the 
side of the molecular weight markers. The gel was equilibrated in transfer buffer for  10 
minutes as were 2 pieces of 3MM paper cut to the size of the gel. Meanwhile, the PVDF 
(Immobilon  P)  membrane  was  activated  in  chilled  methanol  for  1   minute  then 
equilibrated in cold transfer buffer for a further 5 minutes. The gel was transferred to a 
cassette by removing the transfer buffer, placing a 3MM sheet on top and inversing the 
tray.  The  membrane  was  laid  on  the  gel  without  bubbles  followed  by  the  remaining 
3MM sheet. The loaded cassette was then slotted between the blank cassette and the ice 
pack in the transfer tank which was then filled with the remaining transfer buffer and a 
stir bar. The gel was transferred at 80V for 2 hours or 22V for 16 hours.
2.2.13e  Immunoblotting
The membrane was removed from the transfer tank and washed for  10 minutes 
in Tween-20 Tris buffered saline (TTBS;  lOmM Tris/HCl,  150mM NaCl, 0.5% Tween- 
20,  pH 7.4) before being  immersed  in blocking buffer (TTBS,  5% non-fat dried milk) 
for up to 2 hours at room temperature to minimise non-specific binding. The appropriate 
primary antibody was then diluted in blocking buffer and incubated with the membrane 
for 1-2 hours. After washing with three changes of T-TBS, the membrane was incubated 
with the corresponding secondary antibody conjugated to HRP for a further 1-2 hours at 
room temperature (Table 2.2). Following a final three washes with T-TBS, the proteins106
of interest were  detected  by  enhanced  chemiluminescence.  To  ascertain equal  protein 
loading,  membranes  were  re-probed  for  mouse  anti-  p-actin.  western  blots  were 
performed in triplicate therefore blots shown are representative of a single experiment. 
Gel-Pro  software  (version  3.1)  was  used  to  determine  optical  density  and  subsequent 
quantification of protein. iNOS and phospho ERK expression were therefore calculated 
in relation to p-actin.
2.2.14  Reverse transcriptase polymerase chain reaction (RT-PCR1
Control  of gene  transcription  whereby  a  gene’s  DNA  sequence  is  used  as  a 
template  for  DNA  synthesis,  is  critical  in  the  regulation  of  gene  expression.  Gene 
transcription  levels  are  altered  in  response  to  many  signals  that  occur  during  normal 
physiological function but also in response to other factors including disease. This leads 
to changes in levels of individual mRNAs. RT-PCR is used to analyse gene transcripts, 
first mRNA  is extracted  from  cells then used as a template for reverse transcription to 
complimentary  DNA  (cDNA).  Specially  designed  primers  are  then  used  to  amplify  a 
selected cDNA region using the polymerase chain reaction (PCR).
2.2.14a mRNA extraction
Microglia destined for mRNA extraction and PCR were plated in lysate dishes at 
450,000 cells per lysates and used after  1   DIV. Microglia were washed once in medium 
to  remove  dead  cells  and  remaining  debris,  then  lysed  in  1ml  Trizol  reagent  per 
condition (2-6 wells) for 10 minutes at room temperature and transferred to sterile  1.5ml 
eppendorfs.  Neat  chloroform  (200pl  per  sample)  was  then  added  and  samples  mixed 
thoroughly then allowed to  settle  before  being centrifuged  at  1500g for  10  minutes at 
4°C (eppendorf S415R, with rotor F45-24-11). Extracted mRNA remained  in the upper 
aqueous phase which was collected by a sterile glass pipette into a fresh tube, care was107
taken not to aspirate any of the white interfase, then precipitated with isopropyl alcohol 
(500pl  per  sample)  for  10  minutes  at  room  temperature.  mRNA  was  pelleted  by 
centrifugation at  1200g at 4°C for  10 minutes then washed once  in 75% ethanol.  After 
removal  of  supernatant  any  remaining  ethanol  was  left  to  evaporate  before  re- 
suspending the pellet in 40pl DEPC-treated water and heating at 60°C for 10 minutes to 
aid dissolving. The mRNA suspension was then frozen and thawed before removing 3 pi 
into 400pl  sterile water for measurement of total mRNA  quantified  by optical  density 
readings at 260 nm. Purity was estimated by the 260/280nm ratio and only samples with 
an mRNA ratio over 1.8 were used.
2.2.14b  Reverse Transcription
The  cDNA  template  for  PCR  is  synthesised  from  mRNA  by  reverse 
transcription.  Moloney  Murine  Leukaemia  virus  (M-MLV)  reverse  transcriptase  is  an 
mRNA-dependant DNA polymerase which uses single stranded mRNA in the presence 
of Oligo d(T) primer to catalyse the first strand of cDNA.
mRNA  (3pg)  was  added  to  sterile  tubes  with  40U  RNase  inhibitor to  prevent 
degradation  of mRNA  and  made  up  with  sterile  water  to  13.5pl.  Oligo  d(T)  primer 
(250pg)  was  added  to  mRNA  solution  and  heated  at  70°C  for  10  minutes.  After 
quenching  on  ice,  samples  were  reverse  transcribed  into  single-stranded  cDNA  in 
14.5pl  reaction  mixture  (5x  RT  buffer  [50mM  Tris-HCI,  pH  8.3,  75mM  KC1,  3mM 
MgC^],  lOmM  0.1M  dithiothrietol  (DTT),  40U  RNase  inhibitor,  0.5mM 
deoxyribonucleoside  triphosphates  (dNTPs),  600U  MMLV)  at  37°C  for  80  minutes. 
Incubation  at  70°C  for  10  minutes  terminated  the  reverse  transcription  reaction. 
Resultant single stranded cDNA was diluted with sterile water for a final concentration 
of 20ng/pl then boiled for 5 minutes to denature before freezing.108
2.2.1§c  Polymerase chain reaction (PCR)
PCR  is  a  technique  for  amplifying  areas  of  DNA  using  complementary 
fragments  of DNA  flanking  the  region  of  interest  (oligonucleotide  primers).  Primer 
design requires knowledge of the DNA sequence of a gene.  Complementary sequences 
are chosen at sites on the DNA, which are most unique to reduce the chance of primers 
binding to other regions on the template DNA.  A primer length of 17-28 bp is required 
to ensure uniqueness and is usually composed of 50-60% G + C content.  The first stage 
in PCR involves separation of the DNA double helix into single strand segments using a 
high  temperature,  usually  between  91  and  97°C  for  1   min,  following  which  primers 
anneal  to  the  single  stranded  DNA  at  specific  temperatures  related  to  their  basic 
structure.  The  melting  temperature  (Tm )  of  primers  depends  on  their  length  and 
composition  of bases.  The  annealing  temperature  (Ta)  is  directly  related  to  the  Tm 
(Lewin,  1994).  These parameters are calculated by the following formulae:
Tm  = 4 (G + C) + 2 (A + T) °C 
Ta = Tm-4 °C
Most  annealing  temperatures  are  in  the  range  of about  50-65  °C.  A  higher 
temperature means the reaction is more stringent, with less chance of primer mismatch, 
however  if the temperature  is too high, then  less product will  be made.  When using a 
combination  of primers,  the  annealing temperature  should  be  optimised  to  ensure  the 
formation  of  non-specific  low  molecular  weight  products  are  minimised.  After  the 
annealing stage,  the temperature  is then  changed to  allow activation  of a heat-tolerant 
DNA  polymerase,  which  extends the  primer  in  a  5’  to  3’  direction  using  surplus  free 
deoxyribonucleoside triphosphates  (dNTPs).  A third temperature change  denatures the 
DNA strands and the cycle can repeat, allowing the number of cycles to determine the109
degree  of  DNA  amplification.  The  amplification  is  exponential  up  to  a  point  then 
plateaus  out,  with  DNA  polymerase  being  the  rate  limiting  factor.  Taq  DNA 
polymerase (from Thermus aquaticus bacteria) is heat stable and therefore ideal for this 
application.  It has a half life of 30 min at 95 °C thus the number of amplification cycles 
shouldn’t  exceed  30  cycles  without  reducing  the  denaturation  time.  Taq  polymerase 
requires the presence of free magnesium ions to function, with the magnesium acting as 
a  cofactor.  Lower  concentrations  of  magnesium  chloride  (MgCb)  increase  the 
stringency  of the  reaction,  thus  MgCL  titrations  should  be  performed  with  each  new 
primer combination.
As mGluRs are expressed at low levels on microglia, titrations were performed 
for both  MgCh  and  optimum  annealing temperatures  (OATs)  in  order to optimise the 
protocol.  Results  showed  that  for  mGluRl  (Figure  2.5)  a  concentration  of  2.5mM 
MgCL and an OAT of 65°C produced the clearest band.  For mGluR5  (Figure 2.5) the 
optimal  concentration  of  MgCL  was  2.5mM  and  annealing  temperature  was  65°C. 
Primers for group II mGluR subtypes 2 and 3  worked best with 2.5  and 2 mM MgCh 
respectively  and  were  both  annealed  at  61°C  (Figure  2.5).  The  optimal  annealing 
temperature  for  all  group  III  mGluR  primers  was  56°C  (Figure  2.6).  The  MgCL 
concentrations that worked  best for mGluR4 and  6 was  1.5mM while  mGluR  7  and  8 
showed clearer bands using a higher concentration of 2mM.110
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Figure 2.5  Optimisation of PCR protocol for group I and II metabotropic 
glutamate receptors.
(A)  Various  concentrations  of  MgCh  (from  0.5-2.5mM)  were  tested  to 
investigate  which  were  optimal  for  each  set  of primers.  The  arrows  indicate 
MgCh  concentration  used  for  each  set  of primers.  (B)  Primer  pairs  were  also 
tested  at  different  annealing  temperatures  (from  55-65°C).  The  Circled  bands 
indicate  the  optimum  annealing  temperature  used  for  each  primer  pair,  these 
were chosen as at optimum temperatures the bands were notably clearer.Ill
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Figure 2.7  Optimisation of PCR protocol for group III  metabotropic 
glutamate receptors.
(A)  Various  concentrations  of  MgCh  (from  0.5-2.5mM)  were  tested  to 
investigate  which  were  optimal  for  each  set  of primers.  The  arrows  indicate 
MgCh  concentration  used  for each  set of primers.  (B) Primer pairs were also 
tested  at different annealing temperatures  (from  55-65°C).  The  Circled  bands 
indicate  the  optimum  annealing temperature  used  for  each  primer pair,  these 
were chosen as at optimum temperatures the bands were notably clearer.112
PCR  was  performed  on  the  equivalent  of  200ng  of reverse-transcribed  total 
mRNA (lOpl RT product) from each sample as described previously (Copelman et al.,
2000).  RT  product  was  incubated  with  40pl  reaction  mixture  (lOx  Taq  DNA 
polymerase  buffer:  50mM  KC1,  lOmM Tris-HCl,  (pH  9), 0.1%  Triton X-100;  200pM 
dNTPs,  ImM  Forward  PCR  primer,  ImM  Reverse  PCR  primer,  1.5-2.5mM  MgCb, 
2.5U  Taq  DNA  polymerase;  made  up  to  40pl  with  dH20)  in  a  Perkin-Elmer  Life 
Sciences thermocycler (Warrington, UK).
Complementary  DNA  sequences  were  obtained  from  the  nucleotide  sequence 
database GenBank (National Centre of Biotechnology Information, Bethesda, MD), and 
the  resulting  PCR  primer  sequences  (Sigma  Genosys),  MgCh  concentrations,  and 
optimal annealing temperatures (OAT) are shown (Table 2.3).
Wherever  possible,  primer pairs were  designed  to  span  an  intron  boundary  to 
obviate  DNase treatment of total  mRNA  before  reverse  transcription  (RT)-PCR.  PCR 
performed  on  non-reverse-transcribed  total  mRNA  samples  did  not  produce  any 
detectable products. The thermal cycle profile for each set of primers included a primary 
denaturation cycle at 94°C  for  5 min and  a final extension  period  at  72°C  for  10 min. 
The  intervening  PCR  cycle  consisted  of 30  second  segments  of primer  denaturation, 
then annealing, and 45 second segments of extension, and was repeated for 40 cycles for 
each primer pair.113
mGluR Primer
MgCl2
(mM)
OAT
(°C)
mGluRl
Forward:  5’-TGGCTCCGAACAGAGCATCGAAT-3’ 
Reverse: 5’-TTGACTATGTCGAGCATCGCCCTT -3’
2.5 64
mGluR5
Forward: 5’-GTCCTTCTGTTGATCCTGTC -3’ 
Reverse: 5’-ATGCAGCATGGCCTCCACTC -3’
2.5 64
mGluR2
Forward: 5’-GCCCCCTTTCGCCCAGCAGATAC-3’ 
Reverse: 5 ’-CAGGCAGGCGATGGTGACAGGT-3 ’.
2.5 62
mGluR3
Forward: 5’-GCTCCAACATCCGCAAGTCCTA-3’ 
Reverse: 5’-TGTCCATGGCCAGGTGCTTGTC-3’
2 60
mGluR4
Forward: 5'-TGAGCTACGTGCTGCTGGCG-3' 
Reverse: 5'-TGTCGGCTGACTGTGAGGTG-3'
1.5 56
mGluR6
Forward: 5'-CAAGTAGCAAGGTTGAGTGT-3' 
Reverse: 5'-GGTTGTAGTGTTGGATCAAG-3'
1.5 56
mGluR7
Forward:  5'-GAACTCTGTGAAAATGTAGACC-3' 
Reverse: 5'-TTAGGGAGTCCAGAATTACAG-3'
2 56
mGluR8
Forward: 5'-GAGGGTTATAACTACCAGGT-3' 
Reverse: 5'-TAGGTGCTGTGACAGATTTCT-3'
2 56
GAPDH
Forward: 5'-TGGTGCCAAAAGGGTCATCATCTCC-3' 
Reverse: 5'-GCCAGCCCCAGCATCAAAGGTG-3'
2 60
Table 2.3  Forward and reverse primer sequences for each mGluR with optimal 
MgCl concentrations and annealing temperatures
2.2.14d  1% Agarose Gel Electrophoresis
Once  amplified  the  PCR  product  can  be  analysed  by  size  separation  using 
ethidium  bromide  stained  agarose  gel  electrophoresis.  Ethidium  bromide  intercalates 
between the bases of double stranded DNA helices and these complexes fluoresce under 
ultraviolet light.
1%  agarose  was  added  to  lx  Tris-borate-EDTA  (TBE)  buffer  (lOx  TBE  from 
Invitrogen  diluted  with  dH20)  and  heated  on  medium  power  in  a  microwave  for  3114
minutes.  After  cooling,  ethidium  bromide  was  added  to  the  gel  solution  (0.5pg/ml) 
which was then poured and allowed to set. Gels were submerged in running buffer (lx 
TBE). Sucrose loading dye (6x stock: 30% w/v ultra pure sucrose and .35% orange dye) 
was  added  to  equivalent  amounts  of PCR  product  (20pl)  in  order  to  weigh  samples 
down  in the  wells.  Samples were  loaded  by  submerging pipette tip  into the wells  and 
slowly releasing the product avoiding air bubbles. Product size was verified by running 
the samples against a  100 bp DNA ladder (lOpl). The gel was run at  110V for 2 hours 
then viewed under UV light and analysed using GelPro image analysis package (Media 
Cybemectics, Berkshire, UK).
2.2.15  Statistical analysis
Data  was  analysed  with  the  GraphPad  Prism  computer  package  (GraphPad 
Software,  San  Diego  California,  USA).  A  normality  and  quality  of variance  test was 
carried out on all data to determine which test was appropriate.  A t-test,  for normally 
distributed  data sets was  used  with  significance  level  set at  95%.  If variances  of data 
sets were significantly different, then Welch’s correction was applied to correct for this. 
All values are indicated as the mean ± standard error of the mean (SEM).  P-values were 
taken as an indicator of statistical significance with the following nomenclature:  *  - P < 
0.05, ** - P < 0.01  and *** - P < 0.001.  Individual n-numbers are given in each results 
chapter.115
3.0
EXPRESSION OF MICROGLIAL 
METABOTROPIC GLUTAMATE 
RECEPTORS116
3.1  Introduction
Metabotropic  glutamate  receptors  have  important  roles  in  both  neuronal  and 
glial functions  including regulation of neurotransmitter release and neuronal excitation 
(Holscher et al.,  1999; Cartmell and Schoepp, 2000). In the CNS, mGluRs are expressed 
in  regional  and  cellular  specific  patterns  which  may  alter their  modulatory  functions 
(Biber  et  al.,  1999;  Sahara  et  al.,  2001;  Defagot  et  al.,  2002;  Hubert  et  al.,  2004). 
Microglia possess functional group I,  II and III mGluRs.  To date,  microglia have been 
shown  to  express  mGluR5  (Biber  et  al.,  1999)  mGluR2  and  mGluR3  (Taylor  et  al., 
2002)  mGluR4,  mGluR6  and  mGluR8  (Taylor  et  al.,  2002,  2003).  Furthermore, 
stimulation  of microglial  group  II  mGluRs  has  been  shown  to  induce  a  neurotoxic 
phenotype wheras group III microglial mGluRs can promote neuroprotection (Taylor et 
al., 2002, 2003, 2005)
Microglial cells play a vital role in maintaining glutamate homeostasis and  are 
also  a  primary  source  of glutamate  released  during  excitotoxic  stress  in  pathological 
conditions.  This  suggests  that  excess  glutamate  released  from  either  neurones  or 
microglia  themselves  may  stimulate  microglial  mGluRs  culminating  in  a  cycle  of 
activation  and  neurotoxicity  (Taylor  et  al.,  2002).  As  such,  control  of  microglial 
reactivity by modulation of microglial mGluRs may be a potential therapeutic  strategy 
in neurodegenerative diseases where microglial activation is implicated.
Trafficking of mGluRs occurs between the nucleus and plasma membrane. This 
process  has  been  associated  with  the  functional  activation  states  of  the  receptors, 
mGluRs  localised around the nucleus and cytoplasm are thought to be pre-active while 
trafficking  to  the  membrane  has  been  associated  with  a  functionally  reactive  state 
(Roche et al.,  1999; Ciruela et al.,  1999). It is possible that loss of microglial regulation117
and  subsequent  reactivity  and  neurotoxicity  during  disease  progression  could  be  the 
result of increased expression or activation of one mGluR subtype over another.
To  this  end,  primary  and  N9  microglial  mGluR  expression  was  examined  in 
activated compared with untreated control cells by  immunocytochemistiy or RT-PCR, 
to determine whether activation induced changes  in mGluR profile.  Tissue taken form 
the  animal  model  of MS,  EAE,  or  from  control  animals  was  also  analysed  either  by 
immunohistochemistry  or  RT-PCR  to  assess  mGluR  expression  through  disease 
progression.118
3.2  Results
3.2.1  Microglia express group 1 metabotropic glutamate receptors
Immunocytochemical  determination  of mGluRl  expression  on microglia using 
an antibody raised against mGluRl  (1:100, see table 2.2), showed that control untreated 
microglia expressed mGluRl  (Figure 3.1). In all immunocytochemistry experiments the 
specifity of the secondary antibody for the primary antibody was verified by a negative 
control  in which primary antibody was omitted  (Figure  3.17A).  This control  however, 
did not test the reliability of the primary antibody which could be achieved by peptide 
blocking.
Microglia exposed to myelin (lpg/pl) and  LPS (lpg/pl) for 24 hours  showed a 
similar level of mGluRl  expression to that seen in untreated cells.  Microglial mGluRl 
expression was localised around the nucleus with very little staining of processes which 
were  positive  for  cadherin.  RT-PCR of microglial  mRNA  (Figure  3.2A)  showed  that 
microglia express mGluRl. This was detected as a 473bp single stranded DNA product. 
Exposure  to  myelin  increased  microglial  mGluRl  mRNA  while  LPS  treated  cells 
showed  similar  levels to  control  untreated  microglia.  The N9  microglial  cell  line  was 
also analysed by RT-PCR for mGluRl  expression (Figure 3.2B).  In contrast to primary 
microglia, this expression was not altered by exposure to either myelin or LPS.
Immunocytochemical  detection  of  mGluR5  using  an  antibody  raised  against 
mGluR5  (1:100)  showed that microglia constitutively expressed mGluR5  (Figure  3.3). 
Incubation of microglia with myelin and to a lesser extent LPS for 24 hours  increased 
the expression of mGluR5. In contrast to mGluRl, mGluR5 expression was not present 
around  the  nucleus  but  was  localised  to  the  membrane  and  processes  shown  by  co- 
staining  with  the  cadherin  antibody  although  this  was  more  obvious  in  the  myelin 
treated microglia than in the control or LPS treated cells. RT-PCR of microglial mRNA119
(Figure  3.4A)  showed that microglia express mGluR5  which was detected  as a 210bp 
single  stranded  DNA  product.  Interestingly,  microglia  incubated  with  LPS  expressed 
less mGluR5 mRNA than untreated cells and microglia treated with myelin showed no 
mGluR5  mRNA expression.  This was unexpected  so repeated  using different primers 
which  showed the  same result.  The N9 microglial  cell  line was also  analysed  by RT- 
PCR for mGluR5  expression  (Figure  3.4B).  Although N9  cells  expressed mGluR5,  in 
contrast to primary microglia this was not altered by exposure to either myelin or LPS. 
See  table  3.1  for  a  summary  of  group  I  mGluR  protein  and  mRNA  expressed  by 
microglia and N9 cells.120
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Figure 3.1  Expression  and  localisation  of mGluRl  protein  in  untreated 
and activated primary microglia.
Microglia were either left untreated (i and iv) or incubated with myelin (lpg/ml) 
(ii and v) or LPS (lpg/ml) (iii and vi) for 24 hours at 37°C. Untreated cells were 
used  as  negative  controls.  Cells  were  fixed  in  4%  F-PBS.  Microglia were  co­
stained  with  antibodies  to  mGluR 1   and  cadherin,  a  plasma  membrane  protein. 
Fluorescent secondary antibodies conjugated with TRITC and FITC were used to 
detect cells stained with mgluR and cadherin respectively. DAPI, a nuclear stain 
(blue),  was  also  used  toaid  localisation  of mGluRl  expression.  Figures  (i-iii), 
show  representative  images  of microglia co-stained  for  mGluRl,  cadherin  and 
DAPI. Figures (iv-vi), show the same field but only the mGluRl  staining.  These 
figures  are  representative  images  of  staining  repeated  in  three  separate 
experiments  and  showed  that  microglia  expressed  mGluRl  protein  which 
appeared more localised to the nucleus.  Activation of cells with myelin or LPS 
did  not  obviously  alter  mGluRl  protein  immunolocalisation.  (x400121
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Figure 3.2  Expression  of mGluRl  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluRl  mRNA  expression 
(predicted 473bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each  PCR product (200ng single  stranded  DNA) were  size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive control (Mouse/Rat brain +ve). A  lOObp DNA ladder marker was run where 
the  brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified  by  densitometry  using  gelpro  3.1  software  which  allowed  the  correction 
of each  sample  against  their  respective  GAPDH  levels.  Graphs  show  the  OD  for 
microglia  (Aii)  and N9s  (Bii),  OD  represents  mGluRl/GAPDH.  Results  shown  are 
the  average  taken  from  two  separate  experiments  and  indicate  that  in  microglia, 
incubation with myelin increased expression of mGluRl  while incubation with LPS 
had  no  significant  effect  compared  with  control.  N9  cells  also  expressed  mGluRl 
but levels were not altered by exposure to myelin or LPS.Figure 3.3  Expression  and  localisation  of mGluR5  protein  in  untreated
and activated primary microglia.
Microglia were either left untreated (i and iv) or incubated with myelin (lpg/ml) 
(ii and v) or LPS (lpg/ml) (iii and vi) for 24 hours at 37°C. Untreated cells were 
used  as  negative  controls.  Cells  were  fixed  in  4%  F-PBS.  Microglia were  co­
stained  with  antibodies  to  mGluR5  and  cadherin,  a  plasma  membrane  protein. 
Fluorescent secondary antibodies conjugated with TRITC and FITC were used to 
detect cells stained with mGluR and cadherin respectively. DAPI, a nuclear stain 
(blue),  was  used  to  aid  localisation  mGluR5  expression.  Figures  i-iii,  show 
representative images of microglia co-stained for mGluR5,  cadherin and  DAPI. 
Figures iv-vi,  show the  same field but only the mGluR5  staining.  These  figures 
are representative images of staining repeated in three separate experiments and 
showed that microglia expressed mGluR5 protein which appeared localised to the 
membrane.  Activation  of cells  with  myelin  or  LPS  increased  the  expression  of 
mGluR5  protein  in  the  membrane  compared  with  untreated  cells.  (x400 
magnification).123
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Figure 3.4  Expression  of mGluR5  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR5  mRNA  expression 
(predicted 21 Obp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each PCR product (200ng single  stranded  DNA) were  size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive control.  A  lOObp DNA  ladder marker was  run where the  brightest band  is 
equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for  equivalent  amounts  of 
mRNA  from  each  condition  are  shown  below.  Bands  were  quantified  by 
densitometry  using  gelpro  3.1  software  which  allowed  correction  each  sample 
against their respective GAPDH levels. Graphs show the OD for  microglia (Aii) and 
N9s  (Bii),  OD  represents  mGluR5/GAPDH.  Results  shown  are  the  average  taken 
from  two  separate  experiments  and  indicate  that  in  microglia,  incubation  with 
myelin  decreased  the  expression  of mGluR5  while  incubation  with  LPS  had  no 
significant  effect  compared  with  control.  Interestingly  N9  cells  expressed  notably 
higher  levels  of  mGluR5  mRNA  than  any  other  subtype  and  compared  with 
microglial expression although levels were not altered by activation.124
3.2.2  Microglia express group II metabotropic glutamate receptors
Immunocytochemical  detection  of  mGluR2  using  antibodies  raised  against 
mGluR2  (1:100),  showed  that  untreated  microglia  expressed  low  levels  of mGluR2 
protein (Figure 3.5). Expression of mGluR2 protein was localised to around the nucleus 
and  cytoplasm.  Exposure  to  myelin  or  LPS  upregulated  microglial  expression  of 
mGluR2,  demonstrated  by  increased  intensity  of  staining,  and  also  augmented  the 
expression  of mGluR2  on  microglial  membranes  and  processes.  This  effect  was  less 
pronounced in microglia treated with LPS. RT-PCR of microglial mRNA (Figure 3.6A) 
showed that microglia express mGluR2.  This was detected as a 444bp  single  stranded 
DNA  product.  Exposure  to  myelin  or  LPS  increased  microglial  mGluR2  mRNA 
compared with  levels expressed by control untreated cells.  The N9 microglial cell  line 
was  also  analysed  by  RT-PCR  for  mGluR2  expression  (Figure  3.6B)  however  these 
cells  do  not  appear  to  express  mGluR2  as  PCR  amplification  failed  to  show  any 
evidence  of mRNA  expression.  This  was  not  due  to  problems  with  primer  design  or 
PCR  protocol  as  mGluR2  was  expressed  in  both  rat  and  mouse  positive  controls, 
obtained  from whole  rat and  mouse  brains respectively,  which were  run alongside the 
N9 samples.
Expression  of mGluR3  was  also  assessed  using  immunocytochemistry  (Figure 
3.7),  the  antibody  used  has  been  shown  to  bind  with  both  mGluR2  and  mGluR3 
subtypes but with a higher affinity for mGluR3.  Untreated  cells  showed  low  levels of 
mGluR3  expression which was localised around the  nucleus and cytoplasm.  Microglia 
exposed to myelin appeared to express more mGluR3  although this was  still  restricted 
to  the  cytoplasm.  Analysis  of microglial  mRNA  by  RT-PCR  confirmed  these  results 
with  untreated  microglia  expressing  low  levels  of  mGluR3  which  was  markedly 
increased in the samples incubated with either myelin or LPS (Figure 3.8A). N9 mRNA 
from cells treated in the same conditions was also assessed (Figure 3.8B). N9 cells didnot contain mGluR3 mRNA. This was not due to problems with primer design or PCR 
protocol as mGluR3 was expressed in the mouse positive control run alongside the N9 
samples.  See table 3.1  for a summary of group II mGluR protein and mRNA expressed 
by microglia and N9 cells.Figure 3.5  Expression  and  localisation  of mGluR2  protein  in  untreated
and activated primary microglia.
Microglia were either left untreated (i and iv) or incubated with myelin (lpg/ml) 
(ii and v) or LPS (lpg/ml) (iii and vi) for 24 hours at 37°C. Untreated cells were 
used  as  negative  controls.  Cells  were  fixed  in  4%  F-PBS.  Microglia  were  co­
stained  with  antibodies  to  mGluR2  and  cadherin,  a  plasma  membrane  protein. 
Fluorescent secondary antibodies conjugated with TRITC and FITC were used to 
detect cells stained with mGluR and cadherin respectively. DAPI, a nuclear stain 
(blue),  was  also  used  to  aid  localisation  of mGluR2  expression.  Figures  i-iii, 
show  representative  images  of microglia  co-stained  for  mGluR2,  cadherin  and 
DAPI.  Figures iv-vi,  show the  same  field but only the mGluR2  staining.  These 
figures  are  representative  images  of  staining  repeated  in  three  separate 
experiments  and  showed  that  microglia  expressed  mGluR2  protein  which 
appeared localised to both the nucleus and the membrane. Activation of cells with 
myelin  or  LPS  appeared  to  increase  mGluR2  protein  expression.  (x400 
magnification).127
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Figure 3.6  Expression  of mGluR2  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR2  mRNA  expression 
(predicted 444bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each  PCR product (200ng single  stranded  DNA) were  size  fractionated 
on a 1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive control (Rat/mouse +ve).  A  100 bp DNA  ladder marker was run where the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified by densitometry using gelpro 3.1  software which allowed correction each 
sample  against their respective  GAPDH  levels.  Graphs  show the  OD  for microglia 
(Aii) and N9s (Bii), OD represents mGluR2/GAPDH. Results shown are the average 
taken from two separate experiments and  indicate that in microglia,  incubation with 
myelin or LPS  increased  expression of mGluR2.  Using these  primers, N9 cells  did 
not express mGluR2.Figure 3.7  Expression  and  localisation  of mGluR3  protein  in  untreated
and activated primary microglia.
Microglia were either left untreated (i and iv) or incubated with myelin (lpg/ml) 
(ii and v) or LPS (1 jig/ml) (iii and vi) for 24 hours at 37°C. Untreated cells were 
used  as  negative  controls.  Cells  were  fixed  in  4%  F-PBS.  Microglia  were  co­
stained  with  antibodies  to  mGluR3  and  cadherin,  a plasma  membrane  protein. 
Fluorescent secondary antibodies conjugated with TRITC and FITC were used to 
detect cells stained with mGluR and cadherin respectively. DAPI, a nuclear stain 
(blue),  was  also  used  to  aid  localisation  of mGluR3  expression.  Figures  i-iii, 
show  representative  images  of microglia  co-stained  for  mGluR3,  cadherin  and 
DAPI.  Figures  iv-vi,  show the  same  field but only the mGluR3  staining.  These 
figures  are  representative  images  of  staining  repeated  in  three  separate 
experiments  and  showed  that  microglia  expressed  mGluR3  protein  which 
appeared localised to both the nucleus and the membrane. Activation of cells with 
myelin or LPS appeared to increase mGluR3 protein expression.129
A i
m G luR3 
M   396bp
„  GA PDH 
559bp
o o
L P S c o n t r o l m y e lin
T r e a t m e n t s
m G luR3
396bp
GAPDH
559bp
C /5
Q .
Figure 3.8  Expression  of mGluR3  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR3  mRNA  expression 
(predicted 396bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each PCR product (200ng single stranded  DNA) were  size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive  control  (rat/mouse  +ve).  A  lOObp  DNA  ladder marker was  run  where  the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified by densitometry using gelpro 3.1  software which allowed correction each 
sample against their respective GAPDH  levels.  Graphs show the OD for  microglia 
(Aii) and N9s (Bii), OD represents mGluR3/GAPDH. Results shown are the average 
taken from two separate experiments and  indicate that in microglia,  incubation with 
myelin  or  LPS  slightly  increased  expression  of mGluR3.  N9  cells  did  not  express 
mGluR3.130
3.2.3  Microglia express group III metabotropic glutamate receptors
Group  III  subtypes  mGluR4  and  mGluR7  only  were  analysed  by 
immunocytochemistry due to the lack of commercially available antibodies to mGluR6 
and  mGluR8.  Immunocytochemical determination of mGluR4  expression showed that 
untreated microglia expressed low levels of mGluR4  (Figure 3.9).  Exposure to myelin 
or LPS did not significantly alter microglial mGluR4 expression, which appeared to be 
mainly  localised  around  the  nucleus  and  cytoplasm  and  relatively  little  staining  of 
membranes or processes. RT-PCR analysis of microglial mRNA showed that microglia 
expressed mGluR4. This was detected as a 547bp single stranded DNA product (Figure 
3.10A).  Exposure  to  myelin  or LPS  did  not  significantly  alter  the  levels  of mGluR4 
mRNA  although  this  was  hard  to  assess  as  expression  was  so  low.  RT-PCR  of N9 
mRNA showed that these cells contain higher levels of mGluR4 than primary microglia, 
however  this  expression  was  not  affected  by  incubation  with  either  myelin  or  LPS 
(Figure 3.1 OB).
Microglia also expressed  mGluR6 mRNA,  detected as a 363bp  single  stranded 
DNA product (Figure 3.11 A). Expression was very low which made it difficult to assess 
whether  incubation  with  different activators  had  any  effect.  Microglia  expressed  very 
low  levels mGluR6  which  were  unaffected  by  exposure  to  myelin but appeared  to  be 
knocked out by LPS. We were unable to detect mGluR6 in the N9 cell line although this 
may  be  due  to  problems  with  primer  design  as  while  the  rat  brain  positive  control 
contained mGluR6, the mouse brain positive control failed to show mGluR6 expression 
(Figure 3.1 IB).
Immunolocalisation  of mGluR7  protein  showed  no  expression  above  negative 
control (data not shown) this was in accordance with previous data (Taylor et al., 2003). 
Analysis of microglial mRNA by RT-PCR demonstrated that microglia did not express 
mRNA  for  mGluR7  either  in  untreated  cells  or those  incubated  with  myelin  or  LPS(Figure 3.12A). RT-PCR of N9 mRNA confirmed these findings as PCR amplification 
failed to  show  any evidence  of mGluR7  mRNA  (Figure  3.12B).  This  was  not due to 
problems with primer design or PCR protocol as mGluR7 was expressed in both rat and 
mouse positive controls which were run alongside the N9 samples.
Expression  of  mGluR8  mRNA  was  analysed  by  RT-PCR.  Microglial  cells 
constitutively expressed low levels of mGluR8 (Figure 3.13A).which was detected as a 
440bp single stranded DNA product. Exposure to myelin increased mGluR8 expression 
while LPS appeared to have the opposite effect. Analysis of the N9 cell line showed that 
these cells do not express mGluR8 as PCR amplification failed to indicate any evidence 
of mGluR8 in the samples (Figure 3.13B). We verified that this was not due to problems 
with primer design or PCR protocol by running positive  controls of whole  mouse and 
rat brain samples which both came up positive. See table 3.1 for a summary of group III 
mGluR protein and mRNA expressed by microglia and N9 cells.Figure 3.9  Expression  and  localisation  of mGluR4  protein  in  untreated
and activated primary microglia.
Microglia were either left untreated (i and iv) or incubated with myelin (lpg/ml) 
(ii and v) or LPS (lpg/ml) (iii and vi) for 24 hours at 37°C. Untreated cells were 
used  as  negative  controls.  Cells  were  fixed  in  4%  F-PBS.  Microglia  were  co­
stained  with  antibodies  to  mGluR4  and  cadherin,  a plasma membrane  protein. 
Fluorescent secondary antibodies conjugated with TRITC and FITC were used to 
detect cells stained with mGluR and cadherin respectively. DAPI, a nuclear stain 
(blue),  was  also  used  to  aid  localisation  of mGluR4  expression.  Figures  i-iii, 
show  representative  images  of microglia  co-stained  for  mGluR4,  cadherin  and 
DAPI.  Figures  iv-vi,  show the  same  field but only the mGluR4  staining.  These 
figures  are  representative  images  of  staining  repeated  in  three  separate 
experiments  and  showed  that  microglia  expressed  mGluR4  protein  which 
appeared localised to the nucleus. Activation of cells with myelin or LPS did not 
noticeably alter mGluR4 protein expression.133
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Figure 3.10  Expression  of mGluR4  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR4  mRNA  expression 
(predicted 547bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each PCR product (200ng single stranded  DNA) were  size  fractionated 
on a 1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive  control  (rat/mouse  +ve).  A  lOObp  DNA  ladder marker was  run  where  the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified by densitometry using gelpro 3.1  software which allowed correction each 
sample  against their respective  GAPDH  levels.  Graphs  show the  OD  for microglia 
(Aii) and N9s (Bii), OD represents mGluR4/GAPDH. Results shown are the average 
taken from two separate experiments and  indicate that microglia expressed mGluR4 
mRNA  but  that  levels  of mGluR4  were  not  altered  by  activation.  N9  cells  also 
expressed mGluR4 mRNA but again these levels remained the same after activation.134
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Figure 3.11  Expression  of mGluR6  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR6  mRNA  expression 
(predicted 363bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (1 pg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each  PCR product (200ng single  stranded DNA) were size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive  control  (rat/mouse  +ve).  A  lOObp  DNA  ladder  marker was  run  where  the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified by densitometry using gelpro 3.1  software which allowed correction each 
sample against their respective GAPDH  levels.  Graphs  show the OD for  microglia 
(Aii)  OD  represents  mGluR6/GAPDH.  Results  shown  are  the  average  taken  from 
two separate experiments and indicate that microglia expressed extremely low levels 
of mGluR6  mRNA.  N9  cells  did  not  express  mGluR6  but  this  may  have  been  a 
problem  in  primer  design  since  the  mouse  brain  positive  was  also  negative  for 
mGluR6.135
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Figure 3.12  Expression  of mGluR7  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR7  mRNA  expression 
(predicted 321 bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each  PCR product (200ng single  stranded  DNA) were  size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive  control  (rat/mouse  +ve).  A  lOObp  DNA  ladder  marker was  run  where  the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent amounts of mRNA from each condition are shown below.  Results shown 
are representatives from two separate experiments and indicate that neither microglia 
nor  N9s  expressed  mGluR7  mRNA.  This  was  not  due  to  problems  with  PCR 
protocol  or primer design as  mGluR7  mRNA  was expressed  in  both  rat and  mouse 
whole brain samples.136
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Figure 3.13  Expression  of mGluR8  mRNA  in  primary  microglia  or  N9  cell 
lines activated with myelin or LPS.
Microglia  (A)  or  N9  cells  (B)  were  analysed  for  mGluR8  mRNA  expression 
(predicted 440bp). Cells were either left untreated or incubated with myelin (lpg/ml) 
or  LPS  (lpg/ml)  for  24  hours  at  37°C.  Untreated  cells  were  used  as  negative 
controls.  Cells  were  lysed  in  trizol  for  mRNA  extraction  and  RT-PCR.  Equal 
amounts of each PCR product (200ng single  stranded DNA) were size  fractionated 
on a  1% agarose, ethidium bromide stained gel. Equivalent amounts of ssDNA taken 
from  whole  mouse  or  rat  brains  were  also  run  on  the  same  gels  and  used  as  a 
positive  control  (rat/mouse  +ve).  A  lOObp  DNA  ladder marker was  run  where  the 
brightest  band  is  equal  to  500bp.  GAPDH  expression  (predicted  559bp)  for 
equivalent  amounts  of mRNA  from  each  condition  are  shown  below.  Bands  were 
quantified by densitometry using gelpro 3.1  software which allowed correction each 
sample against their respective GAPDH  levels.  Graphs show the OD for  microglia 
(Aii)  OD  represents  mGluR8/GAPDH.  Results  shown  are  the  average  taken  from 
two separate experiments and indicate that microglia expressed extremely low levels 
of mGluR8  mRNA  which  was  increased  by  exposure  to  myelin.  N9  cells  did  not 
express mGluR8  mRNA  but this was not due to problems  in primer design or PCR 
protocol since the mouse brain positive was positive for mGluR8.137
C O N T R O L L P S M Y E L I N
G R O U P   1
m G l u R   1 M i c r o g l i a
p r o t e i n + + +
m R N A + + / - ++
N 9   c e l l s
m R N A + + +
m G l u R   5 M i c r o g l i a
p r o t e i n + -H- -H-
m R N A + ++ -
N 9   c e l l s
m R N A + + + +++ +++
G R O U P   I I
m G l u R   2 M i c r o g l i a
p r o t e i n + + ++
m R N A + ++ ++
N 9   c e l l s
m R N A -
m G l u R   3 M i c r o g l i a
p r o t e i n + + +
m R N A + ++ ++
N 9   c e l l s
m R N A -
G R O U P   I I I
m G l u R   4 M i c r o g l i a
p r o t e i n + + +
m R N A + / - + / - + / -
N 9   c e l l s
m R N A + + +
m G l u R   6 M i c r o g l i a
m R N A + / - + / - -
N 9   c e l l s
m R N A - - -
m G l u R   7 M i c r o g l i a
m R N A - - -
N 9   c e l l s
m R N A - - -
m G l u R   8 M i c r o g l i a
m R N A + + / - + +
N 9   c e l l s
m R N A - - -
Table 3.1  Summary table of mGluR protein and mRNA expression on  microglia 
and N9 cells either left untreated or incubated with LPS or myelin.
+++  very  strong  expression,  ++  strong  expression,  +  some  expression,  +/-  weak 
expression, - no expression.138
3.2.4  Macrophages express metabotropic glutamate receptors
Rat peritoneal macrophages were fixed in 4% F-PBS after  1   hour, 24 hours or 7 
days  in  vitro  and  analysed  for  the  expression  of  group  I,  II  and  III  mGluRs  by 
immunocytochemistry.  Macrophages  expressed  mGluRl  protein  (Figure  3.14A).  In 
accordance  with the  microglial  staining,  macrophage  mGluR 1  expression  appeared  to 
be  localised  aound the  nucleus and cytoplasm,  this remained the case after 24 hours. 
After 7 days, mGluR 1  expression remained at a similar level and although still mainly 
localised  around  the  nucleus  there  was  more  evidence  of staining  in  the  cytoplasm. 
Macrophages expressed higher levels of mGluR5 than mGluRl  protein (Figure 3.14B). 
After  1   hour mGluR5  expression was localised around the nucleus,  this remained the 
case after 24 hours, however after 7 days mGluR5 protein was more localised to the cell 
membranes and cytoplasm which was consistent with our findings in primary microglia.
Expression of group II mGluR2 and 2/3  was noticeably less  intense than either 
mGluRl  or 5  at all time points.  At each time point,  both mGluR2  (Figure  3.15A) and 
2/3 (Figure 3.15B) remained localised around the nucleus and cytoplasm with no visible 
translocation to the  membrane.  Staining  for  mGluR  2/3  was  barely  visible  above  the 
negative control (Figure 3.17B),  it is therefore possible that macrophages express little 
if any mGluR3 protein.
Group III mGluR4 was also expressed by macrophages (Figure 3.16A). After  1  
hour this expression was localised  around the nucleus and cytoplasm and after 24 hours 
was  clearly  more  cytoplasmic.  After  7  days  translocation  of mGluR4  protein  to  the 
membrane had occurred with very little staining around the nucleus. Levels of mGluR7 
protein were  noticeably  lower than mGluR4 and  not visible  until  after 24 hours when 
the  expression  was  clearly  NW  expressed  in  the  cytoplasm  (Figure  3.16B).  After  7 
days,  mGluR7  protein  levels  were  still  very  low  but  had  visibly  translocated  to  the139
membrane.  These  findings  are  in  contrast  with  those  observed  in  microglial  cultures 
since microglia did not express mGluR7.
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Figure 3.14  Expression and localisation of group I mGluRs in primary 
macrophage cells after lh, 24h and 7 days.
Primary macrophages were cultured and left in vitro for  lhr, 24 hrs or 7 days 
before  being  fixed  in  4%  F-PBS.  Cells  were  labelled  with  antibodies  to 
mGluRl  or mGluR5. A secondary antibody conjugated to TRITC was used to 
detect  mGluR  labelled  cells.  The  nuclear  marker  DAPI  (blue  staining)  was 
used to  localise  mGluR staining.  These  figures  are representative  images  of 
the  staining  repeated  in  three  separate  experiments.  The  staining  was  very 
similar to that seen in the microglia with macrophages after 7 days expressing 
mGluR 1   remaining more localised to the nucleus and mGluR5 more localised 
to  membrane.  It  was  also  noticeable  that  between  the  24  hour  and  7  day 
timepoints,  mGluR5  and to  some extent mGluRl  expression  appeared to be 
trafficked away from the nucleus. (x400 magnification)
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Figure 3.15  Expression  and  localisation of group 1  mGluRs in  primary 
macrophage cells after lh, 24h and 7 days.
Primary  macrophages  were  cultured  and  left  in  vitro  for  lh,  24h  or  7  days 
before  being  fixed  in  4%  F-PBS.  Cells  were  co-stained  with  antibodies  to 
mGluR2  or  mGluR3  (both  red  staining)  and  the  nuclear  membrane  marker 
DAPI (blue staining).  These figures are representative images of the staining 
repeated  in  three  separate  experiments.  These  figures  are  representative 
images  of the  staining  repeated  in  three  separate  experiments.  The  staining 
shows that macrophages express more mGluR2 than mGluR3 protein which is 
similar  in  microglia  although  the  mGluR2  remains  more  localised  in  the 
nucleus in  the macrophages. (x400 magnification)141
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Figure 3.16  Expression  and localisation of group I mGluRs  in  primary 
macrophage cells after lh, 24h and 7 days.
Primary  macrophages  were  cultured  and  left  in  vitro  for  lh,  24h  or  7  days 
before  being  fixed  in  4%  F-PBS.  Cells  were  co-stained  with  antibodies  to 
mGluR  1  or mGluR5  (both red  staining)  and the  nuclear membrane  marker 
DAPI (blue staining). These figures are representative images of the staining 
repeated in three separate experiments. The staining shows that macrophages 
express very little mGluR7.  Interestingly, mGluR4 expression increases in 7 
day  old  macrophages  and  appears  to  be  more  localised  to  the  membrane. 
(x400 magnification)142
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Figure 3.17  Negative controls for microglial and macrophage staining
Primary microglia (A) or  macrophages (B) were cultured and left in vitro for 24 
hours  before  being  fixed  in  4%  F-PBS.  Primary  antibody  was  omitted  from 
these cells  but  secondary  antibodies  conjugated to TRITC  were  applied as per 
previous experiments with the nuclear stain DAPI (blue staining). These figures 
are representative images of staining repeated on three separate occasions. There 
was  no  visible  positive  staining  which  suggests  that  the  staining  of mGluR 
protein on both macrophages and microglia was specific. (x400 magnification)143
3.2.5  Group I mGluR expression in EAE
For the following experiments,  expression of mGluRs was examined in both a 
mouse and a DA rat model of MS. Serial spinal cord sections removed from rats during 
the acute and chronic phases of MOG  induced EAE disease and from normal adjuvant 
injected  control  rats  were  generously  supplied  by  Annabellla  Polito  and  Anne  Palser 
from Professor Reynolds lab and were used for immunohistochemistry due to the lack 
of commercially available mGluR antibodies which react with mouse protein.  Sections 
were  double  stained  with  antibodies  raised  against  specific  mGluRs  and  an  antibody 
raised  against  MHC  class  II  antigens  (OX-6)  directly  conjugated  to  FITC  to  detect 
activated  microglia  and  macrophages.  As  discussed,  the  differentiation  of  activated 
microglia from macrophages  is very difficult without the use  of several  markers so  in 
these  experiments  OX-6  labelled  cells  will  be  reffered  to  as  microglia/  macrophages 
(MG/0).
RT-PCR, however, was performed on whole brains and spinal cords taken from 
mice  in  the  first  acute  phase  of EAE  where  most  glial  infiltration  occurs  and  also 
adjuvant injected control mice.  Samples were analysed for mGluR mRNA by RT-PCR 
as  described.  Both  the  brain  and  spinal  cord  homogenates  showed  relatively  high 
expression of mGluR 1   mRNA but there was no visible difference in expression between 
control  and EAE animals either in the  brain or the  spinal cord,  this was confirmed  by 
densitometric analysis (Figure 3.18A).
Spinal cord sections from control animals showed very low expression of MG/0 
and  equally  low positive  staining for mGluRl  (Figure  3.19A) which  suggests that the 
detected mGluR 1   mRNA expression in control animals may be neuronal or astrocytic. 
In spinal cord sections from EAE acute phase animals there was a dramatic increase  in 
the presence of MG/0 especially localised in and around perivascular cuffs. There was 
also increased staining for mGluR 1   but this was not for the most part co-localised with144
microglia  (Figure  3.19B).  In  sections  from  the  chronic  phase  of  EAE  there  were 
markedly reduced numbers of microglia although these cells were positive for mGluR 1  
(Figure 3.19C marked by arrow).
Brain  homogenates  analysed  for  mGluR5  mRNA  revealed  that  there  was  no 
significant  difference  between  mGluR5  expression  in  control  or  EAE  brain  tissue. 
Analysis  of  spinal  cord  homogenates,  however,  revealed  a  significant  reduction  of 
mGluR5 mRNA in the EAE animals compared with control (Figure 3.18B).
Sections analysed as above but for mGluR5 expression showed a similar pattern 
of staining. Control sections had noticeably fewer DAPI positive and no OX-6 positive 
cells  confirming  the  absence  of any  inflammatory  cells  (Figure  3.20A)  which  again 
suggests that the mGluR5 mRNA expression observed in control cords may be neuronal 
or from other glial cell types.  Sections from the acute  phase  of EAE  had a noticeably 
increased  number of MG/0 compared with sections from control amimals, expression 
of mGluR5  in these  sections  was also  increased  although this was  not co-localised to 
microglia  (Figure  3.20B).  Chronic  phase  sections  however  showed  a  notable 
upregulation  of mGluR5  expression with  some  localisation  to  microglial  cells  (Figure 
3.20C marked by arrow).145
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Figure 3.18  Expression of mGluRl and 5 mRNA in brain and spinal cord 
homogenates from EAE and control mice
Brains and spinal cords were removed from mice at the acute phase of disease and 
from adjuvant injected control mice at the same time point. Levels of mGluRl  (Ai 
and ii) and 5 (Bi and ii) mRNA were measured in the brain and spinal cord lysates 
by RT-PCR.  Representative  PCR gels are  shown (Ai  and  Bi).  GAPDH  levels  for 
each  sample  were  also  measured  to  ensure  equal  loading.  Samples  were 
quantitatively  analysed  by  densitometry  scanning.  Results  are  shown  as  arbitrary 
densitometry  units  ±  SEM  for  total  mGluR/GAPDH  mRNA  (Aii  and  Bii). 
Expression of mGluRl  mRNA remained the same in both the brain and spinal cord 
of control  and  EAE  animals.  Levels  of mGluR5  mRNA  were  decreased  in  EAE 
spinal cord compared with control although they remained the same in brain tissue. 
n=4, *P<0.05.Figure 3.19  Expression of  mGluRl  protein in spinal cord sections from acute
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’  lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluRl  and  an  antibody  raised  against  MHC  class  II  antigens  (OX-6)  directly 
conjugated to FITC.  A  fluorescent secondary antibody (TRITC) was used to detect 
cells  labelled  with  mGluR  in  sections taken  from  (A)  adjuvant  controls,  (B)  acute 
phase  or  (C)  chronic  phase  animals.  DAPI  was  used  to  detect  nuclei.  Overlaid 
images of all staining are shown (i and  iii) as well as  images with only mGluR and 
OX-6  staining (ii  and  iv).  Original  magnification x200  (i  and  ii)  and  x400  (iii  and 
iv).Figure 3.20  Expression of  mGluR5 protein in spinal cord sections from acute
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’ lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluR5  and  an  antibody  raised  against  MHC  class  II  antigens  (OX-6  directly 
conjugated to FITC). A fluorescent secondary antibody (TRITC) was used to detect 
cells  labelled  with mGluR  in  sections taken  from  (A)  adjuvant controls,  (B)  acute 
phase  or  (C)  chronic  phase  animals.  DAPI  was  used  to  detect  nuclei.  Overlaid 
images of all staining are shown (i and iii) as well as images with only mGluR and 
OX-6  staining (ii and iv).  Original magnification x200  (i  and ii)  and x400 (iii  and 
iv).148
3.2.6  Group II mGluR expression in EAE
Group II mGluR expression was  analysed as above.  RT-PCR  analysis  showed 
that mGluR2  mRNA  was  expressed  in the  brains  of both  control  and  EAE  mice  and 
there  was  no  significant  difference  between  them  (Figure  3.21 A).  Interestingly,  the 
levels of mGluR2 in the spinal cord were notably lower than in the brain.  In addition, 
cords  taken  from  acute  phase  EAE  animals  showed  significantly  reduced  levels  of 
mGluR2  mRNA  compared  with  control,  almost  to  the  point  of  complete  absence 
(P<0.05).
Spinal cord sections from control animals demonstrated no specific MHC class 
II  or  mGluR2  staining  suggesting  no  expression  of  glial  cells,  again  the  mGluR2 
mRNA expression in control spinal cords may therefore be attributed to neuronal cells 
(Figure 3.22A). Acute EAE sections did have  increased mGluR2 staining although not 
as noticeable as the upregulation of group I receptor staining, and again not localised to 
microglia (Figure 3.22B).  Sections from the  spinal  cords  of chronic  EAE  animals had 
low numbers of microglia compared with acute sections but did show elevated mGluR2 
expression which in some cases was localised to the microglia (Figure 3.22C marked by 
arrow).
Analysis of mGluR3  mRNA  in brain homogenates demonstrated  no significant 
change  between  control  and  EAE  conditions  (Figure  3.2IB).  EAE  spinal  cord 
homogenates, however, had significantly lower levels of mGluR3 mRNA than controls 
cords  (P<0.05).  Stained  spinal  cord  sections  from  control  animals  again  indicated  no 
positive staining for either MHC-II or mGluR3 (Figure 3.23A). Furthermore, acute EAE 
sections did not show  upregulation of mGluR3  (Figure  3.23B).  Sections  from  chronic 
animals also showed little mGluR3 staining although this did seem to be localised to the 
few microglia present (Figure 3.23C marked by arrow).149
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Figure 3.21  Expression of mGluR2 and 3 mRNA in brain and spinal cord 
homogenates from EAE and control mice
Brains and spinal cords were removed from mice at the acute phase of disease and 
from adjuvant injected control mice at the same time point. Levels of mGluR2 (Ai 
and ii) and 3 (Bi and ii) mRNA were measured in brain and spinal cord lysates by 
RT-PCR. Representative PCR gels are shown (Ai and Bi). GAPDH levels for each 
sample  were also measured to  ensure equal  loading.  Samples were  quantitatively 
analysed  by  densitometry  scanning.  Results  are  shown  as  arbitrary  densitometry 
units  ±  SEM  for  total  mGluR/GAPDH  mRNA  (Aii  and  Bii).  Expression  of 
mGluR2  and  3  mRNA  remained  the  same  in  brain  lysates  of control  and  EAE 
animals.  Both mGluR2 and 3  mRNA  levels decreased  in EAE spinal  cord  lysates 
compared with control.  n=4, *P<0.05.A B C
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Figure 3.22  Expression of  mGluR2 protein in spinal cord sections from acute 
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’ lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluR2  and  an  antibody  raised  against  MHC  class  II  antigens  (OX-6  directly 
conjugated to FITC). A fluorescent secondary antibody (TRITC) was used to detect 
cells  labelled with mGluR  in  sections taken  from  (A)  adjuvant controls,  (B)  acute 
phase  or  (C)  chronic  phase  animals.  DAPI  was  used  to  detect  nuclei.  Overlaid 
images of all staining are shown (i and iii) as well as images with only mGluR and 
OX-6  staining  (ii  and  iv).  Original  magnification x200  (i  and ii)  and x400  (iii  and 
iv).A B C
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Figure 3.23  Expression of  mGluR3 protein in spinal cord sections from acute 
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’ lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluR3  and  an  antibody  raised  against  MHC  class  II  antigens  (OX-6  directly 
conjugated to FITC). A fluorescent secondary antibody (TRITC) was used to detect 
cells  labelled  with mGluR  in  sections taken  from  (A)  adjuvant  controls,  (B) acute 
phase  or  (C)  chronic  phase  animals.  DAPI  was  used  to  detect  nuclei.  Overlaid 
images of all staining are shown (i and iii) as well as images with only mGluR and 
OX-6  staining  (ii  and  iv).  Original  magnification x200  (i  and ii)  and x400  (iii  and 
iv).152
3.2.7  Group III mGluR expression in EAE
Group  III  mGluR  expression  was  analysed  as  above.  Homogenates  were 
analysed for mGluR4 mRNA by RT-PCR.  Brain homogenates taken from both control 
and EAE acute phase animals both expressed similar levels of mGluR4 mRNA (Figure 
3.24A).  Interestingly,  expression of mGluR4  mRNA was  significantly  lower in  spinal 
cord  than  in  brain  homogenates  although  there  was  no  significant  change  between 
control and EAE conditions.
Spinal  cord  sections  from  control  animals  showed  a  very  low  number of cells 
positive for MHC class II antigen, which were also stained for mGluR4 (Figure 3.25A). 
Although  the  intensity  of staining  was  extremely  weak,  this  may  imply  that  the  few 
microglia in control cords express low levels of mGluR4.  Acute EAE  sections showed 
slight upregulation  of mGluR4  staining which  seemed  to  be  co-localised  to  microglia 
though  again  this  staining  was  very  weak  (Figure  3.25B).  Microglial  cells  in  chronic 
EAE sections were also positive for mGluR4 (Figure 3.25C).
mRNA  for  mGluR8  was  expressed  in  brain  homogenates  although  this  was 
unchanged in EAE and control conditions (Figure 3.24B). Spinal cord homogenates also 
expressed  mGluR8  mRNA  which  appeared  to  be  lower  in  EAE  cords  compared  with 
controls though this was not significant.  Sections taken from the spinal cords of control 
animals  expressed  extremely  low  levels  of  MHC  class  II  staining.  Cells  that  were 
stained  appeared  very  ramified  suggestive  of microglial  cells  at  rest  (Figure  3.26A). 
Acute EAE sections showed upregulation of mGluR8 staining which was localised to a 
small number of microglial cells (Figure 3.26B).  Sections taken from cords of chronic 
EAE animals showed very weak staining for mGluR8 though this was localised to MHC 
class II  staining (Figure 3.26C marked by arrow).153
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Figure 3.24  Expression of mGluR4 and 8 mRNA in brain and spinal cord 
homogenates from EAE and control mice
Brains and spinal cords were removed from mioe at the acute phase of disease and 
from adjuvant injected control mice at the same time point.  Levels of mGluR4 (Ai 
and ii) and 8 (Bi and ii) mRNA were measured in brain and spinal cord lysates by 
RT-PCR.  Representative PCR gels are shown (Ai and Bi). GAPDH levels for each 
sample  were  also  measured to  ensure  equal  loading.  Samples were  quantitatively 
analysed  by  densitometry  scanning.  Results  are  shown  as  arbitrary  densitometry 
units  ±  SEM  for  total  mGluR/GAPDH  mRNA  (Aii  and  Bii).  Expression  of 
mGluR4 and  8 mRNA remained the  same  in both brain and spinal cord  lysates of 
control and EAE animals.  n=4, *P<0.05.Figure 3.25  Expression of  mGluR4 protein in spinal cord sections from acute
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’ lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluR4 and an antibody raised against MHC class II (OX-6 directly conjugated to 
FITC). A fluorescent secondary antibody (TRITC) was used to detect cells labelled 
with mGluR  in  sections taken  from  (A)  adjuvant controls,  (B)  acute  phase  or  (C) 
chronic  phase  animals.  DAPI  was  used  to  detect  nuclei.  Overlaid  images  of all 
staining are shown (i and iii) as well as images with only mGluR and OX-6 staining 
(ii and iv). Original magnification x200 (i and ii) and x400 (iii and iv).Figure 3.26  Expression of  mGluR8 protein in spinal cord sections from acute
and chronic phase EAE and adjuvant treated control rats.
Spinal cord sections were supplied by Prof. Reynolds’ lab, cords were removed from 
rats at the acute and chronic phase of disease, cut in transverse sections then fixed in 
parafomaldehyde.  Sections  were  double  stained  with  an  antibody  raised  against 
mGluR8 and an antibody raised against MHC class II (OX-6 directly conjugated to 
FITC).  A  fluorescent  secondary  antibody  (TRITC)  was  used to  cells  labelled  with 
mGluR in sections taken from (A) adjuvant controls, (B) acute phase or (C) chronic 
phase animals.  DAPI was used to detect nuclei.  Overlaid images of all staining are 
shown (i and iii) as well as images with only mGluR and OX-6 staining (ii and iv). 
Original magnification x200 (i and ii) and x400 (iii and iv).156
3.3  Discussion
Astrocyte mGluR expression is modulated in response to different types of brain 
injury  (Aronica  et  al.,  2000,  2001;  Ferraguti  et  al.,  2001),  and  microglial  mGluR 
subtypes are modulated  in MS (Geurts et al.,  2003, 2005).  It is known that stimulation 
of  group  II  microglial  mGluRs  induces  a  neurotoxic  microglial  phenotype  and  that 
stimulation  of group  III  mGluRs  on  microglia  can  be  neuroprotective  (Taylor  et  al., 
2002,  2003,  2005).  The  expression  of mGluR  subtypes  on  microglia  is  therefore  of 
particular interest as microglial toxicity during disease could be due to upregulation of 
one  subtype  over  another.  These  findings  demonstrate  that  activation  of  microglia 
induced changes in their mGluR profile compared with unstimulated cells.
Confirming  the  findings  of  Biber  et  al.,  (1999),  we  showed  that  microglia 
constitutively  express  group  I  mGluRs.  Expression  of  mGluRl  was  clearly  more 
localised to the nucleus while mGluR5 expression was concentrated on membranes and 
processes.  This  contradicts  the  findings  of  Hubert  et  al.,  (2001)  who  found  most 
mGluR 1   labelling  in  substantia  nigra  neurones  located  to  the  plasma  membrane, 
whereas mGluR5  was  primarily expressed  in  intracellular compartments,  and  serves to 
highlight the differences in mGluR expression between different cell types.  It has been 
suggested that pre-active mGluRs are localised in the cytoplasm while trafficking to the 
membrane  denotes  a  functionally  active  state.  Indeed,  activity-regulated  increases  in 
homer protein  la expression disrupt binding of homer protein  lb to mGluRs, leading to 
increased trafficking of metabotropic receptors to the plasma membrane and additional 
functional  surface  receptors  (Roche  et  al.,  1999;  Ciruela  et  al.,  1999).  Another 
possibility is that some functions necessitate a large intracellular pool of mGluRs which 
can  be  readily  inserted  into the  membrane  without  the  need  for  new  receptors  to  be 
synthesized and transported (Szekeres et al.,  1998).157
It  was  found  that  microglial  mGluR5  protein  was  more  strongly  expressed  in 
both untreated and activated conditions, than any other subtype and was also primarily 
expressed  in membranes and processes with  little  staining  in the  nucleus  suggesting a 
functionally  active  state.  Interestingly,  analysis  of  mRNA  expression  by  RT-PCR 
showed  only  a  very  weak  signal  for  mGluR5  in  contrast  to  other  subtypes.  Indeed 
activation with myelin which noticeably  increased  intensity of staining compared with 
control cells induced almost complete knock-down at the mRNA level. This may be due 
to mRNA levels being reduced once proteins are trafficked away to the membrane, it is 
possible  that  increases  in  mGluR5  mRNA  did  occur  but  were  transient  due  to  high 
turnover (Eliakim et al.,  1997).
Microglia  but  not  N9  cells  constitutively  expressed  low  levels  of  mGluR2. 
These  results  demonstrate  that unstimulated  microglia  possessed  mGluR2  protein that 
was visibly  localised  in the  nucleus.  Activation of microglia increased the  intensity of 
staining  in  the  cytoplasm  but  also  induced  expression  of  mGluR2  protein  in  the 
membrane  and  processes  which  may  indicate  mGluR  trafficking  and  activation.  This 
was  confirmed  by  RT-PCR  results,  which  showed  that  levels  of microglial  mGluR2 
mRNA were  increased  by exposure to  myelin  and to  a  greater extent by  LPS.  These 
results  are  of interest as  microglial  mGluR2  stimulation  induces  microglial  activation 
and a neurotoxic phenotype (Taylor et al;  2002, 2005).  It  is possible that the  increased 
reactivity of microglia during disease or insult could be due to increased expression of 
‘neurotoxic’  mGluR2.  Indeed,  group  II  mGluRs are upregulated  in activated microglia 
surrounding MS lesions (Geurts et al., 2002).
MGIuR3 was also found to be expressed in microglia but not in the N9 cell line. 
Microglia constitutively expressed higher levels of mGluR3 compared with mGluR2 in 
control untreated cells. It has been suggested that the mGluR3 receptor subtype may be 
neuroprotective as stimulation of mGluR3 in astrocytes induces release of TGFp (Bruno158
et al.,  1998).  Interestingly  however,  levels  of mGluR3  were  increased  by  exposure  to 
LPS. This is possibly in response to cell activation perhaps to minimise damage by toxic 
substances released and balance the increase in mGluR2 expression.
Of the  group  III  mGluRs  (mGluRs  4,  6,  7  and  8)  N9  cells  only  expressed 
mGluR4  subtype  while  microglia  expressed  all  subtypes  bar  mGluR7. 
Immunolocalisation of mGluR4 demonstrated that microglial expression of this protein 
is localised in the cytoplasm around the nucleus suggesting a pre-active state. Analysis 
of group  III  mRNA  levels  showed  that mGluR4  and  6  were  extremely  low  so  it was 
difficult  to  accurately  assess  whether  activation  induced  any  changes  in  expression. 
Microglial  mGluR8  expression,  however,  was  upregulated  by  exposure  to  myelin.  It 
would therefore be of interest to see which subtype of group III mGluR was responsible 
for enhancing the neuroprotective phenotype of microglia. Studies using mGluR4 knock 
out  mice  have  shown  that  selective  activation  of mGluR4  in  cortical  cultures  affords 
neuroprotection  against  excitotoxic  cell  death  (Bruno  et  al.,  2000).  Stimulation  of 
microglial group III mGluRs can also be neuroprotective (Taylor et al., 2003), as such, 
the low constitutive expression of these receptors in resting microglia may explain their 
early reactivity in response to infection or injury.
The  differences  in  mGluR  phenotype  between  primary  mcroglia  and  N9  cells 
were  to  be  expected  since  N9s  are  an  immortalised  cell  line  and  cultured  for  longer 
periods of time.  Indeed, culturing microglia has been shown to change the pattern of a 
number of receptors and ion channels (Kettenmann et al.,  1993; Eder et al.,  1997),  and 
furthermore, differences in culture conditions and age are known to alter mGluR mRNA 
expression (Catania et al.,  1994; Schools and Kimelberg,  1999).
Analysis  of mGluR  mRNA  expression  in  control  and  EAE  mice  showed  no 
significant changes in mGluR mRNA in the brains of EAE compared with control mice. 
This was expected since most pathology in the EAE model  is found  in the  spinal cord.159
As  such,  there  were  distinct  and  significant  reductions  in  the  levels  of  mGluR5, 
mGluR2  and  mGluR3  mRNA  in  EAE  spinal  cords  compared  with  controls.  Since 
sections  of  acute  EAE  showed  dramatic  increases  in  the  number  of  MG/0,  the 
decreased  mGluR  expression  recorded  in  EAE  spinal  cord  homogenates  most  likely 
reflects  decreased  neuronal  or  other  glial  mGluR  mRNA,  which  as  demonstrated  in 
recent  literature have  different functions  compared with  microglial  mGluRs  (Bruno  et 
al.,  1995; Buisson and Choi,  1996; Attwell et al.,  1998; Allen et al.,  1999; Taylor et al., 
2002,  2005).  Immunohistochemistry on  spinal  cord  sections  however,  demonstrated  a 
notable  increase  in  mGluRl,  mGluR5  and  mGluR2  expression  in  the  acute  phase  of 
EAE which is more likely attributable to glial cells in line with the findings of Geurts et 
al.,  (2003),  and  also  since these  subtypes were  either down-regulated  (mGluR5  and 2) 
or unaltered  (mGluR 1)  in  the  EAE  spinal  cord  homogenates.  Although  this  positivity 
was  not  frequently  co-localised  to  microglia,  it  is  possible  that  the  staining  observed 
was astrocytic.
Interestingly,  some  co-localisation  of  microglial  and  mGluR8  staining  was 
observed  in  acute  EAE  sections,  which  is  in  accordance  with  previous  work  showing 
microglial mGluR8 expression  in human actively demyelinating MS  lesions (Geurts et 
al.,  2005).  These  results  are  consistent  with  the  upregulation  of microglial  mGluR8 
mRNA  induced  by exposure to myelin and the finding that mGluR8 was generally not 
observed  in  human  pre-active  lesions  (Geurts  et  al.,  2005)  which  suggests  that 
upregulation of this subtype is not simply the result of activation but possibly influenced 
by demyelination and may indicate an attempt to limit microglial toxicity.
The  low  expression  of  mGluRs  on  microglia,  as  evidenced  by  PCR  data  in 
primary  cultures,  probably  make  it  difficult  to  attain  positive  results  when  staining 
sections.  Furthermore,  modulation of microglial  mGluR expression  in  EAE  is unlikely 
to  be  visible  in  PCR analysis  of whole  brain and  spinal  cord  homogenates  due  to  the160
relatively  small  proportion  of  microglia  to  neurones  and  other  glial  cells,  which  is 
compounded by the  low expression of mGluRs on microglia.  Further work  is required 
to elucidate the microglial expression of mGluRs in different stages of EAE, this could 
possibly  be  achieved  by  isolating  microglia  from  EAE  animals  and  would  allow 
analysis of microglial mGluR expression through disease progression.4.0
MYELIN INDUCES A REACTIVE 
MICROGLIAL PHENOTYPE WHICH CAN BE 
MODULATED BY METABOTROPIC 
GLUTAMATE RECEPTORS162
4.1  Introduction
Microglia  are  implicated  in  the  pathology  of MS  and  have  been  localised  in 
active  lesions  (Hill  et  al.,  2004).  Since  myelin  breakdown  is  a  feature  of  MS  and 
microglia have  been  shown to  actively phagocytose  myelin  (Mosley  et al.,  1996),  the 
effects of myelin on microglial reactivity and subsequent neurotoxicity were examined. 
Reactivity  of  microglia  was  assessed  by  upregulation  of  ED-1,  a  marker  for  the 
lysosomal  compartment  which  is  expressed  by  activated  phagocytic  microglia. 
Microglial  neurotoxicity  was  determined  by applying  microglial  conditioned  media to 
CGCs followed by quantification of apoptotic cells by Hoechst staining.
The  inflammatory  mediators  TNFa  and  iNOS  may  also  be  involved  in 
demyelinating pathology.  Indeed  reactive  microglia  in active  lesions  have  been  shown 
to express iNOS (Hill et al 2004), the enzyme responsible for NO production which  is 
toxic to  oligodendrocytes  (Merrill et al.,  1993).  TNFa  has  also  been  implicated  in the 
death of oligodendrocytes and has been  linked with NO mediated toxicity (Mitrovik et 
al.,  1994),  which  implies a pivotal  role  for both  TNFa and  iNOS  in  lesion  formation. 
Since myelin debris and microglia are both present in MS  lesions, microglial release of 
TNFa and expression of iNOS was examined after incubation with myelin.
It  has  been  shown  that  modulation  of  group  II  microglial  mGluRs  can  be 
neurotoxic  (Taylor  et  al.,  2002)  and  that  activation  of  group  III  mGluRs  can  be 
neuroprotective (Taylor et al., 2003). This work aimed to determine whether modulation 
of  microglial  mGluRs  could  regulate  myelin  induced  microglial  neurotoxicity.  The 
mechanisms  of mGluR  modulation  of microglial  toxicity  were  also  examined.  Since163
mGluRs are not the primary mediators of fast synaptic transmission, the modulation of 
these receptors may represent a therapeutic strategy in MS.164
4.2  Results
4.2.1  Myelin induces a reactive microglial phenotype
In the following experiments microglia were plated at 90,000 cells per coverslip 
as  described  and  incubated  at  37°C  for  24  hours  before  use.  Myelin  was  added  to 
microglia at concentrations ranging from  lng/ml to  lOpg/ml. Microglial activation was 
assessed  in  a  number  of  ways  including  quantification  of  ED-1  expression,  TNFa, 
glutamate and nitrite release, and expression of iNOS.
Localisation  of myelin  within  and  around  microglial  processes  was  confirmed 
by  double  immunocytochemical  detection  of  myelin  oligodendrocyte  glycoprotein 
(MOG)  and  isolectin  B4  a  microglial  marker  (Streit  and  Kreutzberg,  1987)  (Figure
4.1 A).  Myelin  was  stained  with  an  antibody  raised  in  mice  against  rat  MOG  protein 
kindly provided by Professor David Baker.  The secondary antibody was specific for the 
primary  antibody  as  no  staining  was  observed  in  negative  controls  in  which  primary 
antibody  was  ommited  (Figure  4.IB).  Ideally,  the  specifity  of the  primary  antibody 
should also have been tested by peptide blocking.
Activation of microglia incubated with myelin was assessed by positive staining 
with  enhanced  ED-1.  Representative  figures  for  microglial  ED-1  staining  are  shown 
(Figure 4.2). ED-1  positive cells were quantified as a percentage of total number of cells 
per  field  as  determined  by  DAPI  staining  (Figure  4.3).  Untreated  microglial  cultures 
expressed  very  low  (<20%  ±  0.53)  levels  of ED-1  protein.  Exposure  of microglia  to 
0.01 p.g/ml  myelin  induced  significantly  higher  levels  of ED-1  expression  than  those 
observed  in  untreated  cells  (P<0.05).  Greatest  ED-1  expression  was  induced  by 
lOpg/ml  myelin  (PO.01).  There  was  no  significant  difference,  however,  between  the 
ED-1  levels induced by  lOpg/ml and  lpg/ml myelin (P=0.1709).165
To  observe  the  timecourse  of  microglial  reactivity  these  experiments  were 
repeated exposing microglia to  lpg/ml myelin for 1,4, 8, 24 and 48 hours at 37°C. The 
percentage  of cells  expressing  ED-1  was  analysed  at  these  timepoints  (Figure  4.4). 
Quantification of ED-1  expression as described above showed that basal levels of ED-1 
found  in  control  untreated  microglia  were  similar  to  those  found  in  previous 
experiments and were  lower than 20% (±1.1%)  (Figure 4.5).  There was no  significant 
difference  between  ED-1  expression  in control  cells  and  those  exposed  to  myelin  for 
under  8hrs (P=0.7752).  However,  after 24  hours  incubation with myelin,  over 70% (± 
3.6%)  of microglia were  positive  for ED-1  which  was  significantly  higher than  levels 
found  in  untreated  cultures  (PO.Ol).  Continued  exposure  to  myelin  for  a  further  48 
hours did  not significantly  increase the expression  of ED-1  compared  with expression 
after  24  hours  (P=0.0584).  This  was  probably  due  to  cells  dying  and  floating  off the 
coverslips  (Figure  4.5)  since  there  were  consistently  less  microglia  per  field  after 
incubation with myelin for 48 hours  (observation, data not shown).
Western  blotting  for  microglial  iNOS  protein  was  performed  and  revealed  a 
prominent band at the predicted molecular weight for iNOS protein of 110 kDa (Figure 
4.6B).  Treatment with myelin for 8 hours  induced very  low  levels of iNOS expression 
in  microglia  and  this  was  further  increased  by  myelin  exposure  for  24  and  48  hours. 
Microglial lysates were also analysed for phospho-ERK protein, these data suggest that 
untreated  cells  do  not  express  phospho-ERK  while  incubation  with  myelin  for  24-48 
hours induced phospho-ERK expression above control  levels (Figure 4.6A).  The  levels 
of  nitrite  released  by  microglia  were  also  assessed  by  analysis  of  total  nitrite  in 
microglial  conditioned  medium  (MGCM)  collected  from  the  cells  after  24  hours 
incubation with myelin (Figure 4.6C).  Untreated cells released small amounts of nitrite 
at  levels  consistently  less  than  lOOnM/pg/pl.  As  expected,  nitrite  levels  were 
significantly  increased  in  MGCM  from  cells  treated  with  myelin  (PO.05)  although166
exposure  to  LPS  caused  very  high  amounts  of nitrite  release  (PO.OOl)  which  were 
above the levels induced by myelin.
Since  TNFa and  glutamate  have  both been  implicated  in the  pathology  of MS 
and  are  known  to  be toxic to oligodendrocytes  in vitro,  we  also  collected  MGCM  for 
analysis of release of these substances by microglia treated with myelin for  1-48 hours. 
We confirmed previous findings that non-activated microglia release less than 50pg/ml 
TNFa  (Ciesielski-  Treska  et  al.,  1998;  Kim  et  al.,  2004;  Taylor  et  al.,  2005).  These 
levels  did  not  increase  after  24  or  48  hours  (Figure  4.7A).  Both  myelin  and  LPS 
potently induced early TNFa release in microglia after 4 hours.  Treatment with myelin 
for  4  hours  induced  TNFa  release  of  ~400pg/ml  (PO.OOl)  which  increased  to 
~1000pg/ml  by  24  hours  (PO.OOl).  After 48  hours,  TNFa  release  plateaued  and  the 
increases observed were not statistically significant compared with TNFa release after 
24 hours. Levels of microglial glutamate release were also increased by incubation with 
myelin after 24 hours and both myelin and LPS after 48 hours (Figure 4.7B). Untreated 
microglia consistently released -lOpM/pg/pl glutamate while treatment with myelin for 
24 hours caused an increased release of ~22pM/pg/pl (PO.05).Figure 4.1  Myelin  incubated  with  microglia  for  24  hours  is  co­
localised to microglial processes.
Microglia were incubated with myelin (1 jig/ml) for 24 hours before being 
fixed in 4%  F-PBS.  (A) Microglia were co-stained with antibodies raised 
against  myelin  oligodendrocyte  glycoprotein  (MOG).  A  secondary 
antibody  conjugated  to  TRITC  was  used  (red  staining).  Isolectin  B4 
which  is a marker for microglia and  directly  conjugated to  FITC  (green 
staining) and DAPI a nuclear marker (blue staining) were also used. There 
was  noticeable  co-localisation  of  staining  for  MOG  and  isolectin  B4 
showing myelin in and around microglial processes. (B) Negative control 
in  which  primary  antibody  against  MOG  was  omitted.  There  was  no 
TRITC staining which indicates that the positive staining in figure A was 
specific.vii
Figure 4.2  Increasing microglial ED-1  expression following exposure 
to myelin concentrations ranging from 0.001- lOpg/ml
Cultured microglia were either left untreated (i) or  incubated with 0.001  (ii) 
0.01  (iii) 0.1  (iv)  1   (v) or 10 (vi) jrg/ml myelin for 24 hours then fixed in 4% 
F-PBS.  Microglia  were  co-stained  with  an  antibody  raised  against  ED-1 
antigen,  a  marker  for  activation  and  phagocytosis,  followed  by 
diaminobenzadine tetrahydrochloride (DAB), and DAPI, a nuclear stain (not 
shown). A negative control (vii) where primary antibody was omitted shows 
no positive staining which shows that ED-1  staining was specific.169
* *
©
>
Q
111
80-
60-
40-
20-
0 r
O
k . *-* c
o
o
* *
*   JL
©
O
o
©
o
myelin (fig/ml)
Figure 4.3  Percentage of microglia expressing ED-1 after exposure 
to myelin concentrations ranging from 0.001-1 Opg/ml
Percentage  of  ED-1  positive  microglia  after  incubation  with  0.001- 
1  Opg/ml  myelin  for  24  hours  were  assessed  by  counting  the  number  of 
cells positive  for ED-1  (red  staining) as a percentage  of the total  number 
of cells per field  (DAPI -blue staining).  Microglial exposure to myelin at 
concentrations  of  O.Olpg/ml  or  above  induced  significant  increases  in 
expression  of ED-1  compared  with  untreated  cells.  The  graph  represents 
mean  and  SEM  from  at  least  three  separate  fields  from  two  separate 
coverslips  repeated  in  at  least  two  different  experiments.  *P<0.05, 
**P<0.01  versus control.Figure 4.4  Microglial  ED-1  expression  following  exposure  to  lpg/ml 
myelin for 1-48 hours
(A)  Cultured microglia were  either left untreated  (i)  or  incubated with myelin 
(lpg/ml) for  lh (ii) 4h (iii)  8h (iv) 24h (v) or 48h (vi) then fixed in 4%  F-PBS. 
Microglia were then co-stained with an antibody raised against ED-1  antigen,  a 
marker for activation and phagocytosis.  Positive labelling of ED-1  was detected 
by a fluorescent  secondary antibody conjugated to  TRITC.  Microglia were also 
stained  with  DAPI,  a  nuclear  stain  (blue  staining).  A  negative  control  where 
primary  antibody  was  omitted  is  shown  (vii)  and  there  was  no  obvious  red 
staining indicating that the positive staining in the other conditions is specific for 
ED-1.171
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Figure 4.5  Percentage of microglia expressing ED-1  following exposure to 
lpg/ml myelin for 1-48 hours.
Percentage  of microglia  expressing  ED-1  after  incubation  with  lpg/ml  myelin 
for  1,  4,  8,  24,  and  48  hours  were  assessed  by  counting  the  number  of cells 
positive  for ED-1  as  a percentage  of the total  number of cells per field  (DAPI). 
Incubation  of  microglia  with  myelin  for  over  24  hours  obviously  increased 
expression  of ED-1  on  the  cells.  The  graph  represents  mean  and  SEM  from  at 
least  three  separate  fields  from  two  separate  coverslips  repeated  in  at  least  two 
different experiments.  **P<0.01  versus control.172
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Figure 4.6  Expression  of  phospho-ERK  and  iNOS  protein  and  release  of 
nitrite from microglia exposed to myelin for 1-48 hours
Microglia  were  incubated  with  lpg/ml  myelin  for  1-  48  hours  after which  protein 
lysates  were  collected.  Phosphorylated  ERK  (A)  and  iNOS  (B)  expression  were 
analysed  by  western  blotting.  Unstimulated  microglia  were  used  as  a  negative 
control and an IFNy+LPS treated macrophage lysate was used as a positive control. 
The Phospho-ERK blot is representative of lysates taken from  a single experiment. 
iNOS  blots  were  repeated  at  least  twice.  (C)  Conditioned  medium  was  collected 
from  microglia either exposed to myelin or LPS, or left untreated for 24 hours and 
analysed  for total  nitrite release.  Myelin  induced  significant  increase  in the  release 
of nitrite from microglia compared with untreated cells. Results represent mean and 
SEM from at least two  separate experiments *P<0.05,  ***P<0.001  versus control.173
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Figure 4.7  Microglial  exposure  to  myelin  or  LPS  for  1-48  hours  induces 
significant release of TNFa and glutamate after 24 hours.
Microglia were either left untreated or incubated with  lpg/ml myelin or LPS for  1- 
48  hours,  conditioned  medium  was  collected  at  specified  time  points.  (A) 
Conditioned  medium  was  analysed  for  release  of TNFa  by  ELISA.  Incubation  of 
microglia with myelin or LPS  induced significantly increased TNFa release after 4 
hours  compared  with  untreated  cells.  (B)  Glutamate  release  from  microglia  was 
assessed,  after  24  hours  microglia  incubated  with  myelin  released  significantly 
higher amounts of glutamate compared with untreated cells. Values represent means 
+SEM  taken  from  three  different coverslips  per condition  and  repeated  in  at  least 
two  separate  experiments.  *P<0.05,  **P<0.01,  ***P<0.001  versus  control  at  the 
same timepoint.174
4.2.2  Mvelin causes microglia to become neurotoxic
Neurotoxicity  of microglia  was  assessed  by  adding  the  CM  from  microglial 
cultures  to  neurones  in  vitro  for  24  hrs  at  37°C.  Resultant  neuronal  apoptosis  was 
quantified by Hoechst staining where apoptotic nuclei appear condensed, pyknotic and 
brightly stained and can be counted as a percentage of total viable cells per field.  CM 
collected from untreated microglia (used as control CM), or microglia exposed to 0.001- 
lOpg/ml myelin, was applied to neurones in culture (Figure 4.8). Neurones left in their 
own medium were used as negative controls to assess basal  levels of apoptosis.  There 
was  no  significant  difference  between the  levels  of apoptosis  in  basal  conditions  and 
those  caused  by  control  CM  (P=0.2682)  which  induced  less  than  10%  (±  1.6%)  of 
neurones  to  become  apoptotic,  suggesting  that  control  microglia  do  not  release 
neurotoxic  factors.  Microglia  treated  with  O.Olpg/ml  myelin  became  neurotoxic  as  at 
this  concentration  CM  induced  significantly  increased  apoptosis  compared  with  CM 
from untreated cells (P<0.05).  CM from microglia exposed to  lOpg/ml myelin induced 
over 40% (± 3.2%) apoptosis (P<0.001) but there was no significant difference between 
apoptosis  induced  by  lOpg/ml  or  lpg/ml  myelin  MGCM  (P=0.7586).  CM  from 
microglia treated with LPS was used as a positive control for neurotoxicity and both 0.1 
and  lpg/ml LPS induced around 40% (± 2.1%) apoptosis in neuronal cultures, this was 
not  significantly  different  from  the  apoptosis  caused  by  lpg/ml  myelin  (P=0.6411). 
These  results  parallel  data  from  ED-1  experiments  which  demonstrated  that  myelin 
caused  microglia to  become  activated  and  neurotoxic  at concentrations  of  lpg/ml  and 
above  although  increasing  concentrations  above  lpg/ml  did  not  significantly  increase 
neurotoxicity.
To  observe  the  timecourse  of microglial  neurotoxicity  these  experiments  were 
repeated  applying  CM  from  microglia  exposed  to  myelin  for  1,  4,  8  and  24  hours  to 
neurones  in  culture  (Figure  4.9A).  Again  there  was  no  significant  difference  in  thepercentage  of apoptosis  between the  neurones  left untreated  and  those  incubated  with 
control  CM  (P=0.0824).  After  1   hour  incubation  with  myelin  however,  CM  from 
microglia  induced  a  significant  increase  in neuronal  apoptosis  (P<0.05)  although  this 
was  still  less than 20% (±  1.4%).  CM  from microglia exposed to myelin for 24 hours 
induced  -50%  (±  1.3%)  apoptosis  (PO.OOl).  Interestingly  microglia  incubated  with 
myelin for 4 hours  induced -30% (±  1.4%) neurones to become apoptotic,  despite the 
fact  that  no  iNOS  was  detected  at this  time  point.  However,  potent  release  of TNFa 
occurred after 4 hours which suggests an important role in subsequent neurotoxicity.
Myelin was applied directly to neurones to ensure that the toxicity observed was 
not due to any direct toxic effects of myelin on neurones (Figure 4.9B). Adding myelin 
to  neurones  for 24  hours  at the  same  concentration  as  in  MGCM  did  not  induce  any 
significant  apoptosis  above  levels  induced  by  control  CM  (P=0.3636).  Furthermore, 
myelin  added  directly  to  neurones  in  the  presence  of control  CM  did  not  have  any 
deleterious effect on neuronal survival thus demonstrating that the presence of microglia 
and myelin together are required for neurotoxicity.176
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Figure 4.8  Microglia  incubated  with  myelin  releae  factors  which  are 
neurotoxic
Microglia were either left untreated  (control) or incubated  with  0.001-10jAg/ml 
myelin or 0.1-l(ig/ml LPS for 24 hours. Conditioned medium was then collected 
from the  microglia and applied to neurones  in culture  for a further 24  hours.  A 
subset  of neurones  were  left  untreated  for  24  hours  to  asses  basal  levels  of 
apoptosis.  Neurones  were  then  fixed  in  4%  F-PBS  and  apoptosis  measured  by 
Hoechst 33342 nuclear staining. Apoptotic nuclei were condensed and pyknotic 
and counted as a percentage of live cells per field.  MGCM from cells  incubated 
with O.Olpg/ml myelin or above induced significantly higher levels of apoptosis 
in  neurones  compared  with  CM  from  untreated  control  microglia.  Values 
represent  mean  +SEM  from  five  separate  fields  per  condition  repeated  three 
times  in  at  least  three  separate  experiments.  *P<0.05,  **P<0.01,
***P<0.001 versus control CM.MGCM
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Figure 4.9  Microglia incubated with myelin for over 4 hours release factors 
which are  neurotoxic
(A) Microglia were either left untreated or incubated with myelin for  1, 4, 8 and 24 
hours.  Conditioned  medium  was  then  collected  from  the  microglia  and  applied  to 
neurones  in culture for a further 24 hours.  A subset of neurones were  left untreated 
for 24 hours to  asses  basal  levels of apoptosis.  CM  from  microglia  incubated  with 
myelin  for  4  hours  or  more  was  significantly  more  neurotoxic  than  CM  from 
untreated control microglia. (B) As a control, myelin was added directly to neurones 
in  culture  either alone  or in the  presence of control  microglial  CM  for 24 hours to 
negate any direct toxicity to neurones.  Neurones were then fixed  in 4% F-PBS and 
apoptosis  measured  by  Hoechst  33342  nuclear  staining.  Apoptotic  cells  contained 
pyknotic  nuclei  and  were  counted  as  a  percentage  of  live  cells  per  field.  Values 
represent  mean  +SEM  from  at  least  five  separate  fields  per  coverslip  on  three 
different  coverslips  repeated  in  at  least  three  separate  experiments.  ***P<0.001 
versus control CM.178
4.2.3  Mvelin induced microglial toxicity is due to TNFa and  NO release
Since myelin  induced the expression of phospho-ERK in microglia, the  role  of 
phospho-ERK in the process of myelin induced microglial neurotoxicity was examined. 
The  above  experiments  were  repeated,  but  microglia  were  treated  with  the  MEK 
inhibitor U0126  (5pM)  for 30 minutes  before  incubation with myelin.  Microglia were 
also  treated  with  myelin  or  U0126  alone,  or  left  untreated  as  positive  and  negative 
controls  respectively.  The  CM  from  microglia  was  assessed  for  presence  of TNFa 
(Figure  4.10A)  and  nitrite  (Figure  4.1 OB).  Microglia  incubated  with  myelin  released 
significantly increased levels of TNFa compared with control cells as discussed above. 
Treatment  of  microglia  with  U0126  alone  did  not  induce  significant  TNFa  release 
compared  with  release  from  untreated  cells.  However,  pre-treatment  with  this 
compound  significantly  reduced  the  microglial  TNFa  release  induced  by  exposure  to 
myelin  (PO.OOl)  by  around  75%.  Exposure  to  myelin  caused  microglia  to  release 
160nM/pg/pl nitrite (±  17.3nM/pg/pl). Prior treatment with U0126 significantly reduced 
the amount of nitrite released by microglia incubated with myelin alone (P<0.05) down 
to 94nM/pg/pl (±  12.4nM/pg/pl), although these levels were still significantly above the 
nitrite released by untreated cells (P<0.05).
The neurotoxicity of CM from microglia treated with U0126 prior to incubation 
with myelin was assessed (Figure 4.10C). U0126 afforded significant protection against 
the  neurotoxicity  induced  by  myelin  (PO.OOl).  Moreover,  the  levels  of  apoptosis 
induced by CM from microglia treated with U0126 prior to incubation with myelin were 
not significantly different from those induced by CM from untreated cells.
Since  myelin  induced  iNOS  expression  in  microglia,  the  role  of iNOS  in  the 
process  of myelin  induced  toxicity  was  examined.  Microglial  cells  were  treated  with 
AMT-HC1 (150nM), a potent iNOS inhibitor, for 1   hour prior to incubation with myelin 
for a further 24 hours. A subset of cells were left untreated as controls or incubated with179
AMT-HC1 or myelin alone as positive and negative controls respectively.  The effect of 
iNOS  inhibition  on  TNFa  (Figure  4.11 A)  or  glutamate  (Figure  4.1 IB)  release  were 
assessed. Microglia incubated with AMT-HC1 alone did not release significant levels of 
TNFa above control (P=0.3781).  However,  AMT-HC1 failed to have any effect on the 
TNFa release  induced by myelin (P=0.3824).  In the same vein,  AMT-HC1 also had no 
significant effect on the glutamate release induced by myelin (P=0.7292).
The  neurotoxicity  of  CM  from  microglia  treated  with  AMT-HC1  before 
incubation with myelin was  also  assessed  (Figure  4.11C).  CM  from  microglia treated 
with  AMT-HC1  alone  did  not  have  any  detrimental  effect  on  neuronal  survival 
compared with control CM  (P=0.1830).  CM from  microglia treated with myelin alone 
induced  45%  (±1.7%)  apoptosis  consistent  with  previous  data.  Pre-treatment  of 
microglia  with  AMT-HC1  afforded  significant  protection  against  the  neurotoxicity 
induced  by  myelin  alone  (PO.OOl)  bringing the  levels  of apoptosis  down  to  20%  (± 
2%).  However  this  was  still  significantly  above  the  levels  of  apoptosis  caused  by 
control  CM  (10%  ±  0.7%).  Interestingly,  AMT-HC1  had  no  effect  on  TNFa  (Figure 
4.11 A)  or  glutamate  (Figure  4.1 IB)  release,  this  suggests  that  other  factors  may  be 
involved  in  the  toxicity  of  myelin  MGCM  and  would  explain  why  the  microglial 
toxicity induced by myelin was not completely blocked by this compound. This was in 
contrast  to  the  protection  afforded  by  pre-treatment  with  U0126  which  completely 
abrogated  myelin  induced  neuronal  apoptosis.  Since  U0126  significantly reduced  both 
the  microglial  nitrite  and  TNFa  release  while  AMT-HC1  only  inhibited  iNOS 
expression,  these  data  suggest  that  both  iNOS  and  TNFa  have  important  roles  in the 
microglial toxicity induced by myelin.
Direct application to neuronal cultures of AMT-HC1 or U0126 in the presence of 
control CM had no significant effect on neuronal survival  (Figure 4.12A). Furthermore 
when  CM  from  microglia  treated  with  myelin  was  added  to  neuronal  cultures  with180
direct  application  of  AMT-HC1,  there  was  no  significant  modulation  of  apoptosis 
(Figure  4.12B) demonstrating that the neuroprotection afforded  by AMT-HC1  was not 
attributable to a direct action of iNOS  inhibition on neurones but instead by  inhibiting 
microglial  iNOS  expression.  Inhibition  of microglial  iNOS  expression  may  reduce 
microglial  toxicity  by  preventing  feedback  activation  of  microglia  by  NO  release  . 
Direct  application  of U0126  in  the  presence  of  myelin  CM,  however,  significantly 
reduced the  levels of apoptosis induced by myelin CM alone (Figure 4.12B).  This may 
suggest  that  some  of the  protection  afforded  by  U0126  is  due  to  a  direct  action  on 
neurones and not purely due to a reduction of microglial toxixicty.1250*1
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Figure 4.10  Modulation by U0126 of the toxic factors released by microglia 
after exposure to myelin
Microglia  were  incubated  with  MEK  inhibitor  U0126  (5pM)  for  lhr  before 
incubation  with  myelin  for  a  further  24hrs.  Conditioned  medium  from  either 
microglia either left untreated or incubated with U0126 or myelin alone were used 
as controls. (A) Conditioned medium was collected and assessed for TNFa release. 
Incubation of microglia with U0126 prior to  incubation with myelin significantly 
reduced the TNFa release induced by myelin alone.  (B) CM was also analysed for 
nitrite levels. Nitrite release induced by myelin was significantly reduced by prior 
incubation with U0126. (C) CM was also applied to neurone cultures and levels of 
apoptosis  were  assessed  by  nuclear  staining  with  Hoechst  33342.  CM  from 
microglia incubated with U0126 prior to exposure to myelin  induced significantly 
less  apoptosis  than  that  induced  by  CM  from  microglia  incubated  with  myelin 
alone.  Values  represent mean +SEM  from five  separate fields per coverslip  from 
three  different coverslips  repeated  in at  least two  separate  experiments.  *P<0.05, 
**P<0.01, ***P<0.001  versus control unless indicated by a bar.1250'
g  1000-
o>
3   750-
(0  f
%  500- (0
l l
jE  250-
ns
182
Control  + 
AMT-HCI  - 
Myelin
B O )
a
'a s
o
2
E
0)
CB
E
3
3
o
40-i
30-
20-
10-
ns
ns
X
X
Control  + 
AMT-HCI  - 
Myelin
< 0
8
Q . O a 1 0
75 c
o
50-i
40-
30-
20-
10-
ns x
Control  + 
AMT-HCI  - 
Myelin
+  -  + 
+  +
Figure 4.11  Modulation  by  AMT-HCI  of  the  toxic  factors  released  by 
microglia after exposure to myelin
Microglia  were  incubated  with  iNOS  inhibitor  AMT-HCI  (150nM)  for  lhr  before 
incubation with myelin for a further 24hr. CM from microglia either left untreated or 
incubated  with  AMT-HCI  or  myelin  alone  were  used  as  controls.  (A)  CM  from 
microglia was collected and assessed for TNFa release. Incubation of microglia with 
AMT-HCI prior to incubation with myelin did not reduce the TNFa release induced 
by  myelin  alone.  (B)  MGCM  was  also  analysed  for  glutamate  levels.  Glutamate 
release  was not affected by prior incubation  with  AMT-HCI  (C) MGCM was  also 
applied to neurone cultures and levels of apoptosis were assessed by nuclear staining 
with  Hoechst  33342.  CM  from  microglia  incubated  with  AMT-HCI  prior  to 
exposure  to  myelin  induced  significantly  less  apoptosis  than  that  induced  by  CM 
from  microglia  incubated  with  myelin  alone.  Values  represent  mean  +SEM  from 
five separate fields per coverslip from three different coverslips repeated  in at least 
two  separate  experiments.  *P<0.05,  **P<0.01,  ***P<0.001  versus  control  unless 
indicated by a bar.183
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Figure 4.12  Direct application of AMT-HCI has no effect on neuronal 
while direct application of U0126 affords significant 
neuroprotection
(A)  iNOS  inhibitor  AMT-HCI  or  ERK  inhibitor  U0126  were  added  directly  to 
neurones in culture for 24 hours with control MGCM. Neurones were then fixed  in 
4%  F-PBS  and  stained  with  Hoechst  to  detect  apoptotic  cells.  Direct  addition  of 
AMT-HCL or U0126 to neurones had no significant effect on neuronal survival. (B) 
Since  both  AMT-HCL and  U0126  reduced  the toxicity  of microglia  when  applied 
prior to  myelin, these  compounds were added  directly to  neurones  in the  presence 
of myelin  MGCM  to  ascertain that the  protection  afforded  by  either AMT-HCI  or 
U0126  was  not  a  direct  effect  on  the  neurones  themselves.  Direct  application  of 
AMT-HCI had no significant effect on the neuronal death induced by myelin. Direct 
addition of U0126 however afforded significant neuroprotection which may suggest 
that the  protective  effects of U0126  are  due to a direct effect on  neurones.  Values 
represent mean and SEM from 5 different fields per condition repeated 3 times in at 
least two separate experiments. ***P<0.001  versus myelin CM.184
4.2.4  Myelin induced neurotoxicity can be modulated by metabotropic glutamate 
receptors
Since  the  presence  of  functional  microglial  mGluRs  may  affect  microglial 
reactivity when they are exposed to external glutamate we  investigated how activation 
of  these  receptors  modulated  the  reactivity  and  resulting  neurotoxicity  induced  by 
myelin.  To  investigate  the  effects  of  mGluRs  on  myelin  induced  microglial 
neurotoxicity,  selective agonists or antagonists were  incubated with microglial cultures 
prior to the addition of myelin.  This research has at present focused on modulation of 
group II and III mGluRs which have been shown to be neurotoxic and neuroprotective 
respectively  (Taylor et al.,  2002,  2003,  2005).  The  experiments  described  above  were 
repeated  to  analyse  the  mechanisms  by  which  mGluRs  modulated  the  reactive 
phenotype of microglia in vitro.
The  selective  group  II agonists DCGIV (500nM)  and NAAG  (50pM-  selective 
for  mGlu3)  or  antagonist  MCCG  (500pM)  were  applied  to  microglia  for  30  minutes 
prior to incubation with myelin. CM from microglia was then added to CGC cultures for 
24  hours  and  apoptosis  quantified  using  Hoechst  33342  staining  as  described  above 
(Figure 4.13A).  As previously noted, CM from myelin treated microglia induced death 
of cultured neurones by apoptosis.  CM from microglia treated with DCGIV alone was 
neurotoxic  (P<0.05)  leading  to  25%  (±  5%)  apoptosis  in  neuronal  cultures.  This 
confirms the  findings described  by Taylor et al.  (2002).  Furthermore,  when  incubated 
with  microglia  prior to  exposure  to  myelin,  DCGIV  significantly  increased  apoptosis 
compared with that caused by myelin CM alone (P<0.05).  Treatment of microglia with 
NAAG did not induce a neurotoxic phenotype since CM from these cells did not lead to 
increased levels of apoptosis compared with CM from control cells. Indeed exposure to 
NAAG  prior to  incubation  with  myelin  reduced  the  toxicity  of microglia treated  with 
myelin alone  (P<0.01).  Similarly,  CM from microglia exposed to MCCG  did not have185
any significant effect on neuronal survival compared with medium from untreated cells. 
Moreover, medium from cells incubated with MCCG and myelin resulted in significant 
attenuation  of neuronal  apoptosis  compared  with  medium  from  microglia  exposed  to 
myelin  alone  (PO.OOl).  However,  levels of apoptosis  induced by CM  from  microglia 
treated with MCCG  and myelin were  still  significantly above those  caused  by  control 
CM (PO.05) suggesting that other factors not influenced by the modulation of group II 
mGluRs are also responsible for myelin induced microglial neurotoxicity.
These experiments were repeated for analysis of active caspase 3 expression and 
cell death by PI uptake (Figure 4.14). As with Hoechst experiments, the percentage of 
dead cells or cells expressing active caspase were assessed as a percentage of total cells 
per field (Figure 4.13B). As expected, results mirrored the Hoechst findings.  Microglia 
pre-treated  with  NAAG  or  MCCG  before  incubation  with  myelin  showed  reduced 
caspase 3 and PI staining compared with cells exposed to myelin alone, which suggests 
that  factors  released  by  microglia  in  CM  induce  neuronal  apoptosis  via  activation  of 
caspase 3, and that inhibition of group II mGluR2 with MCCG or activation of mGluR3 
with NAAG prevents this.
These observed changes  in levels of neuronal apoptosis were due to substances 
released  from  microglia  in  the  CM  since  direct  application  of  receptor  agonists  or 
antagonists  to  CGCs  had  no  significant  effect  on  neuronal  survival  (Figure  4.15A). 
Furthermore  when  CM  from  microglia  treated  with  myelin  was  added  to  neuronal 
cultures  with  direct  application  of either  NAAG  or  MCCG  there  was  no  significant 
modulation of apoptosis (Figure 4.15B) demonstrating that the neuroprotection afforded 
by  these  compounds  was  not  attributable  to  a  direct  action  on  group  II  receptors  on 
neurones but instead by modulating the toxicity of the microglia.
Since treatment with NAAG did not afford the same level of neuroprotection as 
treatment with MCCG,  further experiments concentrated  on the effects of DCGIV and186
MCCG  alone.  This  research  has  shown  that  TNFa,  glutamate  and  iNOS  have  been 
implicated  in the toxicity of microglial medium and as such the release and expression 
of these compounds was examined after treatment of microglia with DCGIV or MCCG 
either alone or in the presence of myelin. Interestingly, the TNFa release from microglia 
induced by myelin was not significantly altered by prior treatment with either DCGIV 
or MCCG (P=0.9978 and P=0.7221  respectively) (Figure 4.16A). Analysis of glutamate 
concentrations in MGCM showed that although myelin induced a significant glutamate 
release  above  controls,  so  too  did  DCGIV  and  MCCG.  However,  incubation  of 
microglia with these compounds preceding incubation with myelin seemed to potentiate 
glutamate release above levels induced by myelin alone, particularly with co-incubation 
with DCGIV (PO.Ol) (Figure 4.16B).
Finally  the  expression  of  phospho-ERK  (Figure  4.16C)  and  iNOS  protein 
(Figure 4.16D and E) was determined under the conditions described above.  Microglia 
left untreated or incubated with DCGIV or MCCG alone did not express phospho-ERK 
above control  levels.  The phospho-ERK expression  in  microglia was  upregulated after 
incubation  with  myelin  as  shown,  furthermore  this  expression  was  reduced  by  pre­
treatment with MCCG (Figure 4.16C).  Similarly,  neither untreated microglia nor those 
treated with DCGIV or MCCG alone expressed any iNOS protein. As discussed, myelin 
treated  microglia  expressed  iNOS  after 24  hours.  Pre-treatment  with  DCGIV  did  not 
have any effect on this expression but treatment with MCCG visibly reduced the  iNOS 
levels  induced  by myelin  alone  (Figure 4.16D).  These  data  suggest that the  beneficial 
effect  on  neuronal  survival  mediated  by  pre-treatment  with  MCCG  could  be  due  to 
reduced  expression  of iNOS  protein  consistent  with  the  neuroprotection  afforded  by 
iNOS inhibitors (Figure 4.11C).
The  above  experiments  were  repeated  with  the  group  III  agonist  AP4  and 
antagonist MAP4.  CM  from  microglia treated  with  AP4  (500jnM)  or MAP4  (500pM)187
either with or without the presence of myelin for 24 hours was applied to neurones for 
assessment of induced apoptosis (Figure 4.17A), caspase 3 expression and death (Figure 
4.17B). Exposure of microglia to AP4 or MAP4 did not induce a neurotoxic phenotype 
since  levels of apoptosis were not significantly different from those  induced by control 
CM  (P=0.2903  and  P=0.0997  respectively).  As  such  the  stimulation  of  group  III 
mGluRs unlike stimulation of group II mGluRs does not result in the transformation of 
microglia to a neurotoxic phenotype.  CM taken from  microglia  incubated with MAP4 
together  with  myelin  had  no  significant  effect  on  neuronal  apoptosis  compared  with 
levels  induced  by  myelin  alone  (P=0.9016).  However,  medium  from  microglia 
incubated with AP4 together with myelin showed significantly attenuated neurotoxicity 
compared  with  medium  taken  from  microglia  incubated  with  myelin  alone  (PO.Ol). 
Interestingly, the neuroprotective effect of AP4 was not as potent as that induced by the 
group  II  receptor  antagonist  MCCG.  These  data  suggest  that  microglial  reactivity  is 
primarily  mediated  by  group  II  mGluRs  and  that  blocking  this  reactivity  rather than 
stimulating a protective phenotype  is a more  beneficial way of reducing the microglial 
toxicity induced by myelin.
Analysis of active caspase 3  expression and  PI  uptake  in CGCs mirrored these 
results (Figure 4.17B) although CM from microglia incubated with MAP4 alone slightly 
but  significantly  increased  caspase  expression  above  levels  induced  by  control  CM. 
This  suggests  that  although  no  significant  increases  in  apoptosis  or  cell  death  were 
visible, apoptotic mechanisms were upregulated. As shown in previous experiments, the 
CM  from  microglia  incubated  with  myelin  induced  neurones  to  express  significantly 
elevated  caspase  3  expression  and  PI  uptake  (PO.OOl  and  PO.Ol  respectively). 
Furthermore,  AP4  afforded  significant neuroprotection  and  reduction  of the  caspase  3 
expression  and  PI  uptake  induced  by  myelin  alone  (For  representative  images  see 
Figure 4.18).188
The observed changes  in neuronal  apoptosis were  due to factors  released from 
microglia into the CM since direct application of receptor agonists or antagonists had no 
significant  effect  on  neuronal  survival  (Figure  4.19A).  Furthermore  when  CM  from 
microglia treated with myelin was added to neuronal cultures with direct application of 
AP4,  there  was  no  significant  modulation  of apoptosis  (Figure  4.19B)  demonstrating 
that the neuroprotection afforded by AP4 was not attributable to a direct action of group 
III receptors on neurones but instead by modulating the toxicity of microglia.
CM and cell  lysates were assessed for TNFa and glutamate release,  and  iNOS 
expression  respectively  from  untreated  microglia  or  cells  treated  with  AP4  or  MAP4 
either with or without the presence of myelin for 24 hours. Incubation of AP4 or MAP4 
alone  did  not cause  microglia to release  any  significant  levels  of TNFa  above  control 
(P=0.3229  and  P=0.6942  respectively)  (Figure  4.20A).  Treatment  of  microglia  with 
AP4  or MAP4  together with  myelin  however,  potentiated  TNFa  release  above  levels 
induced  by  myelin  alone  which  suggests  that  TNFa  may  not  be  a  factor  in  the 
neuroprotection mediated by AP4. Glutamate levels in media were also assessed (Figure 
4.20B).  We found that as with the group II receptors, treatment of microglia with AP4 
induced  significant increases  in glutamate release to  levels  similar to those  induced  by 
myelin  alone.  Again,  incubation  of  microglial  AP4  or  MAP4  together  with  myelin 
seemed to potentiate the release of glutamate, however, the increases observed were not 
statistically significant (P=0.2443  and P=0.0589 respectively) when compared with the 
release induced by incubation with myelin alone.
Microglial  lysates  were  analysed  for  phospho-ERK  (Figure  4.20C)  and  iNOS 
protein (Figure 4.20D and E) expression by western blotting.  While phospho-ERK was 
not expressed  in control microglia or those treated with AP4 alone,  expression seemed 
to  be  upregulated  by  exposure  to  MAP4  alone  or  by  myelin.  In  contrast  to  the 
modulation of phospho-ERK expression  seen by group  II antagonists,  neither AP4  nor189
MAP4  appeared to  alter phospho-ERK  expression  induced  by  myelin  (Figure  4.20C). 
Microglia  left unstimulated  or cells treated with AP4  or MAP4  alone  did  not  express 
any  iNOS  protein.  Microglia treated with AP4 prior to addition of myelin reduced the 
expression  of iNOS  induced  by  myelin  alone  but  this  effect  was  consistently  not  as 
pronounced as the effect induced by MCCG (Figure 4.16D).MGCM added to CGCs
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Figure 4.13  Stimulation  of  microglial  group  II  mGluRs  induces  microglial 
neurotoxicity.
Conditioned medium from microglia either untreated or stimulated with group II mGluR 
agonists  (DCGIV  500nM,  NAAG  50pM)  or  antagonists  (MCCG  500pM)  in  the 
presence  or absence  of myelin was  applied to  neurones  in  culture.  (A)  Apoptosis was 
assessed  by  Hoechst  33342  nuclear  staining  and  subsequent  counting  of condensed 
pyknotic nuclei. (B) Caspase-3 activity and cell death were determined by staining with 
caspatag and PI respectively. Untreated neurones left without microglial CM (basal) and 
neurones  incubated with medium  from untreated microglia (control  CM) were used as 
negative  controls.  Neurones  incubated  with  medium  from  microglia  treated  with 
DCGIV suffered significant apoptosis above that induced by control CM or MCCG CM. 
Toxicity of myelin CM  was reduced by pre-treating microglia with NAAG or MCCG 
but  increased  by  pre-treating  with  DCGIV.  Medium  from  MG  treated  with  DCGIV 
alone also  induced increased neuronal caspase expression and death. Neuronal caspase 
expression and cell death induced by CM from MG incubated with myelin was reduced 
by  pre-treating  MG  with NAAG  or MCCG.  Values  represent  mean  and  SEM  from  5 
different  fields  per  condition  repeated  3  times  in  at  least  three  separate  experiments. 
*P<0.05,  **P<0.01,  ***P<0.001  (A) versus control  CM unless indicated by a bar.  (B) 
versus control  for DCGIV, NAAG,  MCCG  and myelin conditions,  versus myelin forCaspase  PI Combined
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Figure 4.14  Caspase and PI expression induced by myelin is modulated by 
group II mGluRs
Caspase-3  activity  (green)  and  PI  staining  (red)  were  assessed  in  neuronal 
cultures  exposed  for  24  hours  to  microglial  CM  from  microglia  treated  as 
described in Figure 4.10. Cells were incubated with CaspaTag and PI for 30 min?  
and  staining  was  viewed  using  a  fluorescence  microscope.  Where  CaspaTag 
staining and PI  staining overlap, cells appear yellow.  The number of caspase-3- 
or Pi-positive cells were counted and expressed as a percentage of the total cell 
number per field.192
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Figure 4.15  Direct application of group II agonists or antagonists to neurones 
has  no effect on  neuronal survival following exposure to  myelin 
MGCM
(A) Group II agonists DCGIV or NAAG and antagonist MCCG were added directly 
to  neurones  in  culture  for  24  hours.  Neurones  were  then  fixed  in  4%  F-PBS  and 
stained with Hoechst to detect apoptotic cells. Direct addition of DCGIV, NAAG or 
MCCG  to  neurones  had  no  significant effect on  neuronal  survival.  (B)  Since  both 
NAAG and MCCG reduced the toxicity of microglia when applied prior to myelin. 
NAAG or MCCG were added directly to neurones in the presence of myelin CM to 
ascertain that the protection afforded by these compounds was not a direct effect on 
the neurones themselves. Values represent mean and SEM from 5 different fields per 
condition repeated 3 times in at least three separate experiments.T
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Figure 4.16  Modulation of microglial iNOS expression  and  glutamate  release 
but not TNFa release by group II mGluRs.
Microglia  were  either  left  untreated  or  incubated  with  group  II  mGluR  agonist 
DCGIV  (500nm)  or  antagonist  MCCG  (500pM)  with  or  without  the  presence  of 
myelin,  as  a positive  control  microglia were  incubated  with  myelin  alone.  (A)  The 
CM  from  microglia  was  analysed  for  TNFa  and  showed  that  neither  DCGIV  nor 
MCCG  altered  the  TNFa  release  induced  by  myelin  alone.  (B)  CM  was  also 
analysed  for  glutamate  levels.  Stimulation  with  both  agonists  and  antagonists 
increased  glutamate  release  above  control  levels.  Interestingly  only  DCGIV  had  a 
significant effect on the  levels of glutamate release  induced  by myelin.  MG  lysates 
from  the  above  conditions  were  analysed  for  (C)  phospho-ERK  protein  and  (D) 
iNOS protein by Western blotting The first lane shows non stimulated microglia as a 
negative  control  for  iNOS  expression.  (E)  Densitometric  analysis  of  iNOS 
expression  in rat microglia incubated with myelin as above, values were normalised 
by  the  amount  of B-actin  protein  and  represent  the  means  of three  separate  blots. 
*P<0.05, **P<0.01,  ***P<0.001  versus control unless indicated by a bar..2 2
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Figure 4.17  Stimulation  of microglial  group  III  mGluRs  promotes  neuronal 
survival.
Conditioned  medium  from  microglia  either untreated  or  stimulated  with  group  III 
mGluR  agonists  (AP4  500pM)  or  antagonists  (MAP4  500|JM)  in  the  presence  or 
absence  of  myelin  was  applied  to  neurones  in  culture.  Untreated  neurones  left 
without microglial CM (basal) and neurones incubated with medium from untreated 
microglia (control CM) were used as negative controls. (A) Apoptosis was assessed 
by Hoechst 33342  staining and subsequent counting of condensed pyknotic nuclei. 
(B) Caspase-3 activity and cell death were determined by staining with caspatag and 
PI  respectively.  Values  represent  mean  and  SEM  from  5  different  fields  per 
condition  repeated  3  times  in  at  least  three  separate  experiments.  *P<0.05, 
**P<0.01,  ***P<0.001  (A) versus control CM unless indicated by a bar. (B) versus 
control CM for AP4, MAP4 and myelin conditions, versus myelin for compounds+ 
myelin conditions.C aspase  PI  Com bined
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Figure 4.18  Caspase  and  PI  expression  induced  by  myelin  is  modulated  by 
group III mGluRs
Caspase-3  activity (green)  and PI staining (red) were assessed in neuronal cultures 
exposed  for  24  hours  to  MGCM  from  microglia  treated  as  labelled.  Cells  were 
incubated  with  CaspaTag  and  PI  for  30  min,  and  staining  was  viewed  using  a 
fluorescence  microscope.  Where  CaspaTag  staining  and  PI  staining  overlap,  cells 
appear  yellow.  The  number  of caspase-3-  or  Pi-positive  cells  were  counted  and
ev n re sse d   as a n e rre n ta a e  o f  th e  tn tal  cell  n n m h e r n e r field196
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Figure 4.19  Direct  application  of  group  III  agonists  or  antagonists  to 
neurones has no effect on neuronal survival
(A) Group III agonist AP4 and antagonist MAP4 were added directly to neurones in 
culture for 24 hours. Neurones were then fixed in 4% F-PBS and nuclei stained with 
Hoechst to detect apoptotic cells.  Direct addition of AP4 or MAP4 to neurones had 
no  significant  effect  on  neuronal  survival.  (B)  Since  AP4  reduced  the  toxicity  of 
microglia  when  applied  prior  to  myelin  this  compound  was  added  directly  to 
neurones  in the presence of myelin CM to ascertain that the protection afforded by 
AP4 was not a direct effect on the neurones themselves. Values represent mean and 
SEM from 5 different fields per condition repeated 3 times in at least three separate 
experiments.T
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Figure 4.20  Modulation  of microglial  iNOS  expression  but  not  glutamate  or 
TNFa release by group III mGluRs
Microglia were either left untreated or incubated with group III mGluR agonist AP4 
(500nm) or antagonist MAP4 (500pM) with or without the presence of myelin, as a 
positive  control  microglia  were  incubated  with  myelin  alone.  (A)  The  CM  from 
microglia  was  analysed  for TNFa and  showed  that  both  AP4  and  MAP4  increased 
the TNFa release induced by myelin alone. (B) CM was also analysed for glutamate 
levels.  Stimulation  with  AP4  increased  glutamate  release  above  control  levels. 
Interestingly  neither  AP4  nor  MAP4  had  any  significant  effect  on  the  levels  of 
glutamate  release  induced  by  myelin.  MG  lysates  from  the  above  conditions  were 
analysed  for (C) Phospho-ERK and (D)  iNOS protein  by western  blotting The first 
lane  shows  non  stimulated  microglia  as  a  negative  control  for  iNOS  expression. 
Microglial  iNOS  levels  stimulated  by  incubation  with  myelin  were  reduced  by 
blocking  group  II  mGluRs.  (D)  Densitometric  analysis  of iNOS  expression  in  rat 
microglia incubated with myelin as above, values were normalised by the amount of 
B-actin  protein and  represent the means of three  separate blots.  *P<0.05,  **P<0.01, 
***P<0.001  versus control unless indicated by a bar.198
4.3  Discussion
Previous  work  has  shown  that  macrophages  phagocytose  myelin  (Bruck  and 
Friede,  1990) leading to release of TNFa and NO and expression of iNOS (Williams et 
al.,  1994;  Mosley  and  Cuzner,  1996;  van  der Laan  et  al.,  1996).  Furthermore  a  study 
using the  Long Evans  Shaker rat which exhibits early  demyelination and  later loss  of 
myelin  sheaths  showed  concomitant  increases  in  microglial  MHC-II  expression  and 
upregulated IL1|3, TNFa and iNOS mRNA in the spinal cord (Zhang et al., 2001). Flere, 
primary  microglia  exposed  to  myelin  adopt  a  reactive  phenotype  marked  by 
upregulation  of  ED-1  protein  and  subsequent  release  of  a  number  of  inflammatory 
mediators including TNFa, glutamate and nitrite, and expression of iNOS and phospho- 
ERK.  However,  only  TNFa  release  from  microglia  was  significantly  induced  above 
control after 4 hours  incubation with myelin.  Figure 4.21  shows the possible pathways 
involved in myelin induced microglial release of TNFa and nitrite.
M YELIN
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Figure 4.21  Myelin induces TNFa and nitrite release coupled to ERK in microglia
Myelin  induced  microglia to  release  TNFa and  express  iNOS.  The  MEK  inhibitor U0126 
prevented myelin  induced TNFa and  iNOS expression while  inhibiting iNOS  activity with 
AMT-HC1 prevented NO and downstream products but had no effect on TNFa release.199
The  factors  released  by  microglia  exposed  to  myelin  were  deleterious  to 
neuronal survival since incubation of cultured neurones with CM from microglia treated 
with myelin induced significantly increased levels of apoptosis. This was attributable to 
myelin  induced  factors  released  by  microglia,  since  direct  application  of  myelin  to 
neurones either alone or in the presence of microglial control CM had no adverse effect. 
These findings have important implications in the study of MS pathology since removal 
of myelin  debris  by  microglia  in  MS  plaques  has  been  well  documented  (Lee  et  al., 
1990;  Li  et al.,  1996;  Hill  et al.,  2004;  Tanuma et al.,  2006) and  could therefore  have 
detrimental consequences for neuronal survival by bystander damage.
The CM from microglia exposed to myelin for 4 hours was toxic to neurones in 
culture  which  suggests  a  major  role  for  TNFa  as  a  mediator  of neurotoxicity  since 
TNFa release but no  iNOS expression were observed at this time point.  Indeed,  TNFa 
release from microglia has been shown to induce neuronal death in vitro (Combs et al., 
2001;  Floden  et  al.,  2005).  Furthermore  incubation  of the  MEK  inhibitor U0126  with 
microglia prior to  exposure to myelin  significantly reduced  both the  TNFa and  nitrite 
release  induced  by  myelin  and  as  such  dramatically  reduced  the  neuronal  apoptosis 
compared with that induced by CM from microglia exposed to myelin alone.
It is also possible that iNOS and downstream products  such as nitric  oxide and 
nitrite have a role in the microglial toxicity induced by myelin since pre-treatment with 
the iNOS inhibitor AMT-HC1 also attenuated the neuronal apoptosis induced by myelin 
CM.  This,  however,  contradicts  findings  which  have  shown  that  co-cultured  or  CM 
from  activated  microglia  does  not  induce  NO  or  peroxynitrite  mediated  cell  death 
(Ciesielski-Treska  et  al.,  1998;  Kingham  et  al.,  1999;  Taylor  et  al.,  2005).  However, 
other studies have demonstrated nitric oxide toxicity to neurones  in co-culture systems 
(Bal-Price  and  Brown  2001;  Xie  et  al.,  2002;  Katsuki  et  al.,  2006;  Gibbons  and 
Dragunow, 2006).  Although we used MGCM  instead of co-culture,  it may be possible200
that nitrite and nitrate  in the CM from myelin stimulated microglia is reduced to nitric 
oxide  when  applied  to  cultured  neurones  (Millar,  1995;  Tsuchiya  et  al.,  2005). 
Experiments  using  direct  application  of NO  or  its  derivatives  to  neurones  in  culture 
would determine the toxicity of these compounds. It is more probable that the inhibition 
of iNOS and downstream NO release had neuroprotective effects through reducing the 
overall feedback activation of microglia caused by these substances. It has also recently 
been  shown  that  blocking  NO  activity  prevented  upregulation  of  CR3  through 
modulation of guanylate cyclase and cyclic  GMP pathways (Roy et al.,  2006).  CR3  is 
the receptor by which most myelin is phagocytosed (Reichert et al., 2001; Reichert and 
Rotshenker,  2003).  As  such  the  toxic  downstream  effects  of myelin  phagocytosis  by 
microglia  may  be  blocked  by  inhibition  of  iNOS  activity  which  may  explain  the 
neuroprotective effect of iNOS inhibition in microglial cultures.
It  has  previously  been  demonstrated  that  activation  of  microglial  group  II 
mGluRs  is  neurotoxic  (Taylor  et  al,  2002).  These  data  confirm  these  findings  and 
further show that myelin induced neurotoxicity can also be reduced by blocking group 
II mGluRs prior to incubation with myelin. Furthermore, CM from microglia incubated 
with  DCGIV  prior  to  exposure  to  myelin  induced  significantly  elevated  levels  of 
apoptosis  in  neuronal  cultures  compared  with  CM  from  microglia  incubated  with 
myelin  alone.  These  data  suggest  that  the  reactive  phenotype  stimulated  by  myelin 
mediates its effects through the activation of group II mGluRs, specifically the mGluR2 
subtype  since  stimulation  of mGluR3  subtype  by NAAG  did  not  induce  a  neurotoxic 
microglial phenotype and furthermore reduced the neurotoxicity of microglia incubated 
with myelin alone.
Stimulation  of microglial  group  III  mGluRs  can  be  neuroprotective  (Taylor et 
al.,  2003).  Here,  microglial  group  III  stimulation  also  decreased  the  microglial 
neurotoxicity  induced  by myelin.  Blockade  of microglial  group  III  receptors  however,201
had no  significant effect on the toxicity of CM stimulated with myelin which suggests 
that  group  III  receptors  do  not  mediate  the  toxicity  of myelin  but  may  in  some  way 
promote  a  neuroprotective  phenotype  in  microglia  which  reduces  the  toxic  effect  of 
subsequent  exposure  to  myelin.  Furthermore,  the  neuroprotection  afforded  by 
stimulation  of group  III  mGluRs was  significantly  less  than that  induced  by  block  of 
group  II  mGluRs  which  may  suggest  that  the  neurotoxic  group  II  pathway  is  more 
important  in  myelin  mediated  neurotoxicity.  It  has  also  been  proposed  that  group  III 
mGluRs have a lower coupling efficiency to adenylate cyclase (Kemp et al.,  1996).
CM  from  microglia  exposed  to  myelin  also  induced  neuronal  expression  of 
active caspase 3 which was reduced by pre-treatment with MCCG, NAAG or AP4. This 
may  suggest  that  the  neuronal  apoptosis  induced  by  factors  released  from  myelin 
stimulated  microglia  was  mediated  by  caspase  3,  although  further  work  analysing 
expression of different activator caspases will elucidate the apoptotic mechanism more 
clearly.  These  findings  demonstrate  that  the  microglial  activation  and  neurotoxicity 
induced  by  myelin  can  be  suppressed  by  modulation  of mGluRs  which  may  prove  a 
putative therapeutic strategy in MS.
Further work is necessary to elucidate the mechanisms of mGluR modulation of 
microglial  toxicity.  Microglial  TNFa  release  induced  by  myelin  is  not  attenuated  by 
modulation of mGluRs which may indicate that TNFa release  is not a factor in mGluR 
mediated  neuroprotection.  It  is  possible  that  the  role  of  TNFa  in  myelin-induced 
neuronal  death  is  as  a  mediator  of  downstream  inflammatory  events  rather  than  a 
directly  neurotoxic  molecule,  indeed  it has been  demonstrated  that TNFa alone  is  not 
toxic to neurones but acts in concert with FasL to exert neurotoxic effects (Taylor et al., 
2005).  The  fact that both  AP4  and  MCCG,  shown  here  to  promote  neuronal  survival, 
induced  the  same  release  of  glutamate  as  microglia  incubated  with  myelin  alone 
suggests  that  at  these  levels,  glutamate  is  not  the  primary  mediator  of neurotoxicity202
caused  by  myelin.  Interestingly  however,  treatment  of  microglia  with  DCGIV 
potentiated  the  release  of glutamate  induced  by  myelin  alone  which  may  explain  the 
increased  neurotoxicity  of  DCGIV-myelin  CM.  The  expression  of  iNOS  protein 
induced  by  exposure  to  myelin  was  reduced  by  MCCG  and  to  a  lesser  extent  AP4, 
which  may  indicate  that  attenuated  nitric  oxide  activity  is  involved  in  the 
neuroprotection  mediated  by  these  compounds.  This  is  consistent  with  the 
neuroprotection afforded by iNOS inhibitors.
The mechanisms of mGluR mediated neuroprotection remain unclear but it has 
been  shown  in  astrocytes that  stimulation  of mGluRs  can  reduce  IFNy  induced  iNOS 
expression  (Murphy  et  al.,  1995)  so  it  may  be  possible  that  stimulation  of group  III 
mGluRs  mildly  activates  microglia  which  could  then  desensitise  them  to  further 
activation.  In  other  systems,  activation  of group  III  mGluRs  in  bone  marrow  stromal 
cells reduced intracellular Ca2+ levels and NO production (Foreman et al., 2005).
Future  studies  repeating these  experiments  using  co-culture  would  shed  some 
light on the compounds that are directly involved  in toxicity to neurones.  Further work 
is  required  to  understand  the  mechanisms  involved  in  microglial  toxicity  and 
neuroprotection.  Studies  of  the  effects  of  myelin  and  mGluRs  on  the  signalling 
pathways  upstream  of iNOS  induction  and  TNFa  release,  and  how  these  pathways 
interact, will help to elucidate the mechanisms of myelin mediated toxicity and mGluR 
mediated neuroprotection.203
5.0
MODULATION OF MICROGLIAL MYELIN 
PHAGOCYTOSIS BY METABOTROPIC 
GLUTAMATE RECEPTORS204
5.1  Introduction
Microglia  show  early  reactivity  in  response  to  insult  and  microglial  activation 
has  been  associated  with  release  of  inflammatory  mediators  and  neurotoxicity. 
Activation  of microglia occurs as a graded response with super activated cells adopting 
a phagocytic macrophage like morphology. Microglia have been shown to phagocytose 
myelin  in  vitro.  Indeed,  activated  microglia  show  increased  capacity  for  binding  of 
oligodendrocytes  and  phagocytosis  of  myelin  compared  with  that  of  macrophages 
(Mosley  at  el.,  1996).  Furthermore,  the  presence  of myelin  and  myelin  degradation 
products  within  microglia/M0  in  MS  lesions  (Hill  et  al.,  2004)  strongly  suggests  an 
active role for microglia in the demyelination process.
Phagocytosis is an actin dependent mechanism and is initiated by the binding of 
a  receptor  on  the  phagocyte  with  ligands  on  the  cell  surface  of a  particle.  There  are 
several  receptors  capable  of  inducing  phagocytosis  including  pattern  recognition 
receptors,  Fc  receptors  and  complement receptors.  Fc  mediated  phagocytosis  involves 
recognition  by  the  phagocyte  of the  Fc  region  of antibody  labbeled  pathogens  which 
leads  to  SRC/SYK  mediated  polymerisation  of actin  and  phagocytosis.  Complement 
mediated  phagocytosis  is  a  biochemical  cascade  activated  by  the  binding  of the  Cl 
complex  to  antibodies  or  antigen  leading  to  production  of  C3  onvertase  and  C3 
hyrolysis  which  in  turn  activates  a cascade  of cleavage  and  activation  culminating  in 
internalisation and phagocytosis.  The myelin used  in this project was not opsonised  so 
the method of phagocytosis in this case is uncertain as antibodies or complement were 
unlikely  to  have  been  involved.  However,  phagocytosis  is  a  complex  not  a  linear 
process  influenced  by  a range  of factors  including the  expression  of several  receptors 
capable  of mediating phagocytosis,and  additional  signals  from  complex  particles.  It  is205
possible  that  complex  particles  can  activate  several  receptors  which  may  interact  in 
different ways to influence the phagocytic mechanism.
Here we have shown that incubation with myelin induces microglia to release a 
number  of  potentially  cytotoxic  molecules  which  can  cause  neuronal  death.  Since 
myelin induced microglial reactivity can be modulated by stimulation of mGlu receptors 
this  study  investigated  whether  myelin  phagocytosis  could  also  be  modulated  in  the 
same way. Dextran beads with weights of lOkDa and 40kDa,  or labelled myelin, were 
incubated with microglia for 2, 4 or 24 hours to investigate the timecourse and capacity 
of microglia for phagocytic activity.206
5.2  Results
5.2.1  Microglial phagocytosis is upregiilated bv prior exposure to myelin
In the following experiments microglia were plated at 90,000 cells per coverslip 
as described and  incubated at 37°C for 24 hours before use.  Microglia were  incubated 
with  20pg/ml  of  both  lOkDa  (TRITC  conjugated)  and  40kDa  (FITC  conjugated) 
dextran beads either alone  or after prior  incubation  for 30 minutes with either  lpg/ml 
myelin  or  mGluR  agonists  or  antagonists.  Levels  of phagocytosis  were  assessed  by 
imaging  with  a  Zeiss  fluorescence  microscope  (Oberkochen,  Germany).  Phagocytosis 
was  quantified  by  analysing  the  number  of cells  containing  fluorescent  beads  as  a 
percentage of the total cells per field. These experiments were repeated after 2, 4 and 24 
hours.
Phagocytosis of dextran beads occurred  in untreated control  microglial cultures 
after 2  hours  suggesting that microglia undergo  phagocytosis  ‘at  rest’  (Figure  5.1).  It 
was found that 26% (± 3.1%) of microglia had engulfed the  lOkDa dextran beads after 2 
hours  incubation  while  only  18%  (±  3.3%)  contained  40kDa  dextran  beads  which 
suggests  that  compounds  of  a  smaller  molecular  weight  were  more  readily 
phagocytosed  in  resting  microglia.  Incubation  with  myelin  for  30  minutes  prior  to 
addition of 10 and 40 kDa beads induced a highly significant increase in the percentage 
of  cells  undergoing  phagocytosis  (P<0.001)  to  60%  (±  3.4%)  and  53%  (±  4.2%) 
respectively.  Treatment  of  group  I  mGluRs  with  ADA  (250|liM )  had  no  significant 
effect  on  the  phagocytosis  of either  lOkDa  or  40kDa  dextran  beads  (P=0.3471  and 
P=0.2813  respectively).  Blockade  of  group  I  mGluRs  with  the  antagonist  AIDA 
(250pM),  however,  did  induce  slightly  increased  levels  of phagocytosis  of the  lOkDa 
beads compared with untreated cells (P<0.05) but not of the 40kDa beads (P=0.1861). 
Interestingly,  treatment  of  group  II  mGluRs  with  agonist  DCGIV  (500nM)  clearly207
promoted  a  phagocytic  phenotype  in  microglia,  inducing  55%  (±  4.6%)  of cells  to 
phagocytose  lOkDa beads and 50% (± 3.4%) of cells to phagocytose 40kDa beads. The 
mGluR3  subtype-specific  agonist NAAG  (50pM)  however  did  not  induce  significant 
increases in the percentage of phagocytosing microglia which suggests that the mGluR2 
subtype is responsible for upregulated phagocytosis.  Incubation with group III agonists 
or  antagonists  prior  to  incubation  with  dextran  beads  had  no  effect  on  the  levels  of 
phagocytosis induced by the beads alone (P=0.7139 and P=0.2222 respectively).
These  experiments  were  repeated  after  4  and  24  hours  to  determine  whether 
induced  increases  in  microglial  phagocytic  activity  remained  elevated  after  longer 
periods  of  time.  After  4  hours  incubation  with  10  and  40kDa  beads,  levels  of 
phagocytosis in cultures incubated with the beads alone had risen to 33% (± 3.2%) and 
26%  (±  4.9%)  respectively  (Figure  5.2).  However,  prior  exposure  to  myelin  (lpg/ml) 
for  30  minutes  still  induced  significantly  elevated  microglial  phagocytosis  compared 
with untreated cells (P<0.01). Neither stimulation nor blockade of group I mGluRs prior 
to  incubation  with  the  beads  altered  the  levels  of  phagocytosing  cells  detected  in 
untreated  cultures.  Microglia  treated  with  DCGIV  before  incubation  with  beads 
however, maintained upregulated levels of phagocytosis compared with untreated cells 
while  stimulation  of mGluR3  receptors  still  had  no  significant  effects.  Blockade  of 
group  II mGluRs with antagonist MCCG  (500pM) preceding treatment with the beads 
seemed to reduce the basal  levels of phagocytosing microglia but these results were not 
significant.  Both  stimulation  and  blockade  of group  III  mGluRs  induced  significant 
increases in the levels of phagocytosis compared with those seen in untreated microglia 
this may be explained by the partial agonist effects of MAP4.
Further  incubation  with  10  and  40kDa  beads  for  24  hours  resulted  in  a  basal 
level  of 64%  (±  11.2%)  and  34%  (±  4%)  phagocytosis  respectively  (Figure  5.3).  As 
such, pre-treatment with either myelin or any of the mGluR agonists or antagonists did208
not significantly alter phagocytosis of the lOkDa beads compared with basal levels. This 
suggests that although phagocytosis of beads of this molecular weight can be modulated 
over a period of 2-4 hours, after 24 hours the phagocytic response to substances of this 
weight is  saturated.  It  is interesting however that antagonism of group II receptors did 
not reduce basal levels of dextran bead phagocytosis, and suggests that there is no tonic 
stimulation of group II receptors under basal conditions.
The  percentage  of untreated  microglia  phagocytosing  40kDa  beads,  however, 
remained  relatively  low  after  24  hours  (Figure  5.3),  which  indicates  that  at  rest, 
microglia are  less  likely to phagocytose  compounds  of a higher molecular weight.  As 
found after 2 and 4 hours, pre-treatment of the cells with myelin still induced significant 
upregulation of phagocytosis of 40kDa beads after 24 hours compared with basal levels 
(P<0.01). Prior treatment with group I agonists or antagonists had no significant effect 
on the phagocytosis  of 40kDa beads.  However,  stimulation of group  II  receptors with 
DCGIV  still  maintained  an  increase  in phagocytosis  above  basal  levels  after 24  hours 
incubation.  In accordance with the results found after 2 and 4 hours, NAAG or MCCG 
had  no  significant  effects  on  levels  of phagocytosis  after  24  hours.  Interestingly  pre­
treatment of microglia to either AP4 or MAP4  still  induced more cells to phagocytose 
40kDa beads compared with basal levels after 24 hours.209
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Figure 5.1  Phagocytosis  of dextran  beads  by  microglia  after 2  hours  is 
increased by exposure to myelin, DCGIV or AIDA.
Cultured  microglia  (1  DIV)  were  incubated  with  20|Jg/ml  of  both  10  kDa 
(TRITC conjugated) and 40kDa (FITC conjugated) dextran beads for 2 hours at 
37°C.  Control  cells  were  left  untreated  before  incubation  with  the  beads.  A 
subset  of  cells  were  stimulated  with  either  myelin  or  mGluR  agonists  or 
antagonists  prior  to  incubation  with  the  beads.  Live  cells  were  imaged  and 
captured  by  phase  contrast.  (A)  Phagocytosing  cells  were  counted  as  a 
percentage of total cells per field. These data represent the mean and SEM of at 
least three  fields per condition repeated  in  at least three  separate  experiments. 
Figures  B-J.  Representative  images  of microglial  bead  phagocytosis.  Control 
microglia treated with beads alone (B) or microglia stimulated with myelin (C), 
ADA (D), AIDA (E), DCGIV (F), NAAG (G), MCCG (H), AP4 (I), MAP4 (J) 
prior to incubation with beads.210
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Figure 5.2  Phagocytosis of dextran beads by microglia after 4 hours is 
increased by exposure to myelin, DCGIV, AP4 or MAP4.
Cultured  microglia  (1  DIV)  were  incubated  with  20jig/ml  of  both  10  kDa 
(TRITC conjugated) and 40kDa (FITC conjugated) dextran beads for 4 hours at 
37°C.  Control  cells  were  left  untreated  before  incubation  with  the  beads.  A 
subset  of  cells  were  stimulated  with  either  myelin  or  mGluR  agonists  or 
antagonists  prior  to  incubation  with  the  beads.  Live  cells  were  imaged  and 
captured  by  phase  contrast.  (A)  Phagocytosing  cells  were  counted  as  a 
percentage of total cells per field. These data represent the mean and SEM of at 
least three fields per condition repeated in at least three separate experiments. 
Figures  B-J Representative  images  of microglial  bead  phagocytosis.  Control 
microglia treated with beads alone (B) or microglia stimulated with myelin (C), 
ADA (D), AIDA (E), DCGIV (F), NAAG (G), MCCG (H), AP4 (I), MAP4 (J)
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Figure 5.3  Phagocytosis  by  microglia  of 40kDa  dextran  beads  after 24 
hours  was  increased  by  exposure  to  myelin,  DCGIV,  AP4 
and MAP4.
Cultured  microglia  (1  DIV)  were  incubated  with  20pg/ml  of  both  10  kDa 
(TRITC conjugated) and 40kDa (FITC conjugated) dextran beads for 24 hours 
at 37°C.  Control cells were left untreated before incubation with the beads.  A 
subset  of  cells  were  stimulated  with  either  myelin  or  mGluR  agonists  or 
antagonists  prior  to  incubation  with  the  beads.  Live  cells  were  imaged  and 
captured  by  phase  contrast.  (A)  Phagocytosing  cells  were  counted  as  a 
percentage of total cells per field. These data represent the mean and SEM of at 
least three fields per condition repeated in at least three  separate experiments. 
Figures  B-J.  Representative  images of microglial  bead phagocytosis.  Control 
microglia treated with beads alone (B) or microglia stimulated with myelin (C), 
ADA (D), AIDA (E), DCGIV (F), NAAG (G), MCCG (H), AP4 (I), MAP4 (J) 
prior to incubation with beads.212
5.2.2  Modulation of microglial phagocytosis
It  is  clear that myelin  induces  an  increase  in  the  proportion  of phagocytosing 
cells.  For  this  reason  it  was  determined  whether  stimulation  of  mGluRs  preceding 
exposure  to  myelin  and  dextran  beads  could  modulate  the  increase  in  phagocytosis 
induced  by  exposure  to  myelin  for  two  hours  (Figure  5.4).  This  data  suggested  that 
incubation  with  group  III  agonists  or  antagonists  prior  to  treatment  with  myelin  and 
beads,  reduced  the  amount  of cells  phagocytosing  lOkDa  beads  compared  with  the 
phagocytosis induced by myelin alone. These data contradict the findings showing AP4 
induced  upregulation  of phagocytosis  compared  with  basal  levels  but  may  be  due  to 
different signalling mechanisms induced by exposure to myelin.  Interestingly blockade 
of group  II  receptors  with  MCGC  had  no  significant  effect  on  the  phagocytosis  of 
lOkDa  beads  induced  by  myelin.  Treatment  with  MCCG  prior  to  incubation  with 
myelin did  however significantly reduce the percentage  of cells  phagocytosing 40kDa 
beads.  These  results  suggest  that  myelin  induced  phagocytosis  can  be  modulated  by 
stimulation of mGluRs.213
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Figure 5.4  Prior  exposure  of  microglia  to  MCCG  or  AP4  reduces  the 
phagocytosis  of 40kDa  dextran  beads  induced  by  incubation 
with myelin.
Cultured  microglia  (1  DIV)  were  incubated  with  20pg/ml  of  both  10  kDa 
(TRITC conjugated) and 40kDa (FITC conjugated) dextran beads for 4 hours at 
37°C. Cells were stimulated with mGluR agonists or antagonists then incubated 
with  myelin  prior  to  addition  of  dextran  beads.  Positive  controls  omitted 
stimulation  with  mGluR  agonists  or  antagonists.  Live  cells  were  imaged  and 
captured by phase contrast. Phagocytosing cells were counted as a percentage of 
total  cells per  field.  These  data represent the  mean  and  SEM  of at  least  three 
fields per condition repeated in at least two separate experiments.214
5.2.3  Mvelin is phagocytosed by primary microglia
Since  myelin  and  the  group  II  agonist  DCGIV  consistently  upregulated 
microglial  phagocytosis  of  dextran  beads,  the  uptake  of  pure  myelin  by  using 
fluorescent labelling was determined to observe phagocytosis of myelin under different 
conditions.  For all following experiments, 2pg/ml of fluorescent myelin was incubated 
with primary microglia which were then washed in warm basic solution to remove any 
un-phagocytosed  material  from  the  cells  and  viewed  using  a  Zeiss  fluorescence 
microscope.
To observe the timecourse of microglial uptake of myelin,  labelled myelin was 
incubated  for 2,  4,  6 and 24  hours with primary  microglia (Figure  5.5).  After 2  hours 
only  17%  (±  3.7%)  of cells  were  phagocytosing  myelin  while  after 4  hours  this  had 
risen to 42% (± 3.1%). After 24 hours the percentage of cells phagocytosing myelin had 
reached  80%  (±  2.4%).  Modulation  of dextran  bead  phagocytosis  after  24  hours  was 
less prominent than at earlier timepoints,  so for experiments using  labelled myelin,  an 
incubation  time  of 4  hours  was  used  since  there  was  no  significant  increase  between 
myelin uptake after 4 and 6 hours (P=0.054).
To ascertain that myelin was being phagocytosed and was not simply binding to 
microglia,  cells  were  treated  with  myelin  while  incubating  at  4°C  since  at  this 
temperature  the  phagocytic  but  not  the  binding  mechanism  is  inhibited  (Figure  5.6). 
Cells were also pre-treated with  154mM sodium azide in PBS as described, which acted 
to  metabolically  poison  the  cells  and  block  receptor  mediated  endocytosis.  Levels  of 
phagocytosis in cultures treated with myelin alone and  incubated at 37°C reached 59% 
(± 2.5%). Cells incubated at 4°C however, did not show elevated levels of phagocytosis 
with only 8% (±1.7%) cells positive for TRITC staining. This indicates that only a low 
amount of the  fluorescence  counted as phagocytosis may be  due to  binding.  Blocking 
endocytosis  significantly  reduced  the  amount  of  phagocytosing  cells  compared  toconditions  treated  with  myelin  alone  (P<0.001)  However  the  levels  of phagocytosis 
were still significantly higher than those recorded after incubation at 4°C  so  it may be 
possible  that  sodium  azide  treatment  reduces  but  does  not  completely  block  receptor 
mediated  endocytosis  or  more  likely  that  myelin  phagocytosis  is  also  mediated  by 
different  mechanisms.  A  subset  of  cells  were  also  treated  with  a  stripping  wash 
following  incubation  with  myelin.  This  served  to  remove  myelin  on  the  cell  surface 
allowing detection of internalised fluorescence only. Cultures treated with the acid wash 
post  incubation  with  myelin  still  showed  an  average  of 57%  (±  3.4%)  phagocytosis 
which was  not  significantly different from  levels detected  in  cells treated with  myelin 
alone then washed  in basic medium (P=0.5625). This demonstrated that excess myelin 
not taken up by microglia was effectively removed by washing cells prior to observation 
and that acid-stripping of un-intemalised substances was unnecessary in this case.216
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Figure 5.5  Timecourse of fluorescent myelin phagocytosis
Microglia were  incubated with myelin  (TRITC  labelled)  for 2,  4  ,  6.  and  24 
hours at 37°C and live cells were imaged and captured by phase contrast.  (A) 
The number of cells phagocytosing myelin were counted as a percentage of the 
total cells per field. Representative images of microglia incubated with labelled 
myelin for 2  (B),  4  (C),  6  (D),  24  (E)  hours.  These data represent mean and 
SEM  of at  least  four  fields  per  condition  repeated  in  at  least  two  separate 
experiments.217
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Figure 5.6  Observed microglial ingestion of fluorescent myelin is due to 
phagocytosis not binding.
Microglia  were  incubated  with  myelin  (TRITC  labelled)  either  alone  or  after 
prior  exposure  to  sodium  azide  (154mM  in  PBS;  which  blocks  cellular 
endocytosis)  for 4  hours  at  37°C.  A  subset  of microglia  were  treated  with  an 
acid wash after incubation with myelin to remove any un-intemalised myelin on 
the cell surface. A further subset of cells were incubated with fluorescent myelin 
for 4  hours  at 4°C  to  eliminate  the  possibility that observed  fluorescence  was 
due  to  binding.  Live  cells  were  imaged  and  captured  by  phase  contrast.  The 
number of cells phagocytosing myelin were counted as a percentage of the total 
cells  per field.  These  data represent  mean  and  SEM  of at  least  four fields  per 
condition repeated in at least two separate experiments.218
5.2.4  Microglial  mvelin  phagocytosis  is  modulated  by  metabotropic  glutamate
receptors
Treatment  with  mGluRs  modulated  the  phagocytosis  of  dextran  beads  and 
furthermore, the  increased phagocytosis of beads induced by myelin could be  reduced 
by  pre-treatment  with  group  II  antagonists  and  group  III  agonists.  As  such  it  was 
determined  whether  myelin  phagocytosis  could  also  be  reduced  by  modulation  of 
mGluRs  (Figure  5.7).  For these  experiments  microglia  were  pre-treated  with  specific 
mGluR  agonists  or  antagonists  for  30  minutes  prior to  incubation  with  myelin  for  a 
further 4 hours as described above.
Treatment with the group I agonist ADA reduced the phagocytosis of myelin by 
20% (PO.OOl) while blockade of this receptor had no significant effect.  The group II 
agonist DCGIV which induced increases in the phagocytosis of dextran beads compared 
with  basal  levels,  slightly  increased  the  percentage  of  cells  phagocytosing  myelin 
although  this  was  not  significant.  This  may  suggest  that  the  microglial  phagocytic 
response was overwhelmed by the concentrations of myelin used. Blockade of group II 
receptors  with  MCCG  significantly  reduced  levels  of myelin  phagocytosis  (PO.OOl). 
Treatment of the mGluR3  with subtype-specific group II agonist NAAG,  however,  did 
not lead to any significant changes in levels of myelin phagocytosis which indicates that 
phagocytosis  is modulated  by the mGluR2  subtype.  Interestingly the  group III  agonist 
AP4,  which  caused  increased  phagocytosis  of  dextran  beads  when  incubated  with 
myelin  alone,  induced  a  20%  reduction  in  myelin  phagocytosis  (PO.OOl)  while 
blockade  of group  III  receptors  induced  no  significant  change  in  the  phagocytosis  of 
myelin.  These  data  are  in  accordance  with  the  dextran  bead  data  which  showed  that 
myelin  induced upregulation of phagocytosis could be reduced by prior treatment with 
MCCG or AP4.219
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Figure 5.7  Phagocytosis of fluorescent myelin by microglia is reduced by 
prior exposure to ADA, MCCG or AP4
Microglia were stimulated with group II and III mGluR agonists or antagonists 
prior to  incubation with  fluorescently myelin (TRITC  labelled)  for 4 hours at 
37 °C.  A subset of cells were exposed to myelin alone as a positive control. (A) 
The number of microglia phagocytosing myelin were counted as a percentage of 
total cells per field.  These data represent the mean plus SEM of at least three 
fields per condition repeated in at least three separate experiments. Figures B-I: 
Representative images of microglia incubated with labelled myelin alone (B)  or 
cells first stimulated with ADA (C), AIDA (D), DCGIV (E), NAAG (F), MCCG 
(G),  AP4  (H),  MAP4  (I)  before  incubation with myelin  are  shown.  Labelled 
myelin can be seen within the microglia (captured by phase contrast).220
5.2.5  Modulation  of  myelin  phagocytosis  by  inhibition  of  Src  and  rho  kinase
signalling
The  MEK  inhibitor  U0126  reduced  microglial  reactivity  and  neurotoxicity. 
Furthermore, PP2, a potent and selective inhibitor of the src family of tyrosine kinases 
has been shown to reduce iNOS expression and albumin  induced  intracellular calcium 
increases (Hooper et al., 2005). Here it was determined whether these compounds could 
also  affect  the  phagocytic  mechanism  of myelin  uptake  (Figure  5.8).  Treatment with 
PP2  (lOOnM)  for  30  minutes  prior  to  incubation  with  myelin  for  a  further  4  hours 
significantly  reduced  myelin  phagocytosis  by  20%  (PO.01).  This  effect  was  not 
detected  using  a  lower  concentration  of 50nM.  Incubation  of U0126  with  microglia 
before  further treatment  with  labelled  myelin,  however,  had  no  significant  effect  on 
myelin phagocytosis.
Rho-GTPases  act  as  intracellular  switches  and  have  important  roles  in  cell 
motility.  As  such,  their  involvement  in  myelin  phagocytosis  was  analysed  here.  Y- 
27632  inhibits the small GTPase RhoA or its downstream target Rho-associated coiled 
kinase (ROCK). Microglial cells were exposed to Y-27632 for 24 hours before exposure 
to  labelled  myelin  for  a  further  4  hours  (Figure  5.9  A-C).  This  treatment  induced  a 
potent reduction (50%) in the number of cells phagocytosing myelin (PO.OOl). Lysates 
of microglia treated  with  Y-27632  were  also  assessed  for  iNOS  expression.  Y-27632 
notably  reduced  levels  of iNOS  induced  by  exposure  to  myelin  alone  (Figure  5.9D), 
which  suggests  that  the  mechanisms  involved  in  iNOS  expression  and  phagocytosis 
may be linked.221
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Figure 5.8  Phagocytosis of fluorescent myelin by microglia is reduced by 
prior incubation with PP2
Microglia were stimulated with inhibitors PP2 or U0126 for 30 minutes prior to 
incubation with fluorescently labelled myelin for 4 hours at 37°C.  A subset of 
cells were exposed to  myelin alone as a positive control.  (A)  The number of 
microglia phagocytosing myelin were counted as a percentage of total cells per 
field.  These  data  represent  the  mean  plus  SEM  of at  least  three  fields  per 
condition  repeated  in  at  least  three  separate  experiments.  Figures  B-F: 
Representative images of microglia incubated with labelled myelin alone (B)  or 
cells  first  stimulated  with PP2  50nM  (C),  PP2  lOOnM  (D),  U0126  lpM  (E), 
U0126 5pM (F), before incubation with myelin are shown. Labelled myelin can 
be seen within the microglia (captured by phase contrast).myelin  + 
Y27632  -
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Figure 5.9  Phagocytosis of fluorescent myelin by microglia is reduced by 
prior exposure to rho-kinase inhibitor Y-27637
Microglia  were incubated with labelled myelin either alone  as a positive control, or 
after prior treatment with Y-27632 for 24 hours at 37°C. (A) The number of microglia 
phagocytosing myelin were counted as a percentage of total cells per field. These data 
represent the mean plus SEM of at least three fields per condition repeated in at least 
three separate experiments. Representative images of microglia incubated with labelled 
myelin alone (B) or microglia pre-treated with Y-27632 before incubation with myelin 
(C). (D) iNOS expression in cells treated as described was assessed by western blotting. 
This  blot  represents  preliminary  findings but  shows  that  Y-27632  reduces  the  iNOS 
expression induced by myelin alone.223
5.3  Discussion
The  ability  of microglia  to  phagocytose  myelin  may  have  implications  in  the 
pathology  of MS.  Myelin  phagocytosis  has  been  shown  here  and  by  others  to  induce 
release  of  cytokines  and  nitric  oxide  from  microglia.  Furthermore,  the  monoclonal 
antibodies most effective in promoting EAE also induced the greatest increase in myelin 
phagocytosis  (Van  der  Goes  et  al.,  1999)  which  may  suggest  that  phagocytosis  of 
myelin has a central role in the inflammatory processes in EAE disease. Modulation of 
microglial mGluRs can attenuate the toxicity induced by myelin and other activators. As 
such  it  was  determined  here  whether  the  phagocytosis  of  myelin  could  also  be 
modulated in this way.
Microglial phagocytosis of dextran beads was first assessed to allow analysis of 
phagocytic  activity  of otherwise  unstimulated  cells.  Microglial  cells  incubated  solely 
with  dextran  beads  underwent  phagocytosis  at  rest  suggesting  that  microglia  can  be 
functionally active while maintaining ramified morphology and non-reactive phenotype. 
This is in accordance with the findings of Nimmerjhan et al., (2005), who demonstrated 
that  ‘resting’  microglia  in vivo  were  in  fact highly  active  and  motile  cells.  As  such  it 
would  be  interesting  to  determine  whether  the  medium  from  unstimulated  microglia 
undergoing basal levels of phagocytosis has any effect on neuronal survival.
Previous  research  has  shown  that  myelin  is  taken  up  by  microglia  and 
macrophages  via  receptor  mediated  phagocytosis  involving  complement  receptor  3 
(CR3) (Bruck and Friede,  1990b,  1992; Van der Laan et al.,  1996),  scavenger receptor 
AI/II (SRAI/II) and the Fey receptor (FcyR) (Reichert and  Rotshenker,  2003,  Makranz 
et  al.,  2004,  2006)  although  phagocytosis  by  CR3  dominates  (Reichert  et  al.,  2001; 
Reichert and Rotshenker, 2003). It was found here that myelin induced potent increases 
in  the  number  of  cells  phagocytosing  dextran  beads  which  suggests  that  activation224
primes  microglia  to  become  phagocytic.  These  results  are  in  accordance  with  recent 
work  which  found  that  LPS  (Vallieres  et  al.,  2006)  and  IFNy  (Chan  et  al.,  2001) 
stimulated phagocytosis.
Consistently  increased  phagocytosis  of  dextran  beads  was  observed  over 
timepoints ranging from 2 to 24 hours  in both microglial and N9 cultures treated with 
the  group  II  mGluR agonist  DCGIV.  Current  research  has  shown  that  CR3  and  to  a 
lesser  extent  SRAI/II  mediated  phagocytosis  are  modulated  by  intracellular  levels  of 
cAMP with normal levels activating and high  levels inhibiting the phagocytic response 
(Makranz et al., 2004, 2006), DCGIV is known to activate group II mGluRs which are 
negatively coupled to AC, therefore reducing or maintaining normal intracellular cAMP 
levels.  This  mechanism  may  have  a  role  in  DCGIV-induced  increases  in  phagocytic 
activity compared with untreated cells.  Blockade of this receptor contained  or reduced 
levels of phagocytosis compared with control levels.
Since dextran beads are not physiologic compounds, microglia were also treated 
with  mGluR  agonists  or  antagonists  prior  to  incubation  with  labelled  myelin  to 
determine  whether  myelin  phagocytosis  could  be  modulated  in  the  same  way. 
Stimulation  of group  II  receptors  did not  increase  levels  of myelin  phagocytosis,  this 
may  be  due  to  myelin  induced  saturation  of  the  phagocytic  response.  However, 
blockade of group II mGluRs significantly reduced the phagocytosis of myelin.  This is 
possibly due to  lack of inhibition of adenylate cyclase  (AC) thus  allowing build  up of 
cAMP levels and subsequent inhibition of phagocytosis (Makranz et al., 2006)
Interestingly  pre-treatment  with  AP4  prior  to  incubation  with  labelled  myelin 
also induced a reduction in phagocytic activity. This was in contrast to our findings with 
dextran beads which showed AP4-induced upregulation of phagocytosis.  However, the 
type of inflammatory stimuli received by both macrophages (Slobodov et al., 2001) and 
microglia (Reichert et al.,  2001) affects the functional response of these cells  inducing225
distinct  patterns  of phagocytosis.  Furthermore,  certain  treatments  have  been  found  to 
block myelin phagocytosis while having no effect on the phagocytosis of dextran beads 
suggesting  involvement of different or divergent pathways  (Bruck  and  Friede  1990a). 
This may explain the differential effects of AP4 on the phagocytosis of dextran beads 
and pure myelin since the beads represent non-physiologic stimuli.
Like  group II mGluRs,  group  III mGluRs are  negatively coupled to AC which 
suggests that attenuation of myelin phagocytosis  in this  case  may not be mediated by 
intracellular cAMP levels. However, cAMP levels are regulated by the balance between 
production by AC and degradation by phosphodiesterases (Patel et al., 2001; Cooper et 
al., 2003) which are also subject to modulation.  Furthermore the differential regulation 
of ligand  and  voltage  gated  ion  channels  such  as  potassium  or  calcium  channels  by 
groups  II  and  III  mGluRs  has  been  shown  in other cell types  which demonstrates the 
possibility of divergent functions in these two groups (Conn and Pin,  1997; De Blasi et 
al., 2001).
Activation  of  PKC  has  also  been  implicated  in  the  modulation  of  CR3  and 
SRAI/II  mediated  phagocytosis,  DAG  which  is  a  second  messenger  that  stimulates 
PKC, has a dose dependent dual effect, activation of phagocytosis at low concentrations 
and  inhibition  at  high  concentrations  (Cohen  et  al.,  2006).  Stimulation  of  group  I 
mGluRs  significantly  reduced  myelin  phagocytosis.  This  is  possibly  due  to  PKC 
sensitive mechanisms since group I receptors are positively coupled via Gq  to PLC and 
as  such  their  stimulation  results  in  upregulation  of  intracellular  DAG  which  may 
subsequently inhibit phagocytosis.
We  analysed  phagocytic  transduction  pathways  by  using  specific  inhibitors  of 
cell signalling pathways. Pre-treatment with PP2, a potent and selective inhibitor of the 
src  family  of tyrosine  kinases,  prior  to  incubation  with  labelled  myelin  significantly 
reduced  myelin  phagocytosis.  This  is  consistent  with  Srk/Syk  involvement  in  early226
FcyR signalling and suggests modulation via the FcyR (Song et al., 2004). Treatment of 
microglia with PP2,  however,  did not completely abrogate  myelin phagocytosis which 
suggests  involvement  of  other  pathways  consistent  with  the  observation  that  most 
myelin phagocytosis  is mediated  via CR3.  Treatment with the  MEK  inhibitor U0126, 
however, had no effect on myelin phagocytosis. These results are in accordance with the 
findings  of  Song  et  al.,  (2004)  who  showed  that  ERK  was  involved  in  activation 
induced  microglial  expression  of macrophage  inflammatory  protein  but  not  in  FcyR 
mediated phagocytosis.
Rho  GTPases  act  as  intracellular  molecular  switches  transducing  extracellular 
signals  to  the  actin  cytoskeleton  and  therefore  have  important  roles  in  cell  motility. 
Inhibition of microglial rho kinase prior to  incubation with myelin  induced significant 
reduction in phagocytic activity. This may be explained in part by the importance of rho 
GTPase  in  rearrangement of the  cytoskeleton  required  during the  phagocytic  process. 
Indeed,  it has been demonstrated that rho activity  is required for actin assembly in the 
phagocytic  cup  for  subsequent  particle  engulfment  in  CR3  but  not  FcyR  mediated 
phagocytosis (Caron and Hall,  1998; Olazabel et al., 2002). We found that inhibition of 
Rho kinase activity with Y27632 was most effective  in preventing the phagocytosis of 
myelin  by  microglia  which  further  suggests  that  myelin  phagocytosis  is  primarily 
mediated by CR3.
CR3  mediated  phagocytosis  has  been  shown  to  induce  NO  production  in 
macrophages (Goodrum et al.,  1994) and microglia (Corradin et al.,  1993; Van der laan 
et  al.,  1996)  consistent  with  their  role  in  innate  immunity.  Furthermore,  NO  induces 
upregulation  of CR3  expression  (Roy  et al.,  2006) which  suggests  a  possible  positive 
feedback  mechanism.  It  is  possible  that the  neuroprotection  afforded  by  blocking  the 
action of group II or stimulation of group III mGluRs on microglia could be the result of 
a reduced capacity for phagocytosis and subsequent reduction of myelin  induced iNOS227
expression.  Interestingly,  blocking  rho  kinase  activity,  known  to  be  vital  in  CR3 
mediated phagocytosis, also reduced iNOS expression compared with levels induced by 
myelin alone.
Future work will involve repeating these experiments using western blotting for 
MBP  or MOG  within  cells,  or  fluorescent  activated  cell  sorting  (FACS)  analysis  for 
more quantitative results.  FACS analysis would allow  investigation of the total myelin 
phagocytosed  for  different  conditions  instead  of the  percentage  of cells  undergoing 
phagocytosis.  This  would  probably  reveal  larger differences  between  conditions  since 
purely counting the number of phagocytosing cells negates the possibility of differences 
in  cellular myelin  load.  It  is also possible that the  levels  of phagocytosis  recorded  for 
the 40kDa beads were  influenced by the fact that the cells were always  incubated with 
both  lOkDa  and  40kDa  beads  together.  If the  phagocytic  response  is  potentiated  by 
activation  then  perhaps  the  presence  of  lOkDa  beads  promoted  the  phagocytosis  of 
40kDa beads. Further experiments incubating the beads  separately would  answer these 
questions.  It would also be of interest to measure the effect of iNOS  inhibitors  such as 
AMT-HCL on myelin phagocytosis since this compound has been shown to reduce the 
myelin induced microglial neurotoxic phenotype.228
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Figure 5.10  Possible signalling pathways regulating microglial myein 
phagocytosis
Microglial phagocytosis of myelin is regulated by inhibition of rho kinase which 
is  responsible  for reorganisation  of the  actin  cytoskeleton  and  as  such  must  be 
central  to the  phagocytic  mechanism,  it  has  also  been  shown  that  inhibition  of 
rho-kinase  activity  can  reduce  iNOS  expression,  this  may  also  play  a  part  in 
regulation  of  phagocytosis  since  NO  regulates  CR3  expression  in  microglia. 
Inhibition  of Src  activity  also  reduced  phagocytosis,  this  is  consistent with  the 
role of Src in FcR signalling and suggests that not all myelin is phagocytosed by 
CR3 (Song et al., 2004).229
6.0
CONCLUSIONS AND FUTURE WORK230
6.1  Conclusions
Metabotropic  glutamate  receptors  in  the  CNS  are  expressed  in  regionally  and 
cellular  specific  patterns  that  govern  their  modulatory  functions.  Microglia  express 
subtypes  from  group  I,  II  and  III  mGluRs.  shown-  Stimulation  of group  II  microglial 
mGluRs has been shown to be neurotoxic while stimulation of group I mGluRs can be 
neuroprotective.  As such,  microglial  reactivity and toxicity during disease progression 
may be the result of increased expression of one subtype of mGluR over another. This 
study  found  that  activation  of  microglia  induced  changes  in  mGluR  phenotype 
compared with untreated cells. Both group I (mGluR 1) and II (mGluR2 and 3) mGluRs 
were upregulated after exposure to myelin.  Interestingly group II  subtype  mGluR2 has 
been  shown  to  induce  a  neurotoxic  microglial  phenotype  (Taylor  et  al.,  2002,  2005) 
while  mGluR3  stimulation  has  been  associated  in  astrocytes  with  neuroprotection  via 
TGFp  release  (Bruno  et al.,  1998).  It  is possible  that  microglial  upregulation  of both 
subtypes may reflect an attempt to regulate the toxic effects  of activation.  In  line with 
these  findings,  we  also  show  here  that  myelin  induced  upregulation  of  microglial 
mGluR8. These findings are in agreement with work by Guerts et al., (2003) who found 
that  microglia/M0  in  MS  plaques  also  showed  increased  expression  of this  subtype. 
Given that group III microglial mGluRs can promote neuroprotection, it is possible that 
upregulation of mGluR8 is in an attempt to control the toxic effects of activation. These 
results suggest that functional microglial phenotype regulates the mGluR profile and as 
such may modulate reactivity.
Microglial exposure to myelin induced a reactive phenotype involving release of 
inflammatory  mediators  including  TNFa,  glutamate  and  nitrite,  and  upregulated 
expression  of iNOS  and  Phospho-ERK.  Treatment  with  myelin  induced  microglia  to 
become neurotoxic since medium from these cells was deleterious to neuronal  survival231
in culture. This was attributable to factors released by microglia since direct application 
of  myelin  to  neurones  induced  no  such  effect.  It  is  possible  that  myelin  induced 
microglial neurotoxicity is due to the high TNFa release or the downstream products of 
iNOS  expression  since  compounds  blocking  these  mediators  were  neuroprotective. 
Indeed TNFa is toxic to neurones when released from  microglia  in concert with FasL 
(Taylor  et  al.,  2005)  and  glutamate  (Floden  et  al.,  2005)  possibly  mediating  NO 
dependent death in neurones (Combs et al., 2001).  Microglial reactivity after exposure 
to  myelin  has  important  implications  in  the  study  of MS  pathology  where  microglial 
phagocytosis  of myelin  debris  is  known  to  occur  and  as  such  could  be  cauing  by­
stander  damage  to  neurones  and  other  supporting  cells  thus  further  exacerbating  the 
inflammatory  cascade.  These  data  highlight  the  importance  of strategies  that  reduce 
microglial reactivity as a potential treatment in MS.
Interestingly,  myelin  induced  microglial  neurotoxicity  was  modulated  by 
microglial  mGluRs and could be attenuated by blocking group  II  or stimulating group 
III  mGluRs.  Furthermore,  modulation  of  microglial  mGluRs  reduced  the  iNOS 
expression  induced  by  myelin,  consistent  with  the  neuroprotection  afforded  by 
inhibition  of  microglial  iNOS.  The  phagocytosis  of  myelin  is  thought  to  induce 
respiratory  burst  activity  in  microglia  where  NADPH  oxidase,  which  is  normally 
dormant in resting phagocytes, is activated and subsequenty catalyses the production of 
superoxide  from  oxygen.  Superoxide  readily  reacts  with  NO  to  form  peroxynitrite 
which  recent  studies  have  suggested  is  more  toxic  to  neurones  and  oligodendrocytes 
than NO alone (Li et al., 2005) It is possible that reduced NO therefore leads to reduced 
ONOO' preduction which may reduce the overall feedback activation of microglia.
Interestingly  the  phagocytosis  of myelin  could  also  be  similarly  attenuated  by 
blocking group  I  or  II  mGluRs  and  stimulating  group  III  mGluRs.  It  has  been  shown 
that  microglial  and  macrophage  phagocytosis  mediated  by  CR3  induces  NO  release(Van  der  laan  et al.,  1996;  Roy  et  al.,  2006)  which  would  be  expected  as  part  of an 
innate  immune  response.  It  is  possible  that  the  reduced  neurotoxicity  and  iNOS 
expression shown here by modulation of group II and III mGluRs could therefore be a 
result of attenuation of the inflammatoiy phagocytic response mediated by myelin.
Taken  together,  these  findings  indicate  that  changes  in  microglial  mGluR 
expression  may  be  of  relevance  in  the  microglial  activation  in  MS.  Furthermore, 
modulation  of microglial  mGluRs  may  therefore  represent  possible  pharmacological 
targets for therapeutic interventions in multiple sclerosis.233
6.2  Future work
Attenuation of microglial neurotoxicity and reactivity by modulation of mGluRs 
may be of therapeutic benefit in MS.  As  such,  future work will  involve elucidation of 
precisely which mGluR subtypes are most effective at promoting a protective phenotype 
by  repeating  neurotoxicity  experiments  using  a  wider  range  of  potent  and  selective 
mGluR  agonists  and  antagonists.  Microglial  neurotoxicity  experiments  will  also  be 
repeated after stimulation of group I microglial mGluRs which have been shown here to 
modulate  phagocytosis.  The  signalling pathways  involved  in  attenuation  of microglial 
toxicity mediated  by mGluRs will also be investigated using co-culture  systems which 
will  provide  data more  closely  related to  in  vivo  situations.  Microglial  activation  was 
shown here to modulate mGluR expression,  future work determining non-toxic factors 
capable  of upregulating neuroprotective  microglial  mGluR  phenotype  would  therefore 
be of therapeutic relevance for inflammatory diseases of the CNS.
This  work  has  shown  that  mGluR  expression  is  markedly  altered  in  the  EAE 
mouse model of MS compared with untreated controls.  Since mGluR expression varies 
in different cell types, the use of brain and spinal cord homogenates could only provide 
a  broad  overview  of  the  general  mGluR  profile.  Further  research  will  involve  the 
isolation  of  primary  microglia  from  an  EAE  model  which  will  allow  the  specific 
analysis of microglial mGluR expression during disease progression.  This would be of 
particular  interest  as  expression  of  microglial  mGluR  subtypes  could  be  compared 
during  inflammatory  attack,  remission  or  the  progressive  chronic  phase  of  disease. 
Further work will also involve the development of a single cell RT-PCR protocol, this 
would  not  only  enable  quantitative  analysis  of microglial  mGluR  expression  but  also234
allow  region  specific  analysis  of microglial  mGluR  profiles  in  preactive  or  chronic 
plaques compared with normal appearing white matter.
Quantitative  determination  of  microglial  phagocytic  activity  will  also  be 
analysed  using  western  blotting  for  MOG  proteins,  and  FACS  analysis.  This  will  be 
interesting since this study,  analysing the percentage of phagocytosing cells,  could not 
properly account for differences in myelin load within cells.  Further investigations into 
the  signalling  pathways  involved  in  myelin  phagocytosis  and  consequent  reactive 
phenotype  are  necessary  to  understand  how  myelin  induces  microglia  to  become 
neurotoxic.  This  could be explored using specific  inhibition  of CR3  or FcR signalling 
and  subsequent  assessment  of phagocytic  activity  and  neurotoxicity.  Specific  iNOS 
inhibition  will  also  allow  analysis  of  the  role  of  iNOS  in  phagocytosis.  Inducing 
effective phagocytic activity and clearance without this associated reactivity will also be 
an important avenue of research for the future.7.0  REFERENCE LIST236
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